Lösliches Endoglin (sCD105) : diagnostische Wertigkeit bei chronischen Lebererkrankungen und funktionelle Bedeutung für die Signaltransduction von transforming growth factor (TGF-beta) by Rizk, Mohamed Soliman
  
 
 
 
 
 
Lösliches Endoglin (sCD105) 
Diagnostische Wertigkeit bei chronischen Lebererkrankungen und 
funktionelle Bedeutung für die Signaltransduction von transforming 
growth factor (TGF)-β 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mohamed Soliman Rizk 
 
 Lösliches Endoglin (sCD105) 
Diagnostische Wertigkeit bei chronischen Lebererkrankungen und 
funktionelle Bedeutung für die Signaltransduction von transforming 
growth factor (TGF)-β 
 
 
Von der Medizinischen Fakultät  
der Rheinisch-Westfälischen Technischen Hochschule Aachen  
zur Erlangung des akademischen Grades 
eines Doktors der Medizin 
genehmigte Dissertation 
 
 
vorgelegt von 
 
Mohamed Soliman Rizk 
M. B. B. Ch. 
M. Sc. in Clinical Biochemistry  
 
aus 
El-Menofyia (Ägypten) 
 
 
Berichter:      Herr Universitätsprofessor 
                      Dr. med. Prof. h.c. (RCH) Axel M. Gressner 
                    
          Herr Privatdozent  
                      Dr. med. Andreas Geier 
 
 
Tag der mündlichen Prüfung: 6. September 2007 
 
Diese Dissertation ist auf den Internetseiten der Hochschulbibliothek online verfügbar 
 
 
  
 
 
  
Soluble endoglin (sCD105) 
Diagnostic validity for chronic liver diseases and functional 
relevance in signal transduction of transforming growth factor 
(TGF)-β 
 
 
Faculty of Medicine 
AACHEN UNIVERISTY 
 
 
MD Thesis 
To approbate MD degree  
 
 
 
Presented by 
 
Mohamed Soliman Rizk 
M. B. B. Ch. 
M. Sc. in Clinical Biochemistry 
 
 
From 
El-Menofyia (Egypt) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To  
my parents,  
my wife 
and my children:  Ahmed, Asmaa and Soliman 
   
Table of Contents 
            Page 
List of abbreviations  V 
1 Introduction   
1.1 Pathogenesis of liver fibrosis  1 
1.2 Resolution of liver fibrosis  3 
1.3 Molecular basis of fibrosis  4 
1.3.1 HSC activation  4 
1.3.2 Fibrogenic signaling of transforming growth factor-β (TGF-β)  5 
1.3.3 Further cytokines involved in hepatic fibrosis  8 
1.4 The auxiliary TGF-β receptor endoglin (CD105)  8 
1.4.1 Structure of the transmembrane receptor endoglin  8 
1.4.2 Expression of endoglin  10 
1.4.3 Regulation of endoglin expression  10 
1.4.4 Endoglin function and its association with vascular dysfunction  11 
1.4.4.1 Endoglin function in TGF-β signaling  11 
1.4.4.2 Endoglin function in angiogenesis  12 
1.4.4.3 Endoglin as a biomarker for clinical conditions  13 
1.4.4.3.1 Endoglin and antiangiogenic strategies  13 
1.4.4.3.2 Endoglin as a biomarker for tumor imaging and tumor prognosis  13 
1.4.4.3.2.1 Transmembrane endoglin  13 
1.4.4.3.2.2 Soluble circulating endoglin  14 
1.5 Diagnosis of liver fibrosis  14 
1.5.1 α-fetoprotein and chronic liver disease  15 
1.6 Aim of the work  17 
 
2 Materials and Methods   
2.1 Material   
2.1.1 Human serum samples  18 
2.1.1.1 Patients  18 
2.1.1.2 Controls  18 
2.1.2 Chemicals  19 
2.1.3 Disposable material  21 
2.1.4 Kits for assays  21 
 I
2.1.5 Technical equipement  22 
2.1.6 Biochemical Material  23 
2.1.6.1 Enzymes  23 
2.1.6.2 Antibodies  23 
2.1.6.2.1 Primary antibodies  23 
2.1.6.2.2 Secondary antibodies  23 
2.1.6.3 Cytokines  24 
2.1.6.4 Protein Size Markers  24 
2.1.7 Molecular biological Material  24 
2.1.7.1 Primers  24 
2.1.7.2 Vectors  25 
2.1.7.3 Molecular size Markers  25 
2.1.8 Cell culture  25 
2.1.8.1 Prokaryotic cell culture  25 
2.1.8.1.1 Media for prokaryotic cell culture  25 
2.1.8..1.2 Bacterial strain  25 
2.1.8.2 Eukaryotic cell culture  25 
2.1.8.2.1 Media for eukaryotic cell culture  25 
2.1.8.2.2 Cells  26 
2.1.9 Buffers and Solutions  26 
 
2.2 Methods   
2.2.1 Biochemical Methods   
2.2.1.1 Protein isolation from cell monolayers  32 
2.2.1.2 Protein enrichment by tri-chloro-acetic acid precipitation  33 
2.2.1.3 Protein measurement using the Bio-Rad DC protein assay  33 
2.2.1.4 Analysis of proteins by polyacrylamide gel electrophoresis  34 
2.2.1.5 Detection of proteins by immunological methods  34 
2.2.1.5.1 Western blot analysis  34 
2.2.1.5.2 ELISA Measurement  35 
2.2.1.5.3 Immunoturbidometric Assay  36 
2.2.2 Molecular biological methods   
2.2.2.1 Preparation of competent bacteria (Hanahan method)  36 
2.2.2.2 Transformation of competent bacteria  36 
 II
2.2.2.3 Preparation of plasmid-DNA from bacteria  37 
2.2.2.4 Purification and analysis of nucleic acids  38 
2.2.2.4.1 Phenol/Chloroform extraction  38 
2.2.2.4.2 Ethanol precipitation  39 
2.2.2.4.3 Quantification of nucleic acids (Spectrophotometry)  39 
2.2.2.4.4 Analysis of DNA by Agarose DNA-gel electrophoresis  39 
2.2.2.4.5 Purification of DNA from Agarose gel slices  40 
2.2.2.4.5.1 DNA preparation by electroelution  40 
2.2.2.4.5.2 DNA preparation using the QIAEX II system  40 
2.2.2.5 Manipulation of nucleic acids  41 
2.2.2.5.1 Restriction of plasmid-DNA  41 
2.2.2.5.2 Preparation of blunt-end DNA fragments  41 
2.2.2.5.3 Molecular cloning of DNA fragments by ligation  42 
2.2.2.6 Isolation of total RNA from cells (RNeasy®Mini Kit)  42 
2.2.2.7 Preparation of first strand cDNA  42 
2.2.2.8 RT-PCR analysis (Polymerase chain reaction)  43 
2.2.2.9 Purification of PCR-products  44 
2.2.2.10 DNA sequencing  44 
2.2.3 Heterologous gene expression in eukaryotic cells  45 
2.2.3.1 Collagen coating of culture dishes  45 
2.2.3.2 Eukaryotic cell culture  45 
2.2.3.3 Subculture of cells  46 
2.2.3.4 Cryopreservation and storage of cell lines  46 
2.2.3.5 Thawing of cryopreserved cells  47 
2.2.3.6 Transient transfection of eukaryotic cells  47 
2.2.4 Luciferase measurement  49 
2.2.5 FPLC fractionation of serum proteins  49 
2.2.6 Statistical analysis  50 
 
3 Results   
3.1 Soluble endoglin as biomarker for the diagnosis of cirrhosis  51 
  and developing primary liver cell carcinoma 
3.1.1 Clinical and laboratory data of the analyzed patients and  51 
 control groups 
 III
3.1.2 Measurement of serum sCD105 concentrations by ELISA  52 
3.1.3 Measurement of the serum α-fetoprotein concentrations (AFP)  55 
3.1.4 Correlation between sCD105 and AFP   55 
3.1.5 Diagnostic sensitivity and specificity of sCD105 and AFP  57 
3.1.6 C-reactive protein in liver fibrotic and cirrhotic subgroups  58 
3.2  Functional analysis of soluble endoglin   
3.2.1  Cloning of the extracellular domain of rat endoglin  59 
3.2.2 Expression of the soluble endoglin in COS-7 and CHO cells   65 
3.2.3           Function of heterologously expressed rat soluble endoglin  69 
 in both L6E9 and primary rat hepatocytes. 
3.2.4 Characterization of serum endoglin  79 
 
4 Discusscion   
4.1 Clinical value of sCD105  81 
4.2 Functions of sCD105        84 
 
5 Summary  88 
 
6 References  90 
 
7 Appendix  105 
 
8 Acknowledgements  118 
 
9. Curriculum Vitae         119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 IV
List of abbreviations 
 
 
AFB1, aflatoxin B1 
AFP, α-fetoprotein 
ALK, Activin receptor like kinase 
AVM, arterial venous malformations 
α-SMA, alpha-smooth muscle actin 
A, absorbance 
Aa, amino acid(s) 
ALT, alanine amino transferase 
AMP, ampicillin 
AST, aspartate aminotransferase 
AUC, area under the ROC curve 
BSA, bovine serum albumin 
CD, Cluster of differentiation 
CD105, endoglin 
CD95 L, also called APO-1L/Fas-L  
Cf, Compare figure 
CI, confidence interval 
CMV, cytomegalovirus 
Col, collagen 
CLD, chronic liver disease 
dest. water, destilled water 
dGTP, 2-deoxyguanosine 5´-triphosphate 
DMEM, Dulbecco´s modified Eagle medium 
DMSO, dimethyl sulfoxide 
DNA, deoxyribonucleic acid 
dNTP, deoxyribonucleotide triphosphate 
DOC, sodium deoxycholate 
Ds, double stranded 
DTT, dithiothreitol 
ECD, extracellular domain(s) 
ECM, extracellular matrix 
Eng, Endoglin 
EDTA, ethylene diamine tetraacetic acid 
EGFP, enhanced green fluorescent protein 
ELISA, enzyme-linked immunosorbent assay 
et al., et altera 
Et.Br, ethidium bromide 
f, female 
FCS, fetal calf serum 
FGF, fibroblast growth factor 
GFP, green fluorescent protein 
h, hour(s) 
HCC, hepatocellular carcinoma 
HBSS, Hank´s balanced salt solution 
HRP, horse radish peroxidase 
HHT, human hereditary telangectisa  
HSC, hepatic stellate cell(s) 
IB, immunoblotting 
(Id), inhibitor of differentiation 
ΙL, interleukin 
Kbp (kb), kilo base pair(s) 
kDa, kilo Daltons 
1l or 1L, one litre 
LB, Luria-Bertani medium 
m, male 
MMP, matrix metalloproteinase 
Mab, monoclonal antibody 
MAD1 or Mothers against decapentaplegic 
homolog 1 (Drosophilia –protein) 
MFB, myofibroblast-like cell(s) 
Min, minute(s) 
MOPS, 3-[N-Morpholino] propansulfonic 
acid 
NFκB, nuclear factor kappa B 
 V
NP 40, Nonidet P 40 
NSS, normal saline solution 
Nt, nucleotide(s) 
OD, optical density 
PAGE, polyacrylamide gel electrophoresis 
PAI, Plasminogen activator inhibitor 
PBS, phosphate buffered saline 
PCR, polymerase chain reaction 
PDGF, platelet-derived growth factor 
PEG, polyethylene glycol 
PIC, protease inhibitors cocktail 
PLC, primary liver cancer 
PVP, polyvinyl pyrrolidone 
PPabE1, purified polyclonal antibody E1 
p53, phosphoprotein 53 
rh, recombinant human 
RNA, ribonucleic acid 
ROS, reactive oxygen species 
Rpm, rotation cycle per minute 
RT, room temperature 
RT-PCR, reverse transcriptase polymerase 
chain reaction 
SC, Santa Cruz 
 
 
sec, second (time) 
SCID, severe combined immunodeficient  
SDS, sodium dodecyl sulphate 
SSC, saline-sodium citrate solution 
sTβRII, soluble transforming growth factor-β 
receptor type II 
STE buffer, saline-Tris-EDTA buffer 
sCD105, soluble endoglin  
TBS, Tris buffered saline 
TBST, Tris buffered saline with Tween-20 
99TCm, radiochemical technetium  
TCA, trichloroacetic acid 
TE, buffer Tris-EDTA buffer 
TGF-β, transforming growth factor-β 
TIMP, tissue inhibitor of metalloproteinase  
TY, tryptone-yeast extracted medium 
µ, micro 
V, volt(s) 
v, volume 
v/v, volume per volume 
w/v, weight per volume 
Y, years 
 
 
 VI
1 Introduction 
 
1.1 Pathogenesis of liver fibrosis 
 
Hepatic fibrosis is the result of an unrestricted wound healing response due to repeated injury 
of the liver. Acute liver injury (e.g., viral hepatitis) leads to regenerating parenchymal cells 
replacing the necrotic or apoptotic cells. This process is associated with an inflammatory 
response and a limited deposition of extracellular matrix (ECM). If the process of hepatic 
injury persists, then eventually the liver regeneration fails, and hepatocytes are substituted 
with abundant ECM, including fibrillar collagen. The distribution of this fibrous material 
depends on the cause of the liver injury. In chronic viral hepatitis and chronic cholestatic 
disorders, the fibrous tissue is initially located around portal tracts (porto-portal fibrosis), in 
alcohol-induced liver disease, it locates pericentral and in perisinusoidal areas [Pinzani, 
1999]. In schistosomiasis periportal fibrosis and granulomas are found [Silva et al., 2006; Da 
Silva and Carrilho, 1992; Andrade and Peixoto, 1992]. Liver fibrosis is associated with major 
alterations in both the quantity and composition of the ECM [Benyon and Iredale, 2000]. In 
advanced stages, the liver contains approximately 6 times more ECM than normal, including 
collagens (I, III, and IV), fibronectin, undulin, elastin, laminin, hyaluronan, and 
proteoglycans. Accumulation of ECM results from both increased synthesis and decreased 
degradation [Arthur, 2000]. Decreased activity of ECM-removing MMPs is mainly due to an 
overexpression of their specific inhibitors (TIMPs).  
The key pathologic features of cirrhosis reflect irreversible chronic injury to the hepatic 
parenchyma, resulting in excessive fibrosis and conversion of normal liver architecture into 
structurally abnormal regenerative nodules (Fig.1A-D). 
A                                             B           
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Figure 1: Representation of healthy and cirrhotic liver. Depicted is an excised normal human liver (A) and a 
liver which shows signs of cirrhosis (B) with regenerating nodules and contraction of condensed fibrous tissue 
later on. A focus on a liver lobule of the normal liver (C) and under the pathologic condition of cirrhosis (D). 
The massive ECM deposition is stained in grey, surrounding the lobule in the cirrhotic liver. The liver lobule 
area has decreased and the central vein is strongly compressed (C&D microscpic bild were taken from the 
website: http://www.gastroenterologe.de). 
 
 
This process is the common, irreversible, and final pathway for a variety of liver diseases. The 
excessive deposition of ECM components in the space of Disse has an impact on the 
exchange capacity between sinusoidal lumen and the liver parenchyma due to the loss of 
fenestration of the sinusoidal endothelial cells. Because of the higher mechanical resistance of 
the sinusoids the blood pressure is increased leading to portal hypertension [Rockey, 2001] 
(Fig. 2). 
 
 
Figure 2: Cellular changes in the hepatic sinusoidal compartment in the course of fibrosis. Following 
chronic liver injury, inflammatory lymphocytes infiltrate the hepatic parenchyma. Hepatocytes loose their 
microvilli and some hepatocytes undergo apoptosis. Kupffer cells are activated, releasing fibrogenic mediators. 
As one of the main events, HSC undergo a dramatic phenotypical activation resulting in the 
“transdifferentiation” to a myofibroblast-like cell (MFB), showing an increased proliferation rate and secreting 
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large amounts of extracellular matrix proteins. Sinusoidal endothelial cells loose their fenestrations and the tonic 
contraction of HSC causes increased resistance to blood flow in the hepatic sinusoid (taken from Friedman 
2000). 
 
 
Unfortunately, cirrhosis is associated with high morbidity and mortality affecting many 
persons during the most productive years of life. The spectrum of characteristic clinical 
manifestations and potentially life-threatening consequences that can result from cirrhosis 
includes hepatic encephalopathy, bleeding from esophageal and gastric varices, ascites, 
hepatorenal syndrome, hepatocellular carcinoma (HCC), and liver failure [Arthur, 2001]. In 
most countries, HCC comprises 85–90% of primary liver cancer (PLC) and so the terms are 
often used interchangeably. PLC is the fifth most common cancer in the world [Parkin, et al., 
1999], and the fourth most common cause of cancer mortality [Pisani, 1999]. HCC rates have 
an extremely wide geographic variation, such that 80% of the cases arise in developing 
countries, particularly those of southeast Asia and sub-Saharan Africa. Even within a confined 
geographic area, certain ethnic groups have higher PLC rates than others. In these high-rate 
populations, chronic infection with hepatitis B virus (HBV), and contamination of foodstuffs 
with aflatoxin B1 (AFB1) are recognized as major risk factors [Jin et al., 1999]. In developed 
world the most likely causes are alcohol ingestion and increasingly hepatitis C infection. In 
this chronic inflammatory liver disease which has the potential to promote the development of 
HCC, the pathophysiologic process most commonly associated with is cirrhosis, found in up 
to 80%. It is not known whether cirrhosis itself or the mechanism underlying cirrhosis is 
responsible for malignant transformation of hepatocytes [Flicker et al., 1997]. 
 
1.2 Resolution of liver fibrosis 
 
During recovery from acute human and experimental liver injury, the number of activated 
HSC decreases as tissue integrity is restored [Iredale 1998]. A pivotal unresolved issue is 
whether activated HSC can revert (back) to a quiescent state. Regression of activated HSC, 
clearance of MFB and a diminished availability of soluble, activating cytokines leads to the 
reconstitution of the normal subendothelial ECM. When HSC are grown on a basement 
membrane substratum they remain quiescent [Olaso et al., 2001]. The other potential fate of 
activated HSC is apoptosis. HSC apoptosis associated with reduced TIMP-1 expression has 
been documented during the recovery phase of experimentally induced liver injury [Iredale, 
1998]. HSC also undergo apoptosis during spontaneous activation, paralleled by increased 
expression of CD95L (Fas ligand), Bcl-2 and p53. HSC are central to the whole process of 
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liver tissue injury, repair, fibrogenesis, ECM remodeling and resolution [Gressner, 1998]. The 
process describing this excessive ECM deposition is called fibrogenesis and occurs in the 
most types of chronic liver diseases. Although fibrosis results from a wide spectrum of insults 
to the liver, the underlying basis for the excessive overproduction of ECM is common and due 
to the activation of HSC.  
 
1.3 Molecular basis of fibrogenesis 
 
1.3.1 HSC activation 
 
Insults of the liver regardless of the cause leads in a first step to the damage of hepatocytes 
constituting the liver parenchyma. The damage of the hepatocytes in turn leads to the release 
of signals triggering an inflamatory response, which are accompanied by signals released by 
liver resident Kupffer cells and infiltrating inflammatory cells. The release of a diverse set of 
cytokines causes finally the activation of hepatic stellate cells (HSC). Activated HSC 
“transdifferentiate” and aquire a myofibroblast-like phenotype (MFB), which is characterized 
by an excessive production of extracellular matrix (ECM) proteins [Gabele et al., 2003; 
Gressner and Weiskirchen, 2006]. HSC reside in the space of Disse at the interface between 
the fenestrated sinusoidal endothelium and the liver parenchyma, and they are the major 
storage sites of vitamin A. HSC have been considered as immunmodulatory cells [Sato et al., 
2003], as well as mediating neurologic function. Following chronic injury, HSC activate and 
transdifferentiate into MFB, acquiring contractile, proinflammatory, and fibrogenic properties 
[Milani et al., 1990 ; Iredale, 2007] (Fig.3).  
Activated HSC migrate and accumulate at the sites of tissue injury, where the repair by 
secreting large amounts of ECM is initiated. Interestingly, HSCs express a number of 
neuroendocrine markers (e.g., reelin, nestin, neurotrophins, synaptophysin, and glial-fibrillary 
acidic protein) and bear receptors for neurotransmitters [Geerts, 2001; Sato et al., 2003; Oben 
et al.,2003]. 
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Figure 3: Characterization of the transdifferentiation process. Activation of quiescent HSC to activated HSC 
and finally to MFB is governed by the release of cytokines and reactive oxygen species (ROS) from leucocytes, 
Kupffer cells, platelets as well as hepatocytes (not shown). The activation process is accompanied by an increase 
in ECM synthesis and α-smooth muscle actin (α -SMA) expression. Proliferation takes place and cytokines like 
TGF-β1 are actively synthesized. Moreover, MFB acquire contractility (modified from Gressner, 1998). 
 
 
1.3.2 Fibrogenic signalling of transforming growth factor-β (TGF-β) 
 
Cytokines regulating the inflammatory response to injury modulate hepatic fibrogenesis in 
vivo and in vitro [Schwabe et al., 2003]. TGF-β is a member of transforming growth factor-β 
superfamily of proteins. The biologically active form of TGF-β is a dimer of 25 kDa in which 
the two subunits are linked by a disulfide-bridge [Roberts and Sporn, 1985]. TGF-β which 
acts as potent growth inhibitor for many different (preferentially epithelial) cell types, plays a 
key role in the control of parenchymal apoptosis, and stimulates the production of ECM 
components, during hepatic fibrogenesis. TGF-β1 appears to be a key mediator in human 
fibrogenesis. It has a pivotal role in initiating, promoting, and progression of the 
transdifferention process from HSC into MFB. Concomitant with increased release/activity of 
TGF-β during fibrogenesis, activated HSC increase the production and deposition of collagen 
leading to progressive scarring and loss of organ function. Thus, overexpression of TGF-β in 
the liver induces severe liver fibrosis [Friedman, 2000]. Conditionally regulated expression of 
TGF-β further reveals that the induction of fibrogenesis is directly linked to the concentration 
of this ligand [Ueberham et al., 2003]. Conversely, the blockade of TGF-β synthesis or 
signalling using different experimental strategies prevents ongoing liver fibrosis in various 
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animal models [George et al., 1999; Qi et al., 1999; Nakamura et al., 2000; Arias et al., 
2003].  
 
Signalling by TGF-β isoforms is initiated by binding to the type I activin-receptor-like kinase-
5 (ALK-5) or ALK-1 and the type II serine/threonine kinase receptor the so called signaling 
receptors, which are essential for the TGF-β activity [Massague, 2000]. The TGF-β binding is 
further modulated by accessory receptors, i.e. betaglycan (TβRIII ) and endoglin (CD105) 
which lack a cytoplasmic kinase domain. CD105 appears to interact not only with TGF-β but 
also with activin and bone morphogenetic proteins (BMP) in the presence of their respective 
type I and type II receptors [Barbara et al., 1999; Lopez-Casillas et al., 1993]. The ligand 
binding to the dimeric type II receptor leads to the recruitment of a type I receptor dimer into 
the complexes, in which the type II phoshorylates the type I receptor in the GS domain [rich 
in glycine and serine residues]. The activated type I receptor kinase propagates the signal 
inside the cell through the phosphorylation of receptor-regulated Smads (R-Smads). The 
specificity of R-Smad phosphorylation is dictated by the corresponding type I receptor. ALK-
5 interacts and activates R-Smad2 and R-Smad3, whereas ALK-1 directs the signal to R-
Smad1 and R-Smad5 [Massague, 2000]. Activated R-Smads form heteromeric complexes 
with the common Smad4. These complexes accumulate in the nucleus, where they control 
gene expression in a cell-type specific and ligand dose-dependent manner through interactions 
with transcription factors, coactivators and corepressors [Massague, 2000] (Fig. 4). In case of 
the accessory receptor CD105, the binding of TGF- β requires the presence the receptor II, 
because endoglin is not able to bind ligand by itself [Barbara et al., 1999; Torsney et al., 
2002]. Upon association, the cytoplasmic domain of CD105 is phosphorylated by the type I 
and type II receptor resulting in increased phosphorylation of Smad2 but not Smad3. Since 
Smad2 can interact with a variety of transcription factors, coactivators, and repressors, 
phosphorylated Smad may act as an integrator of multiple signals to modulate gene 
transcription [Barbara et al., 1999; Guerrero-Esteo et al., 2002]. Inhibitory Smads (i.e I-
Smads; Smad6, Smad7) can associate with activated TGF-β type I receptors and inhibit R-
Smad phosphorylation . In primary cultured HSC undergoing transdifferentiation the effects 
of TGF-β on intracellular signalling is dependent on the cellular activation state. TGF-β 
causes phosphorylation and nuclear translocation of Smad2 primarily in quiescent HSC and 
Smad3 in transdifferentiated HSC [Liu et al., 2003]. Furthermore, this cytokine is able to 
inhibit proliferation of quiescent but not transdifferentiated HSC or MFB [Liu et al., 2003; 
Dooley et al., 2000]. In addition, phosphorylated nuclear Smad2 but not Smad3 is present  
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Figure 4: TGF-β signaling cascade in endothelial cells. Depicted is the signaling pathway in response to TGF-
β in endothelial cells because this the best analyzed system. Endoglin has been shown to promote ALK-1 
signaling (left) and to inhibit ALK-5 (right) signaling. Activation of these two receptors leads to different 
transcriptional responses. ALK-1 causes induction of Id1 and Smad6 whereas ALK-5 induces PAI-1, collagen I 
and Smad7. In HSC it was shown that both of these signaling pathways are active, too. The function of endoglin 
in HSC is currently under investigation. KD; Kinase Domain (For a detailed discussion of the signaling 
pathways see text.) 
 
 
constitutively and TGF-β independent in activated HSC [Liu et al., 2003], suggesting that the 
two R-Smads have distinct roles in the process of cellular activation and transdifferentiation. 
A more recent study demonstrated that the overexpression of Smad3 was sufficient to exhibit 
increased deposition of fibronectin and type 1 collagen and increased α-SMA organization in 
stress fibers [Uemura et al., 2005]. These characteristics were not noticed when Smad2 was 
overexpressed supporting the notion that Smad3 plays the more important role in transmitting 
the morphological and functional maturation of activated HSC and that Smad3 is a direct 
mediator of matrix production in activated HSC. Interestingly, MFB which produce high 
amounts of matrix are insensitive towards TGF-β and devoid of phosphorylated Smad3 
[Dooley et al., 2001]. Hence, given the prominent role of Smad3 in mediating the 
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pathobiology of fibrotic diseases, inhibition of Smad3 signalling could be a prime target for 
intervention in fibrotic conditions [Uemura et al., 2005; Schnabl et al., 2001].  
 
1.3.3. Further cytokines involved in hepatic fibrosis 
 
Beside TGF-β1, several other members of the TGF-β-superfamily have been shown to be 
involved in the process of fibrosis. Platelet-derived growth factor (PDGF) is the most potent 
mitogen for HSC, mainly produced by Kupffer cells and is up-regulated in the fibrotic liver 
[Pinzani et al., 1989]. PDGF inhibition attenuates experimental liver fibrogenesis [Borkham-
Kamphorst et al., 2004]. Adipokines, which are cytokines mainly derived from the adipose 
tissue are also involved in the regulation liver fibrogenesis. Leptin is required for HSC 
activation and fibrosis development [Marra, 2007; Ikejima et al., 2002; Saxena et al., 2004]. 
In contrast, adiponectin markedly inhibits liver fibrogenesis in vitro and in vivo [Kamada et 
al., 2003]. The actions of these cytokines may explain why obesity influences fibrosis 
development in patients with chronic hepatitis C [Ortiz et al., 2002]. Angiotensin II is the 
effector peptide of the renin-angiotensin system, which is a major regulator of arterial 
pressure homeostasis in humans. Key components of this system are locally expressed in 
chronically injured livers, and activated HSC de novo generate angiotensin II [Paizis et al., 
2002; Bataller et al., 2003a]. Importantly, pharmacological and/or genetic ablation of the 
renin-angiotensin system markedly attenuates experimental liver fibrosis [Kanno et al., 2003; 
Jonsson et al., 2001; Paizis et al., 2001; Ramalho et al., 2002; Wei et al., 2000]. Angiotensin 
II induces hepatic inflammation and stimulates an array of fibrogenic actions in activated 
HSC, including cell proliferation, cell migration, secretion of proinflammatory cytokines, and 
collagen synthesis [Bataller et al., 2000; Bataller et al., 2003b; Bataller et al., 2003c]. In 
addition it is critical to note, that the endoglin expression in endothelial cells and in cardiac 
fibroblasts is upregulated by angiotensin II [Chen et al., 2004]. 
 
1.4 The auxiliary TGF-β receptor endoglin (CD105) 
 
1.4.1 Structure of the transmembrane receptor endoglin 
 
CD105 is expressed on the cell surface as a 180 kDa homodimeric transmembranal protein, 
first isolated by immunoaffinity purification from HOON pre-B leukemic cell line using the 
monoclonal antibody 44G4 [Gougos and Letarte, 1988a]. CD105 was purified from human 
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placenta as a glycoprotein since it binds to ricinus communis agglutinin, wheat germ 
agglutinin [Gougos and Letarte, 1990]. It has a disulfide-linked extracellular region and a 
short, constitutively phosphorylated cytoplasmic tail [Yamashita et al., 1994; Koleva et al., 
2006]. The extracellular domain binds TGF-β1 and 3 isoforms with high affinity [Cheifetz et 
al., 1992; Barbara et al., 1999]. There have been two endoglin splice variants (S and L) 
identified. The predominantly expressed L-form consists of an extracellular domain of 561 
amino acid (aa) residues, a single transmembrane domain of 25 aa and a short intracellular 
domain of 47 aa, while the S-endglin comprises a 14 aa cytoplasmic region [Bellon et al., 
1993] (Fig 5). The S-form is expressed in a variety of mouse tissues and has in contrast to the 
L-form an antiangiogenic function [Perez-Gomez et al., 2005]. Whereas the extracellular 
ligand binding domain of endoglin shows only low homology to betaglycan, the cytoplasmic 
domain of endoglin is 70% homologous to betaglycan, leading to the interaction with 
common binding partners like β-arrestin 2 by this domain [Cheifetz et al., 1992; Chen et al., 
2003; Meurer et al., 2005; Lee and Blobe, 2007]. Endoglin and betaglycan differ widely in 
their cellular distribution and functionally they appear to have opposing effects [Letamendía 
et al., 1998]. The human endoglin sequence contains an RGD tripeptide, which is missing in 
the mouse and rat orthologues [Ge and Butcher, 1994; Meurer et al., 2005]. The presence of 
RGD, a key recognition structure in cellular adhesion, suggests a critical role for endoglin in 
the binding of endothelial cells to integrins and/or other RGD receptors [Gougos and Letarte, 
1990].  
 
 
 
Figure 5: Schematic representation of the full length- and soluble endoglin structure. The human full length 
endoglin receptor comprises 625 amino acids (aa) including a extracellular ligand binding domain (blue), a 
transmembranal domain (purple) and an intracellular domain (red). In the extracellular domain of the human 
ortholog there is a RGD tripeptide located, which is not present in the rat and the mouse endoglin. Putative N-
glycosylation sites are indicated by yellow circles. In the C-terminal domain a serine is indicated which is 
phosphorylated by the TGF-β receptor II. The soluble endoglin comprises only the extracellular domain and is 
shedded by a specific yet unknown protease in a membrane proximal part. It consists of 553 aa. 
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The most conserved regions of CD105 are the transmembrane and cytoplasmic domain, with 
95% identity between human and murine forms, which strongly suggests that the cytoplasmic 
domain of CD105 interacts with other intracellular proteins and is likely to be involved in the 
transduction of signals associated with the TGF-β receptor system [Ge and Butcher, 1994; St.-
Jacques et al.,1994]. In addition to these genomically encoded variants of endoglin it has been 
detected a soluble form of endoglin with a high diagnostic potential in preeclampsia [Lopez-
Novoa, 2007] (Fig. 5). The soluble endoglin is released from the cells by posttranslational 
modification of the membrane receptor by proteolytical cleavage of the extracellular domain 
[Llorca et al., 2007] facilitated by a yet unknown protease. 
 
1.4.2 Expression of endoglin 
 
CD105 was discovered by Letarte's group during staining of  a variety of human tissue 
sections (lymph node, tonsil, spleen, thymus, kidney, lung, and liver) using mab 44G4, which 
was produced against a human pre-B leukemic cell line. The antibody was strongly reactive 
with vascular endothelium [Gougos and Letarte, 1988a; Gougos and Letarte, 1988b] while the 
other cell types observed in these tissues were unreactive. Cells from some patients with non- 
T cell acute lymphoblastic leukaemia reacted weakly with this antibody, most of T cell acute 
lymphocytic leukaemia were negative [Gougos and Letarte, 1988a]. In contrast to HIVEC 
(Human Iliac Vein Endothelial Cells), murine platelets do not express endoglin. In addition, 
murine platelets do not express betaglycan as revealed by TGF-β1 crosslinking studies 
[Hoying et al., 1999]. Endoglin is expressed in stromal cells in vivo [St.-Jacques et al.,1994; 
Balza et al., 2001], in syncytiotrophoblasts [Kruse et al., 1999], developing bone marrow 
[Rokhlin et al., 1995; Barry et al., 1999]. Moreover, expression of endoglin was detected in 
basal epidermal keratinocytes [Quintanilla et al., 2003], in monocytes/macrophages from 
different tissue compartments and at different stages of differentiation [Lastres et al., 1992], 
vascular smooth muscle cells [Adam et al., 1998] and human as well as rat mesangial cells 
[Rodriguez-Barbero et al., 2001]. In the liver, expression of endoglin is confined to HSC, 
Kupffer cells and sinusoidal endothelial cells, but is not expressed in hepatocytes [Meurer et 
al., 2005, and manuscript in preparation]. 
1.4.3 Regulation of endoglin expression 
Hypoxia is a common feature of ischemic tissues and tumors. It has been shown that hypoxia 
is a potent stimulator of CD105 gene expression in vascular endothelial cells and this effect is 
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potentiated in the presence of TGF-β1 [Sanchez-Elsner et al., 2002]. It was found that the 
CD105 promoter is 2.6 kb in length but does not contain TATA or CAAT transcription 
initiation boxes. However, it has two GC-rich regions, consensus motifs for Sp1, ETS, 
GATA, Ap-2, NFκB, and Mad, as well as TGF-β response elements [Rius et al., 1998; 
Botella et al., 2001]. The basal level of transcription appears to require ETS and Sp1 sites, but 
the relative restriction of expression, to endothelial cells, appears to involve multiple 
regulatory regions [Graulich et al., 1999]. CD105 is up-regulated by TGF-β requiring  a 
critical Sp1 site upstream of SBE sites binding Smads 3 and/or Smads4 which are activated by 
TGF-β signalling [Botella et al., 2001]. As mentioned before, endoglin expression is also 
upregulated by angiotensin II [Chen et al., 2004]  
1.4.4 Endoglin function and its association with vascular dysfunction 
1.4.4.1 Endoglin function in TGF-β signaling 
Most of the knowledge about the physiological role of endoglin has been derived from the 
human disease hereditary haemorrhagic telangiectasia (HHT). The clinical symptoms of HHT 
include bleeding from the nose, mouth, tongue, gastrointestinal tract, lungs, skin, and, less 
frequently, other organs. Other symptoms of HHT include shortness of breath, fatigue, 
strokes, transient ischemic attacks (TIAs), brain abscesses, migraine headaches, and chronic 
anemia. Currently, it is estimated that liver involvement occurs in 8% to 31% of patients 
affected by HHT. Thirty percent to 50% of those remain asymptomatic. Thus, the true 
prevalence of the disease is unknown [Larson, 2003; Gallione et al., 2004]. There are four 
diagnostic criteria [Larson, 2003]. If three or four are met, a patient has definite HHT, while 
the appearance of two gives a possible diagnosis: 
1. Spontaneous recurrent epistaxis 
2. Multiple telangiectasias on typical locations 
3. Proven visceral arteriovenous malformation (AVM) in lung, liver and brain 
4. First-degree family member with HHT 
It has been recognized that HHT-1 patients suffer from haploinsufficiency of endoglin due to 
defects in the corresponding gene [McAllister et al., 1994]. The finding that HHT-2 patients, 
having mutations in the ALK-1 gene [Johnson et al., 1996], and display a similar phenotype 
compared to the HHT-1 patients, led to the hypothesis that both receptors act in the same 
signaling pathway. The molecular nature of these defects have been derived from the 
corresponding endoglin and ALK-1 deficient mouse models. The Eng-null mice die at mid 
gestation from defective angiogenesis and severe cardiovascular abnormalities, while the 
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heterozygous mice have normal life spans and are predisposed to develop HHT-1-like 
vascular abnormalities [Srinivasan et al., 2003; Bourdeau et al., 1999]. By analysis of these 
models it was demonstrated that endoglin is a component of the TGF-β signaling pathway 
[Fernandez et al., 2006]. It was shown that endoglin promotes the ALK-1 pathway and 
inhibits the ALK-5/Smad3 dependent signaling in endothelial cells [Lebrin et al., 2004]. This 
inhibitory function of endoglin on the ALK-5/Smad3 mediated responses to TGF-β have now 
been established in other systems, including fibroblasts and L6E9 cells as a model system for 
TGF-β signaling [Letamendia et al., 1998; Chen et al., 2004; Obreo et al., 2004; Scherner et 
al., 2007]. 
 
1.4.4.2 Endoglin function in angiogenesis 
 
A study with an antisense approach has demonstrated that suppression of CD105 expression 
in human umbilical vein endothelial cells (HUVEC) resulted in marked inhibition of in vitro 
angiogenesis in the presence of TGF-β. Thereby, it was suggested that CD105 is a 
proangiogenic component in endothelial cells [Fernandez et al., 2006]. Moreover, as 
mentioned above CD105 knock out mice exhibit multiple vascular and cardiac defects in the 
form of failure of primitive vascular plexus of the yolk sac to remodel into mature vessels, 
causing vascular channel dilation, rupture, and haemorrhage, failed endocardial cushion 
formation, pericardial edema, leading finally to death at an early embryonic stage [Bourdeau 
et al., 1999; Fernandez et al., 2006]. Owing to the observations that CD105 is strongly up-
regulated in the endothelium of various tumour tissues compared with that in the normal 
tissues, it was proposed that endoglin may be associated with tumour angiogenesis [Burrows 
et al., 1995; Takahashi et al., 2001a]. The discrepancies in intensity of immunological tissue 
staining between different monoclonal antibodies (mabs) could be explained in several ways, 
such as the criteria for grading, the negative and positive control used, the specific epitopes 
recognised by the mabs, and the definition of normal tissue. In general, these mabs revealed 
an increased expression of CD105 in tumour endothelium than corresponding normal tissues 
[Kumar et al., 1999; Fonsatti et al., 2001].  
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1.4.4.3 Endoglin as a biomarker for clinical conditions 
1.4.4.3.1 Endoglin and anti-angiogenic strategies 
 
Due to these characteristics, CD105 represents an ideal target for antiangiogenic tumour 
therapies. However, it is difficult to test these using in vivo animal tumour models, because 
most anti-CD105 antibodies do not react with the vasculature in engrafts of human tumours, 
due to the fact that endothelial cells in the transplanted tumours are derived from the host’s 
blood vessels. Seon’s group has partially overcome this problem by developing a series of 
anti-CD105 antibodies that cross-react weakly with murine CD105 [Matsuno et al., 1999; 
Tabata et al., 1999; Takahashi et al., 2001b]. Their studies have demonstrated long-lasting 
complete abrogation of human breast tumors in SCID mice using mab to CD105 conjugated 
to immunotoxins [Tabata et al., 1999] and growth suppression of human solid tumors using a 
radiolabeled mab to CD105 [Seon et al., 1997; Tabata et al., 1999]. They have observed 
synergism between naked anti-CD105 antibodies and conventional chemotherapeutic 
schedules in a human skin/SCID mouse chimera model [Seon et al., 1997]. By using 99Tcm-
labeled mab E9, they have shown specific localization of the labeled antibody in the tumour 
vasculature of the kidneys [Duff et al., 2003] (Fig. 6).  
 
Figure 6: Tumour imaging using labeled mab to CD105. After perfusion of a kidney from a patient with renal 
cell carcinoma using 99Tcm mab E9, immunoscintigraphy clearly shows two hot spots of radioactivity. Although 
a pre-surgery MRI scan found only one tumor mass (a), the histopathology report identified two tumors—one 
corresponding to “a” and another, a well-vascularized 0.75 cm diameter tumor “b” (b). These findings strongly 
indicate that 99Tcm-labeled mab E9 should be useful for detection of occult metastatic disease that conventional 
imaging modalities are unable to locate [taken from Duff et al., 2003].  
 
 
1.4.4.3.2 CD105 as a marker for tumor imaging and tumor prognosis 
 
1.4.4.3.2.1 Transmembrane endoglin 
 
Early studies suggest that the use of radiolabeled antibodies against CD105 is a feasible 
approach for immunoscintigraphy of tumors. The overexpression of CD105 in the 
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proliferating endothelium and its location on the luminal surface make it an ideal target for 
tumor detection by an antibody and thereby selecting the patients who would have a benefit 
from the antiangiogenic therapy. Pharmacokinetics demonstrated that 97% of the injected 
dose of anti-CD105 was removed from the circulation within 15 min and the blood half–life 
was less than 1 min. Optimization of imaging an endothelial target requires that the 
background blood pool activity and ligand extravasation is minimized. This can be achieved 
by using small doses. Autoradiography and immunohistology showed that anti-CD105 
accumulated at the tumor edge (Fig. 6), where the highest density of blood vessels was found 
[Bredow et al., 2000].  
 
1.4.4.3.2.2 Soluble circulating endoglin 
 
Circulating sCD105 was marked elevated in plasma samples of breast cancer patients 
compared with healthy controls, and sCD105 was significantly increased in those patients 
who subsequently developed distant metastasis [Burrows et al., 1995; Kumar et al., 1999]. In 
blood samples from patients with colorectal, breast, lung and other cancers with metastasis, 
sCD105 had significantly elevated levels in comparison with metastasis-negative individuals 
and healthy controls. Chemotherapy significantly reduced the level of CD105 [Kumar et al., 
1999]. 
1.5 Diagnosis of liver fibrosis 
In general hepatic fibrosis can be estimated by imaging techniques. Ultrasonography, 
computed tomography, and MRI can detect changes in the hepatic parenchyma due to 
moderate to severe fibrosis [Hirata et al., 2001]. Due to its low cost, ultrasonography is an 
appealing technique. It is able to detect liver cirrhosis based on changes in liver echogenicity 
and nodularity as well as signs of portal hypertension. However, ultrasound is highly 
operator-dependent, and the presence of increased liver echogenicity does not reliably 
differentiate hepatic steatosis from fibrosis.  
Liver biopsy is considered now the gold-standard method for the assessment of liver fibrosis 
[Afdhal and Nunes, 2004]. Histologic examination is useful in identifying the underlying 
cause of liver disease and assessing the necroinflammatory grade and the stage of fibrosis. 
Fibrosis stage is assessed by using scales such as Metavir (stages I–IV) and Ishak score 
(stages I–V) [Bedossa and Poynard, 1996; Ishak et al., 1995]. Specific staining of ECM 
proteins (e.g., with Sirius red) can be used to quantify the degree of fibrosis, using computer-
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guided morphometric analysis. Liver biopsy is an invasive procedure, with pain and major 
complications (as bleeding) that may occur in 40% and 0.5% of patients, respectively 
[Thampanitchawong and Piratvisuth, 1999]. Sampling error can occur, especially when small 
biopsies are analyzed. Histologic examination is prone to intra- and interobserver variation 
and does not predict disease progression [Regev et al., 2002; Guido et al., 2004]. Therefore, 
there is a need for reliable, simple, and non-invasive methods that include routine laboratory 
tests, such as platelet count, aminotransferase serum levels, prothrombin time, and serum 
levels of acute phase proteins for assessing liver fibrosis scores have been proposed [Imbert-
Bismut et al., 2001; Forns et al., 2002]. Serum levels of proteins directly related to the hepatic 
fibrogenic process including N-terminal propeptide of type III  collagen, hyaluronic acid, 
tissue inhibitor of metalloproteinase type 1 (TIMP-1) could be used as markers of liver 
fibrosis [Fontana and Lok, 2002]. On the other hand, Fibrosis-specific markers may reflect 
fibrogenesis in other organs (i.e., pancreatic fibrosis in alcoholic patients). Although these 
scores are useful in detecting advanced fibrosis (cirrhosis) in patients, as well as minimal or 
no fibrosis, they are not effective for differentiating intermediate grades of fibrosis. These 
tests give the physician an alternative before going straight to a liver biopsy, and are sensitive 
to changes associated with disease progression and/or response to therapy. They provide an 
effective means for more frequent monitoring as compared to a biopsy. Efforts are made to 
find the suitable new blood protein marker. 
 
1.5.1 α-fetoprotein and chronic liver disease 
 
α-fetoprotein (AFP) is a fetal protein produced during the embryonic period by the visceral 
endoderm of the gestational sac and, later on, by the liver. Its re-expression in patients with 
HCC has been described first over 40 years ago. Some studies have demonstrated that the 
presence of elevated levels of AFP in patients with liver cirrhosis is a risk factor for the 
development of HCC [Harada et al., 1980; Arrieta et al., 2006] thus suggesting that increased 
AFP-production in patients with liver cirrhosis might reflect, largely and abnormal or altered 
liver cell regeneration. 
Although screening for HCC in patients with liver cirrhosis includes assessing AFP, the use 
of ultrasound and a variety of other radiological techniques and at present, assessment of AFP 
levels in conjunction with ultrasound is the “gold standard” for screening of high-risk patients 
[Pateron et al., 1994]. It was found that AFP is produced by only 40%-75% of HCCs and AFP 
serum concentrations are also elevated during pregnancy, in germ-cell tumours, in diseases 
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such as ataxia telangiectasia, hereditary tyrosinaemia and teratocarcinoma. Elevation in 
benign hepatic diseases, such as acute or chronic hepatitis, is usually transient [Zhou et al., 
2006; Tong et al., 2001]. Therefore, the clinical application of HCC diagnosis by AFP 
assessment is limited, especially for the early cancer stages [Sherman, 2001; Yuen and Lai, 
2005]. The reported diagnostic value of AFP for detecting HCC varies widely (sensitivity of 
39-97%, specificity of 76-95%, and a positive predictive value of 9-32%) when used for 
screening of high-risk populations [Sherman et al., 1995; Gebo et al., 2002]. Thus, early 
identification of HCC in high-risk patients who are at a potentially curable stage is still an 
unresolved clinical problem. 
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 1.6 Aim of the study 
 
It is known that liver cirrhosis is considered as a premalignant state for developing a HCC, 
since about 80% of HCC is associated with liver cirrhosis. Identification of HCC in high-risk 
patients is still an unresolved clinical problem. Therefore the aim of this study was focused on 
two topics : 
1. To analyse the diagnostic potential of soluble endoglin in serum of patients with liver 
cirrhosis at a high-risk to develop a hepatocellular carcinoma. Therefore, the sCD105 
should be measured in patients without disease, with fibrosis, cirrhosis, cirrhosis in 
combination with HCC or HCC as the sole pathologic event. Because of the low 
abundance of soluble endoglin, being present in nanomolar concentrations, the 
measurement will be performed with a commercially available ELISA for the 
detection of human endoglin.  
2. To determine the functional relevance of the soluble endoglin in the serum, which is 
currently under debate. It should be clarified, if the soluble domain of endoglin indeed 
is able to influence TGF-β signalling. For this purpose the extracellular domain of rat 
endoglin should be cloned and heterologously overexpressed. If the secretion of this 
extracellular domain is accomplished, the respective construct will be used in TGF-β 
sensitive cells to evaluate the functional impact of soluble endoglin on Smad3 
dependent TGF-β signaling. 
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2 Material and Methods  
2.1 Material 
2.1.1 Human serum samples 
2.1.1.1 Patients 
 
Blood samples were taken from 121 patients with chronic liver diseases [CLD]. With respect 
to the gender there were 79 males and 42 females. Patients were subdivided into liver fibrosis 
subgroup (19 patients); liver cirrhosis subgroup (57 patients); liver cirrhosis plus HCC 
subgroup (45 patients) and 9 patients with hepatocellular carcinoma (HCC) without suffering 
from liver cirrhosis. The patients were admitted to the Department of Medicine III and 
Gastroenterology at the University Hospitals in Aachen and Regensburg (Germany). The 
serum was separated from the samples, and was stored in aliquots at – 80°C. Patients with 
liver fibrosis had persisting high aspartate-aminotransferase and alanine-aminotransferase 
levels for more than 6 months but were negative for markers of viral hepatitis. Patients were 
diagnosed using ultrasound-guided liver biopsy. Liver specimens were analysed in a blinded 
fashion, by an experienced pathologist according to the score proposed by Batts and Ludwig, 
1995. The diagnosis of liver cirrhosis was based on clinical findings, regular laboratory and 
ultrasound analysis. The patients did not show any ultrasound and radiological signs of HCC. 
Computed tomography (CT) scans were performed in 35 patients with liver cirrhosis. 
Informed consent was obtained from the participants in the study. 
 
2.1.1.2 Control group 
 
The control group consisted of 70 blood donors from the Department of Transfusion Medicine 
at the University Hospital Aachen. The healthy volunteers had normal levels of amino-
transferases, normal blood counts and negative markers for viral hepatitis and HIV.  
Another control group consisted of 94 non-liver-diseased patients. The five most frequent 
diagnoses in the this group were non-malignant, cardiovascular, pulmonary, gastropancreatic 
and bowel diseases. Such an inhospital control population was selected, as recommended, to 
minimize bias [Schultz and Grimes, 2002a; 2002b]. 
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2.1.2 Chemicals 
Chemicals  Providers 
Albumin (Cat N. 17-0442A) Amersham Pharmacia-Biotec,  
[as a standard protein for FPLC] Uppsala, Sweden 
Acetic acid (glacial) Merck, Darmstadt, Germany 
Aceton  Merck, Germany 
Agarose Sigma, Taufkirchen, Germany 
Albumin (BSA) Sigma, Taufkirchen, Germany 
Ammonium acetate Merck, Hohenbrunn, Germany 
Ampicillin Sigma, Taufkirchen, Germany 
BactoTMAgar Becton & Dickinson, USA 
BactoTMPeptone  Becton & Dickinson, USA 
BactoTMYeast Extract  Becton & Dickinson, USA 
Bio-Rad protein assay Bio-Rad laboratories, Hercules, CA, USA 
Bicin  AppliChem, Germany 
Bis-Tris  AppliChem, Germany 
Blue Dextran 2000 (Cat N17-0441E) Amersham Pharmacia-Biotec,  
 Uppsala, Sweden 
BM blue POD  Roche, Mannheim, Germany 
Boric acid  Merck, Hohenbrunn, Germany 
Bromphenol blue  Serva, Heidelberg, Germany 
BSA  Sigma, Germany 
Calcium chloride dehydrate  Merck, Hohenbrunn, Germany 
Catalase (Cat N. 17-0441) Amersham Pharmacia-Biotec,  
 Uppsala, Sweden 
Chlorobutanol  Fluka, Swiss 
Chloroform J. T. Baker, Deventer, The Netherlands 
Collagen type I  Becton & Dickinson, USA 
Collagenase Roche, Germany 
Complete Protease Inhibitor Cocktail  Roche, Germany 
Coomassie Brilliant Blue Serva, Heidelberg, Germany 
Dimethylsulfoxide (DMSO)  Fluka, Swiss 
Deoxycholate (DOC) Merck, Darmstadt, Germany 
di-Sodium hydrogen phosphate Merck, Darmstadt, Germany 
Dithiotreitol (DTT) Carl Roth GmbH, Karlsruhe, Germany 
EDTA  Merck, Darmstadt, Germany 
Ethanol  Merck, Darmstadt, Germany 
Ethidium bromide Sigma, Taufkirchen, Germany 
Ferritin (Cat N. 17-0441) Amersham Pharmacia-Biotec,  
 Uppsala, Sweden 
Ficoll 400  Pharmacia, Bromma, Sweden 
Fugene6TM  Roche, Germany 
Glucose Sigma, Taufkirchen, Germany 
Glycerol Merck, Darmstadt, Germany 
Glycine Merck, Darmstadt, Germany 
guanidine hyhrochloride Sigma, Taufkirchen, Germany 
Guanidine thiocyanate Sigma, Taufkirchen, Germany 
Gel filtration standard (Nr.151-1901) Bio-Rad laboratories, Hercules, CA, USA 
(composed of Thyroglobluin; Ig G;Ovalalbumin: 
Myoglobulin;& Cynacoblamin(Vit B12) 
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Hydrochloric acid 32% Merck, Darmstadt, Germany 
Isoamylalcohol  Merck, Germany 
Isopropanol  Merck, Germany 
Lithium chloride Sigma, Taufkirchen, Germany 
Lipofectamine  Invitrogen, USA 
L-Tyrosine (Cat. N8371) Merck, Germany 
Magnesium chloride hexahydrate  Merck, Darmstadt, Germany 
Magnesium sulfate heptahydrate Merck, Darmstadt, Germany 
Mangnesium chloride Merck, Darmstadt, Germany 
Methanol RWTH, Aachen, Germany 
Milk powder (non fat)  Roth, Germany 
MOPS Sigma, Taufkirchen, Germany 
2-Mercaptoethanol Fluka Biochemika, Germany 
NP-40  Roche, Germany 
Nycodenz® Nycomed Pharma AS, Oslo, Norway 
Paraffin oil Caesar & Loretz, Hilden, Germany 
PBS Dulbecco without Ca2+/Mg2+ Biochrom AG, Berlin, Germany 
Phenol  Sigma, Germany 
Phosphatase Inhibitor Cocktail 2  Fluka, Swiss 
Protein-G Plus agarose  SantaCruz, USA 
Polyethylenglycol Sigma, Taufkirchen, Germany 
Polyvinyl pyrrolidone Sigma, Taufkirchen, Germany 
Ponceau-S Sigma, Taufkirchen, Germany 
Potassium acetate Merck, Darmstadt, Germany 
Potassium chloride Merck, Darmstadt, Germany 
Potassiumdihydrogenphosphate  Merck, Germany 
Dipotassiumhydrogenphosphate  Merck, Germany  
Pronase E Merck; Darmstadt, Germany 
Roti-Phenol Carl Roth GmbH & Co 
 Karlsruhe, Germany 
Rubidium chloride Sigma, Taufkirchen, Germany 
Sodium acetate Merck, Darmstadt, Germany 
Sodium azide  Merck, Germany 
Sodium hydrogencarbonate Merck, Darmstadt, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium dihydrogen phosphate Merck, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS)  Bio-Rad Laboratories,  
 Hercules, CA, USA 
Sodium hydroxide 50% solution  Merck, Darmstadt, Germany 
Sodium hydroxide pellets Merck, Darmstadt, Germany 
Sulfuric acid Merck, Darmstadt, Germany 
Supersignal Chemiluminescent Substrate Pierce, Rockford, IL, USA 
Trichloroacetic acid (TCA) Carl Roth GmbH & Co 
 Karlsruhe, Germany 
tri-Sodiumcitrate-dihydrate Merck, Darmstadt, Germany 
Triton X-100 Fluka Biochemika, Neu-Ulm, Germany 
TRIZMA® Base Sigma, Taufkirchen, Germany 
Tryptone phosphate broth DIFCO, USA 
Tween 20 Merck, Hohenbrunn, Germany 
Xylene Merck, Darmstadt, Germany 
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2.1.3 Disposable material 
Products  Providers 
Autoclave bags  Roth, Germany 
Centri-Sep columns for sequencing  Princeton Separations, Adelphia, NJ, USA 
Cryo tubes  Nunc, Denmark 
Culture plates: 6-well Nunc, Germany 
Cuvetts for nucleic acid  Carl Roth GmbH, Karlsruhe, Germany 
Cuvetts for protein and bacteria (6774) Sarstedt, Nuembrecht, Germany 
Dialysis bags (Visking® 44101) Serva, Heidelberg, Germany 
Dialysis clips  Spectrum Medical Industries.USA 
ELISA 96-well plates (C8 Maxisorp 445101) Nunc, Wiesbaden, Germany 
Falcon centrifuge tube (15,50 ml) Greiner bio-one, Frickenhausen, Germany 
Filter units Sartorius AG, Göttingen, Germany 
F16 BlackMaxisorp 96 Wells  Nunc, Denmark 
Plastic wrap, SARAN WRAP  SARAN, USA  
Gauze bandage  Fuhrmann Verbandstoffe, Deutschland 
Gloves, semper med  Semperit technical products, Austria 
GSA beaker Beckman, Munich, Germany 
Low protein binding tubes  Eppendorf, Germany 
Microreaction tube (1.5 ml) Sarstedt, Nuembrecht Germany 
Microreaction tube (2 ml)  Sarstedt, Germany 
Microvette® (Monovette for new born) Sarstedt, Nuembrecht, Germany 
Microwell black 96-wells plates (475515) Nunc, Nidderau, Germany 
Nunc Cryotube 1.8 ml (363401) Nunc, Intermed, Denmark 
Pasteur pipettes Faust, Germany 
Peleusball  Faust , Germany 
Petri dishes (for bacterial culture, 821473) Sarstedt, Nuembrecht, Germany 
Petri dishes (for cell culture, 831802) Sarstedt, Nuembrecht, Germany 
Pipette 1 ml, 2 ml, 5 ml,10 ml, 25 ml Falcon, Germany 
Pipette Tipps, 1-20 µl, 200 µl, 1000 µl Sarstedt, Nuembrecht, Germany 
PP-tubes, 15 ml, 50 ml  Greiner, Germany 
Polyallomer Centrifuge Tubes (328874) Beckman, Munich, Germany 
Protran® membrane (0.22 µm) Schleicher & Schuell, Dassel, Germany 
Scalpel Feather Safety Razor Co, Japan 
Whatman 3MM chromatography paper Whatman, Kent, UK 
µMACS beads ProteinG (130.071.101) Miltenyi Biotec, Bergisch Gladbach, 
Germany 
MACs multistand (130-42-602) Miltenyi Biotec, Bergisch Gladbach, 
µMACS colums (130.042.701) Germany 
 
2.1.4 Kits for assays 
System      Provider 
Bigdye Terminator Cycle Sequencing  Applied Biosystems, USA 
Ready reaction kit 
Bradford Protein assay    Bio-Rad, USA 
DC Protein Assay     Bio-Rad, USA  
Human Endoglin ELISA    R&D Systems, USA 
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BCA Protein assay     Pierce 
QIAquick Gel Extraction kit    Qiagen, Germany 
RNeasy Mini Kit     Qiagen, Germany 
Steady-Glo-Luciferase Assay System  Promega, USA 
SuperScript Reverse Transcriptase AMV Kit Roche, Germany 
High Fidelity PCR System     Roche, Germany 
NuPage Bis-Tris precast gels (10 %, 4-12 %) Invitrogen, USA 
NuPage® Tris-Acetate precast gels (3-8 %)  Invitrogen, USA 
NuPage® LDS-sample buffer    Invitrogen, USA 
NuPage® transfer buffer    Invitrogen, USA 
 
2.1.5 Technical equipement 
System        Provider 
ABI 310 Genetic Analyzer       Aplied Biosystems, USA 
Agarosegel-Electrophoresisystem DNA Pocket Bloc-UV  Biozym, Germany 
Beckmann Avanti™J-15 centrifuge     Beckman Coulter, USA 
Beckman Optima L-70k Ultracentrifuge    Beckman Coulter, USA 
Cell culture lamina flow Hera safe, HS 12 and HSP 12  Heraeus, Germany 
Gel jet imager (computer device)     Lot-Oriel , Germany 
INTAS digital graphic printer UP-D895    INTAS, Germany 
INTAS GDS software      INTAS, Germany 
Transilluminator CN-UV/WL Vilbert-Lourmat   MWG-Biotech 
Ice facility        Ziegra,Germany  
Heraeus Biofuge 15R table top centrifuge    Heraeus, Germany  
Heraeus Biofuge primo table top centrifuge    Heraeus, Germany 
Lumi-ImagerTM ECL-Documentationsystem   Boehringer, Germany  
LumiAnalyst 3.0 software      Boehringer, Germany 
Microbeta 1450 Jet Liquid Scintillation & Luminescence Counter PerkinElmer, USA 
Microscope Axiovert 135 M      Zeiss, Germany 
Microskoce Leica DMLB      Leica, Germany 
MilliQ water destillation system     Millipore, France 
PCR-Automat Biometra T3 (Thermocycler)    Biometra, Germany 
pH-Meter        WTW, Germany 
Pipette 10 µl, 20 µl, 200 µl, 1000 µl     Eppendorf, Germany 
Sartorius 1212MP scale      Sartorius, Germany 
Sartorius 1364MP scale      Sartorius, Germany  
Shaker Biometra WT16      Biometra,Germany 
Speed Vac concentrator      Fa. Savant 
Powersupply PAC 300      Bio-RAD, USA     
Spectrophotometer Cary 50 Probe UV-Visible   Varian, USA  
Thermomixer 5436       Eppendorf, Germany 
Overhead tumbler       Heidolph, Germany 
VictorTM 1420 Multilabel Counter     Turku, Finland 
Vortexer Vortex Genie2      Fisher Scientific, USA 
XCell Blot Module       Invitrogen, USA 
XCell SureLock™ Mini-Cell      Invitrogen, USA 
FPLC(Äkta Purifier) Amersham 
Pharmacia Biotec, Sweden 
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2.1.6 Biochemical material 
 
2.1.6.1 Enzymes 
Restriction enzymes     Providers 
EcoR I       Roche, Germany 
Not I       Roche, Germany 
 
Other enzymes      Providers 
 
T4-DNA-Ligase     Roche, Germany 
Expand high fidelity PCR system   Roche, Germany 
Klenow enzyme     Roche, Germany 
Lysozyme      Sigma, Germany 
RNase A      Roche, Germany 
Taq DNA-polymerase    Roche, Germany 
Trypsin      Roche, Germany 
 
Enzyme buffers      Providers 
Restriction enzyme buffers: 
A-Buffer (10x)                                                     Roche, Germany 
B-Buffer (10x)                                                    Roche, Germany 
H-Buffer (10x)                                                     Roche, Germany 
L-Buffer (10x)                                                     Roche, Germany 
M-Buffer (10x)                                                     Roche, Germany 
  
2.1.6.2 Antibodies 
 
Primary antibodies were detected with the corresponding secondary antibody conjugated to 
HRP. Blots were developed by using the Supersignal chemiluminescence deection system or 
alternatively by using the chromogen Fast Red stain. 
 
2.1.6.2.1 Primary antibodies 
 
antibody species provider   epitope  clonality 
 
MAB1097 mouse  R&D systems   human CD105 monoclonal 
MAB10972 mouse  R&D systems   human CD105 monoclonal 
sc-6199 goat  SantaCruz   human Betaglycan polyclonal 
PPabE1 rabbit  Davids Biotechnology rat CD105  polyclonal 
sc-1060 goat  SantaCruz   human HSP70  polyclonal 
A5441  mouse  Sigma    β-actin   monoclonal 
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2.1.6.2.2 Secundary antibodies 
 
antibody species provider   epitope  conjugate 
SC-2055 goat  SantaCruz   mouse   HRP 
SC-2056 donkey SantaCruz   goat   HRP 
SC-2007 goat  SantaCruz   rabbit   HRP 
BA-9200 goat  Vector Laboratories  mouse   Biotin 
 
P 0397  Streptavidin DAKO   Biotin   HRP 
 
2.1.6.3  Cytokines 
 
Cytokine        Provider 
rhTGF-β1        R&D systems, USA 
 
2.1.6.4  Protein Size Marker 
Material        Provider 
SeeBlue Plus2 Pre-stained Standard     Invitrogen, USA 
 
2.1.7 Molecular biological material 
2.1.7.1 Primers 
 
Gene Acc. No. Primer Provider MWG Biotech AG, Ebersberg, Germany 
rendoglin AY562420 forward SM012 5’-d(CTC CCG GGT GGA CAG C)-3’ 
rendoglin AY562420 reverse SM091 5’-d(GCG GCC GCT CAG CCA GAC AGG 
TCA GGA C)-3’ 
rendoglin AY562420 Forward SM010 5’-d(CAG GCA TCC AAC ACC ATA G)-3’ 
rendoglin AY562420 Reverse SM011 5’-d(CGA TGC TGT GGT TGG TAC)-3’ 
rendoglin AY562420 Forward SM014 5’-d(CCA AGG CTG CCA CTT GG)-3’ 
CMV 
Promoter 
 - Forward MA001 5’-d(AAT GTC GTA ACA ACT CCG CC)-3’ 
M13/pUC  - Forward For 5’-d(GTT TTC CCA GTC ACG AC)-3’ 
M13/pUC  - Reverse Rev 5’-d(AAC AGC TAT GAC CAT G)-3’ 
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2.1.7.2  Vectors 
Vector        reference 
(CAGA)12-MLP-Luc (Appendix 7.6)    Dennler et al., 1998 
pcDNA3.1 (Appendix 7.4)      Invitrogen, USA 
pGEM®-T Easy (Appendix 7.3)     Promega, USA 
pcDNA3.1(+)-endoglin (Appendix 7.1)    Meurer et al., 2005  
 
2.1.7.3 Molecular Size Markers 
Marker        Provider 
GeneRuler 100 bp DNA Ladder Plus    Fermentas, Germany 
Lambda λ Hind III Ladder       NEB, USA 
 
2.1.8 Cell culture 
2.1.8.1 Prokaryotic cell culture 
2.1.8.1.1 Media for prokaryotic cell culture 
Medium  component 
LB-Medium 1000 ml: 10 g Tryptone (Bacto), 5 g Yeast extract and 10 g NaCl 
desolved in 950 ml H2O and adjusted to a pH 7.4 using 1 N NaOH. The 
solution was adjusted to a volume of 1 l and autoclaved. For the agar 
medium, 15 g of agar was added, and proper antibiotics when required. 
2 x TY-Medium 1000 ml : 16 g Tryptone (Bacto), 10 g Yeast extrakt and 5 g NaCl 
desolved in 1 l H2O and autoclaved. 
 
2.1.8.1.2 Bacterial strain 
Strain       genotype 
JM105       F’traD36 laclq Δ(lacZ)M15 proA+B+/thi 
rpsL(Strr endA sbcB15 sbCC hsdR4 (r-
Km+K)Δ(lac-proAB) 
 
2.1.8.2 Eukaryotic cell culture 
2.1.8.2.1 Media for eukaryotic cell culture 
Articles      Providers 
DMEM      Bio-Whittaker Europe, Verviers, Belgium 
DMSO      EGA-Chemie, Steinheim, Germany 
FCS       Biochrom KG, Berlin, Germany 
HBSS       PAA Laboratories, Austria 
Hepatozyme      Gibco, USA 
L-Glutamin      PAA Laboratories, Austria 
Penicillin/Streptomycin    PAA Laboratories, Austria 
Trypsin solution (10x)    PAA Laboratories, Austria 
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Media       compositions 
 
Freezing medium (2x)  20 ml: 11 ml DMEM, 5 ml FCS and 4 ml 
DMSO were mixed. 
Growth medium  10 % FCS, 2 % L-Glut und 1 % Pen/Strep 
Starvation medium     0.5 % FCS, 2 % L-Glut und 1% Pen/Strep 
Stimulation medium     0.2 % FCS, 2% L-Glut und 1% Pen/Strep 
 
2.1.8.2.2 Cells 
Celltype      Origin  
COS-7       SV-40 transformed Fibroblast cell line 
 from kidney (monkey, African green) 
 ATCC® Number: CRL-1651™ 
 Cercopithecus aethiops 
CHO  Cricetulus griseus ( hamster, Chinese ) 
 ATCC® Number CCL-61   
L6E9  Myoblast cell line from thigh muscle of 
neonate rats 
rHEP       primary rat hepatocytes 
 
2.1.9 Buffers and Solutions 
 
All buffers and solutions were prepared using autoclaved MilliporeTM-water. 
Solution     composition 
Ammonium acetate (10 M) 20 ml: 15.42 g Ammonium acetate were 
dissolved in 20 ml H2O and sterilized by 
filtration. 
Ampicillin (100 mg/ml) 50 ml: 5 g Ampicillin were dissolved in 50 ml 
H2O, sterilized by filtration and stored in 1 ml 
aliquots at –20°C. 
Bromophenol blue solution 0.5% (w/v) 10 ml: 50 mg Bromophenol blue were dissolved   
in 10 ml H2O and stored at 4°C. 
CaCl2 (1 M) 100 ml: 14.7 g Ca Cl2 x 2 H2O were dissolved in 
100 ml H2O. 
Collagen solution (coating) 50 ml: 50 µl Acetic acid (100%) dissolved in 50 
ml H2O plus 1.25 ml of a 2 mg/ml concentrated 
Collagen-Stock solution.  
Coomassie Brilliant Blue stain 500 ml: 2.5 g Coomassie Brilliant Blue R-250 
were dissolved in the solution of 250 ml 
methanol, 50 ml acetic acid, and 200 ml distilled 
water. 
Decoloration buffer (for Coomassie gel) 500 ml: 150 ml Methanol, 50 ml acetic acid and 
300 ml dest H2O were mixed. 
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Glucose (1 M)  100 ml: 19.8 g Glucose x H2O were dissolved in 
100 sterile H2O, sterilized by filtration and stored 
at 4°C. 
Glycerol     Glycerol was autoclaved before use. 
HCl (1 M) 200 ml: 19.64 ml 32% HCL was dissolved in 200 
ml H2O. 
Immunoprecipitation fixing buffer (25% 2-Propanol, 10% Acetic acid) 1 l: 250 ml 2-
Propanol and 100 ml acetic acid were added to 
650 ml dest H2O. 
Immunoprecipitation washing buffer I  (0.05 M Tris-HCl, 0.15 M NaCl, 0.01 M EDTA, 
1% Triton X-100, 0.1% SDS, 1% Deoxycholate) 
1 l: 6.05 g Tris, 8.766 g NaCl, 3.72 g EDTA, 1 g 
SDS and 10 g deoxycholate were dissolved in 
800 ml dest H2O. A pH of 7.5 was established 
with HCl and the solution was filled up to 1 L 
with dest H2O. 
Immunoprecipitation washing buffer II (0.02 M Tris-HCl, 0.5 M NaCL, 1% Triton X-
100) 1 L: 2.42 g Tris, 29.22 g NaCl and 10 ml 
Triton X-100 were dissolved in 800 ml dest H2O, 
a pH of 7.5 was established with HCL and the 
solution was filled up to 1 L with dest H2O. 
Potassium acetate (5 M) 100 ml: 49.07 g Potassium acetate were dissolved 
in 100 ml H2O. 
Lithium chloride (5 M) 100 ml: 21.2 g LiCL was dissolved in 100 ml 
H2O. 
Lysozyme solution (10 mg/ml) 5 ml: 50 mg Lysozyme were dissolved in 5 ml 
0.01 M Tris-HCL (pH 8.0). The solution was 
applied immediately upon preparation. 
MgCl2 (1 M) 100 ml: 20.33 g MgCL2 x 6 H2O were dissolved 
in 100 ml H2O and autoclaved. 
MgSO4 (1 M) 100 ml: 24.6 g MgSO 4 x 7 H2O were dissolved in 
100 ml H2O and autoclaved. 
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MOPS (1 M) 100 ml: 20.93 g MOPS were dissolved in 60 ml 
H2O. A pH of 7.0 was established with 5 M 
NaOH and the solution was filled up to 100 ml 
with sterile H2O, further sterilized by filtration. 
MOPS (20 X) (1 M MOPS, 1 M TrisBase, 69.3 mM SDS und 
20.5 mM EDTA) 1000 ml: 209.2 g MOPS, 
121.12 g TrisBase, 20 g SDS und 6 g EDTA were 
dissolved in H2O ad 1000 ml.  
MnCl2 (1 M) 20 ml: 3.96 g MnCl2 x 4 H2O were dissolved in 
20 ml H2O, sterilized by filtration and stored at –
20°C. 
Net-G buffer (immunoprecipitation) (Tris-HCl 50 mM, NaCl 150 mM, NP40 0.1 % 
(v/v), EDTA 1 mM, 0.25% (v/v) Gelatine; pH 
7.4) 1000 ml: 6.07 g Tris, 8.7 g NaCl, 0.4 g 
EDTA, 1 ml NP-40 und 1 ml Gelatine were 
dissolved in 1000 ml H2O. A pH of 7.4 was 
established by HCl. 
PBS (10 x) 1 L: 11.45 g Na2HPO4, 2 g KH2PO4, 2 g KCl and 
80.0 g NaCL were dissolved in 800 ml H2O, the 
pH was approximately 7.2 without adjusting and 
filled up with H2O to 1 l. The solution was 
autoclaved or filtered sterile and stored at RT. 
Ponceau-S staining    (0.2% (w/v) Ponceau-S, 3% Trichloroacetic acid) 
500 ml: 1 g Ponceau-S and 15 g TCA were 
dissolved in 500 ml H2O. 
Potassium acetate (5 M) 500 ml: 245.38 g CH3COOH was dissolved in 
500 ml H2O. 
Protein lysis buffer (0.05 M Tris-HCL, 0.25 M NaCl, 2% (v/v) NP40, 
0.0025 M EDTA, 0.1% (w/v) SDS, 0.5% 
(w/v)deoxycholate) 1 l: 6.05 g Tris, 14.61 g NaCl 
and 0.93 g EDTA were dissolved in 800 ml dest 
H2O, 20 ml NP40, 1 g SDS and 5 g deoxycholate 
were added. A pH of 8.0 was established with 
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HCl and the solution was filled up to 1 L with 
dest H2O. 
Protein lysis buffer +   1 tablet PIC CompleteTM was dissolved in 50 ml 
proteases inhibitor cocktail (PIC)  protein lysis buffer. Aliquots of 5 ml were stored  
      at –20°C, remaining stable for up to 3 month. 
RIPA buffer (0.02 M Tris, 0.15 M NaCl, 2% NP40, 0.1% SDS, 
0.5% Sodium deoxycholate, pH 7.2) 1 l: 2.42 g 
Tris, 8.766 g NaCl, 1 g SDS and 5 g deoxycholate 
were dissolved in 800 ml dest H2O. After that 20 
ml NP40 were added. A pH of 7.2 was 
established with HCL and the solution filled up to 
1 l with dest H2O.  
RNase A solution (10 mg/ml) 5 ml: 50 mg RNase A were dissolved in 5 ml 
sterile H2O, cooked 10 min and stored in 1 ml 
aliquots at –20°C. 
Rubidium chloride (4 M) 20 ml: 9.67 g RbCl were dissolved in 20 ml 
sterile H2O and sterilized by filtration. 
SDS 20% (Sodium dodecyl sulfate) 100 ml: 20 g SDS were dissolved in 80 ml sterile 
H2O, filled up to100 ml. 
Sodium acetate (3 M) pH 6.0 100 ml: 24.6 g Sodium acetate were dissolved in 
(RNA precipitation) 60 ml sterile H2O. A pH of 6.0 was adjusted with 
acetic acid (glacial) and the solution was filled up 
to 100 ml with sterile H2O. 
Sodium acetate (0.3 M) pH 6.0 100 ml: 10 ml 3 M Sodium acetate were mixed 
(RNA resuspension) with 90 ml sterile H2O and stored at 4°C. 
Sodium acetate (3 M) pH 4.5 100 ml: 24.6 g Sodium acetate were dissolved in 
(DNA sequencing) 60 ml sterile H2O. A pH of 4.5 was adjusted with 
acetic acid (glacial) and the solution was filled up 
to 100 ml with sterile H2O. 
Sodium acetate (3 M) pH 6.8 100 ml: 24.6 g Sodium acetate were dissolved in 
(DNA precipitation) 60ml sterile H2O. A pH of 6.8 was adjusted with 
acetic acid (glacial) and the solution was filled up 
to 100 ml with sterile H2O. 
Sodium chloride (5 M) 200 ml: 58.44 g of NaCl were dissolved in  
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200 ml H2O. 
Sodium chloride (1.6 M)/PEG 20% (w/v)100 ml: 20 g PEG and 9.35 g NaCl were dissolved 
(Plasmid isolation)    in 200 ml sterile H2O.  
Sodium hydroxide (2 M) 100 ml: 8 g NaOH pellets were dissolved in 100 
ml sterile H2O and stored in a polyethylene bottle. 
Sodium hydroxide (5 M) 100 ml: 20 g NaOH pellets were dissolved in  
100 ml sterile H2O and stored in a polyethylene 
bottle. 
Sodium dihydrogen phosphate, 100 ml: 13.79 g NaH2PO4 x H2O were dissolved 
monohydrate (1 M)  in 100 ml sterile H2O and sterilized by filtration. 
Di-sodium hydrogen phosphate, 100 ml: 17.79 g Na2HPO4 x 2 H2O were 
dihydrate (1 M) dissolved in 100 ml sterile H2O and sterilized by 
filtration. 
Sodium phosphate buffer (1 M) 1 M Sodium dihydrogen phosphate monohydrate 
and 1 M disodium hydrogen phosphate dihydrate 
were mixed under pH-control until a pH of 7.0 
was obtained. 
Solution I (Plasmid preparation) (0.05 M Glucose; 0.01 M EDTA; 0.025 M Tris-
HCl; pH 8.0) 100 ml: 5 ml 1 M Glucose, 2 ml 500 
mM EDTA (pH 8.0), 2.5 ml Tris-HCl (pH 8.0) 
and 90.5 ml sterile H2O were mixed and stored at 
4°C. 
Solution II (Plasmid preparation) (1% SDS; 0.2 M NaOH) 100 ml: In 85 ml sterile 
H2O were dissolved 10 ml 2 M NaOH and 5 ml 
20% SDS (w/v). The solution was prepared and 
applied immediately. 
Solution III (Plasmid preparation) 200 ml: 120 ml 5 M Potassium acetate, 23 ml 
acetic acid (glacial) and 57 ml sterile H2O were 
mixed and stored at 4°C. 
STE buffer  (0.1 M NaCl ; 0.001 M EDTA; 0.01 M Tris-HCl; 
pH 8.0) 1 L: 20 ml 5 M NaCl, 2 ml 0.5 M EDTA 
and 10 ml 1 M Tris-HCl pH 8.0 were dissolved in 
968 ml sterile H2O. 
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Stop-mix (5 x) (Gel electrophoresis) (0.02 M EDTA; 30% (v/v) Glycerol; 0.5% SDS 
(w/v); 0.1% (w/v) Bromophenol blue) 5 ml: 0.2 
ml 0.5 M EDTA (pH 8.0), 1 ml bromophenol blue 
solution, 1.7 ml glycerol and 0.125 ml 20% (w/v) 
SDS-solution were mixed and sterile H2O was 
added up to 5 ml. l: 200 g Trichloroacetic acid 
were dissolved in 1 l H2O and stored at 4°C. 
TBE (10 x)  (0.89 M Tris-HCl; 0.89 M Boric Acid; 20 mM 
EDTA) 1 l: 108 g TrisBase, 55 g boric acid and 
7.44 g Tritiplex III were dissolved in 1 l H2O and 
autoclaved. 
TBS (0.01 M Tris-HCl pH 7.6; 0.15 M NaCl) 1 l: 1.21 
g Tris and 8.766 g NaCl were dissolved in 800 ml 
dest H2O. A pH of 7.6 was adjusted with HCl and 
the solution filled up to 1 l with dest H2O. 
TBST (0.01 M Tris-HCl pH 7.6, 0.15 M NaCl, 0.1% 
Tween 20) 1 l: 1.21 g Tris, 8.766 g NaCl and 1 ml 
Tween 20 were dissolved in 800 ml dest H2O. A 
pH of 7.6 was adjusted with HCl and the solution 
filled up to 1 l with dest H2O. 
TE (pH 8.0)  (0.01 M Tris-HCl of pH 8.0 and 0.001 M EDTA) 
100 ml: 1 ml 1 M Tris-HCl pH 8.0 and 0.2 ml 0.5 
M EDTA pH 8.0 were dissolved in 98.8 ml sterile 
H2O. 
TFB I (0.1 M RbCl; 0.05 M MnCl2; 0.01 M CaCl2, 0.03 
M Potassium Acetate pH 6.0; 15% (v/v) 
Glycerol) 100 ml: 2.5 ml 4 M RbCl, 5 ml 1 M 
MnCl2, 1 ml 1 M CaCl2 , 3 ml 1 M potassium 
acetate pH 6.0, 15 ml Glycerol and 73.5 ml sterile 
H2O were mixed. The solution was prepared and 
freshly used. 
TFB II (0.01 M MOPS pH 7.0; 0.075 M CaCl2, 0.01 M 
NaCl, 15% (v/v) Glycerol) 100 ml: 1 ml 1 M 
MOPS pH 7.0, 7.5 ml 1 M CaCl2, 1 ml 1 M NaCl, 
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15 ml glycerine and 75.5 ml sterile H2O were 
mixed and the solution used freshly. 
Tris-HCl (1 M) pH 7.5; pH 8.0; pH 8.4 1 L: 121.1 g Tris was dissolved in 800 ml H2O. 
The required pH was adjusted with HCl and H2O 
was added up to 1 l and autoclaved. 
Tris/NP40 buffer (10 mM Tris-HCl, NP40 0.1 % (v/v); pH 7.5) 
1000 ml: 1.2 g Tris und 1 ml NP40 were 
dissolved in 1000 ml H2O. A pH of pH 7,5 was 
established with HCl. 
Western blot blocking buffer (5% non-fat milk in TBST (0.02 M Tris-HCl pH 
7.5; 0.15 M NaCl) 100 ml: 5 g non-fat milk were 
dissolved with constant agitation in 90 ml TBST 
for 2 h and the solution filled up to 100 ml and 
filtered. 
Western blot running buffer NuPage Mops SDS running buffer (20 x): 0.5 l: 
104.6 g MOPS(1M),:60.6 g Tris base(1M),69.3 g 
SDS (1mM), and 3 g EDTA (20.5 mM) were 
dissolved in distilled H2O to a final volume of 
500 ml. 
Western blot transfer buffer NuPage transfer buffer (20x): 0.5 L: 40.8 g Bicine 
(500 mM), 52.24 g Bis-Tris (500mM), 3 g EDTA 
(20.5 mM), and chlorobutanol 1 m M dissolved in  
distilled H2O to have 500 ml. Methanol is added 
before preparation to be 10%. 
 
2.2 Methods 
2.2.1 Biochemical Methods 
2.2.1.1 Protein isolation from cell monolayers  
 
To prepare protein lysate from monolayer cell cultures, the culture medium was removed and 
cells were rinsed three times with ice-cold PBS. The ice-cold RIPA protein lysis buffer 
(denaturing but not reducing) supplemented with the protease inhibitor cocktail (1 tablet per 
50 ml, Roche) was added, the adherent cells were detached from the culture dish with a cell 
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scraper and the cell-lysate transferred into a microfuge tube. The lysate was passed through a 
21 G needle to shear the DNA, incubated on ice for 60 min, and centrifuged (10.000 rpm,  
4 °C, 10 min). The supernatant containing the solubilized proteins was transferred to a new 
microfuge tube, conserved on ice for protein quantification and stored at –20 °C for further 
analysis. 
 
2.2.1.2 Protein enrichment by TCA precipitation 
 
To concentrate proteins from culture supernatants, proteins were precipitated using 
Trichloracetate (TCA). Supernatants were first centrifuged (2000 rpm, 5 min, 4 °C). to 
remove floating cells. This was necessary to discriminate between secreted and cytosolic (not 
secreted) soluble endoglin. To 1 ml of the supernatant 100 µl TCA (72 %) and 150 µl DOC (1 
mg/ml) were added, the sample was mixed by vortexing and incubated for 30 min at 4 °C. 
Thereafter precipitated proteins were pelleted by centrifugation (13.000 rpm, 15 min, 4 °C). 
The pellet was washed two times with 500 µl aceton and centrifuged as before. The aceton 
was aspirated and proteins were resolved in 30 µl RIPA buffer. 
 
2.2.1.3 Protein measurement by using the Bio-Rad DC protein assay 
 
The Bio-Rad protein assay is a dye-binding assay in which a differential color change of dye 
occurs in response to various concentrations of protein. This assay was compatible with the 
buffer formulations of the standard protein lysates and with luciferase samples in 1x luciferase 
buffer. As a standard a linear range of BSA was used. 5 µl of each standard or the samples 
were pipetted into the cavities of a microtiterplate. Thereafter, 25 µl of reagent A’and 200 µl 
of reagent B were added and the samples in the cavities were mixed by gentle agitation. The 
samples were incubated for 15 min at room temperature and the absorbance was measured at 
a wavelength of 750 nm in a Victor 1420 Multilabel Counter using the multicalc programm. 
 
Composition of reagent A’
1 ml   reagent A 
20 ml reagent S 
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2.2.1.4 Analysis of proteins by denaturing polyacrylamide gel electrophoresis 
 (SDS-PAGE)  
 
The negatively charged detergent SDS (sodium dodecylsulfate) binds in a constant amount 
per unit weight of protein (1.4 g of SDS per g of protein). As a result, the proteins behave as if 
they had a uniform shape (because SDS denatures the proteins) and identical charge-to-mass 
ratio. Equal amounts of proteins were supplemented with 5 x LDS-Loading buffer and boiled 
10 min at 75 °C. Samples were centrifuged and run on precasted 4-12 % Bis-Tris gradient 
gels using MOPS-running buffer. The samples were run at a constant voltage of 150 V until 
the protein standard was sufficiently resolved. After the run gels were processed for 
Coomassie Brilliant Blue staining or blotted onto nitrocellulose membrane for Western blot 
analysis.   
The gel with the resolved proteins in the SDS-PAGE was removed from the pre-cast 
gelcassette and placed in NuPage-transfer buffer for 10 min to equilibate. Whatman-papers 
and sponges used for blotting were also equilibrated in NuPage transfer buffer. The 
nitrocellulose membrane was activated in 30 % methanol prior to equilibration in NuPage 
transfer buffer. The transfer stack was prepared as depicted in Fig. 7. The transfer was 
performed in an XCell Blot Module at a constant voltage of 35 V for 2 – 3 hrs. The whole 
blotting apparature was placed in an ice box to cool the facility during the transfer.  
 
2.2.1.5 Detection of proteins by immunological methods 
2.2.1.5.1 Western Blot 
 
 
 
Figure 7: Preparation of a Western blot stack for the transfer of proteins from a polyacrylamide gel onto 
a nitrocellulose membrane. When an electric field is applied the proteins, which are soluble by 
dodecylsulfate and thereby achieve an overall negative charge, migrate to the anode.  
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After the transfer the membrane was soaked in TBST for 5 minutes. To monitor equal 
loading, the membrane was incubated in Ponceau S which binds reversible and unspecific to 
the transferred proteins. The membrane was scanned and Ponceau S was removed by washing 
in TBST. Thereafter the membrane (free binding sites) was blocked by incubation in 5 % non 
fat milk powder for 2 hrs at room temperature. Primary antibodies were applied with the 
indicated concentartions over night in 2.5 % at 4 °C. The unbound antibodies or antibodies 
that unspecifically bound to proteins were removed by 4 washing steps in TBST (each 5 min). 
The corresponding secondary antibody was diluted 1: 5000 and applied for 2 hrs at room 
temperature. Both, primary and secondary antbodies were diluted in 2.5 % non fat milk 
powder including 0.1 % (v/v) Tween 20. Again, the unspecific bound and unbound secondary 
antibodies were removed by washing in TBST (4 times, each 5 min) and TBS (2 times, each  
5 min min). The secondary antibody was detected by using the Supersignal West Dura 
Extended substrate. The membrane was pre-incubated for 5 min prior to analysis with the 
Lumi-ImagerTM ECL-Documentationsystem. 
 
2.2.1.5.2 ELISA measurement 
 
For the determination of serum CD105 concentrations in patient and control groups a 
quantitative sandwich enzyme linked immunoassay (ELISA, R&D Systems, Minneapolis, 
MN, USA) was carried out. For the measurement 50 µl of standards and 50 µl of the samples 
were diluted with 100 µl assay diluent and were pipetted into the wells of a microtiterplate 
which was pre-coated with a monoclonal antibody specific for human CD105. After 
incubation for 2 hrs and washing 4 times with washing buffer, 200 µl horseradish-peroxidase-
conjugated monoclonal antibody specific for human CD105 was added to the wells, incubated 
2 hrs and washed 4 times again with washing buffer. For the detection of the 
immunocomplexes 200 µl substrate solution (100 µl solution A + 100 µl solution B) was 
added to the wells. After an incubation time of 30 min, 50 µl stop solution was added. The 
colour intensity was measured as specified by the manufacturer using a (VictorTM 1420 
Multilabel Counter, Turku, Finland). 
 
AFP was determined using an automated AxSYM analyzer (AxSYM Abbott Laboratories, 
Abbott Park, IL, USA) by microparticle enzyme immunoassay (MEIA) with an alkaline-
phosphatase-conjugated monoclonal anti-AFP antibody, according to the manufacturer`s 
instructions. 
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2.2.1.5.3 Immunoturbidimetric measurement 
 
This method was used for invitro quantitive determination of C-reactive protein (CRP). 
The general principle for this method that antibodies coupled to latex microparticles react 
with antigen in the sample to form antigen/antibody complex. Following agglutination, this is 
measured turbidimetrically. 
 
2.2.2 Molecular biological methods 
2.2.2.1 Preparation of competent bacteria (Hanahan, 1985) 
 
Under normal conditions most bacteria take up only limited amounts of foreign DNA. In 
order to increase transformation efficiency, bacteria are made “competent” by chemical 
treatment that enhances their ability to take up DNA. Competent cells are capable of 
incorporating exogenous DNA that is initially adsorbed in a double stranded form. All steps 
have been performed at 4 °C. An overnight culture of JM105 bacteria was inoculated 1:100 in 
2 x TY-Medium (+1/100 VT 1 M KCl, +1/50 VT 1 M MgSO4) and incubated at 37°C and 
225 rpm until an absorbance of OD600= 0.5, corresponding to the mid-exponential growth 
phase. The bacteria suspension was conserved on ice and transferred into sterile 50 ml PP 
tubes, followed by centrifugation (3000 rpm, 10 min, 4 °C). The bacterial pellet was 
resuspended gently in 50 ml of ice cold TFB I solution per initial 100 ml culture and 
incubated 10 min on ice. The suspension was centrifuged again (3000 rpm, 10 min, 4 °C), and 
the pellet was re-suspended with 4 ml/100 ml culture of TFB II solution. Aliquots of 200 µl 
were stored at –80 °C. 
 
2.2.2.2 Transformation of competent bacteria 
 
The uptake of the DNA by competent cells is stimulated by briefly raising the temperature to 
42 °C. For this purpose, a 200 µl aliquot of competent bacteria was thawed on ice 
(approximately 15 min) and 10 µl of ligation mix was added and incubated for 30 min on ice. 
A heat shock was performed for 2 min at 42 °C, followed by 2 min on ice. After adding  
600 ml of LB Medium, the bacterial suspension was incubated 1 h at 37 °C with 225 rpm 
agitation. Different dilutions of the bacterial suspension were plated on an agar plate 
including the appropriate selection marker and cultured overnight at 37°C. 
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2.2.2.3 Preparation of plasmid-DNA from bacteria 
2.2.2.3.1 Plasmid small scale preparation (Birnboim and Doly, 1979) 
 
The small-scale preparation (miniprep) is used to extract plasmid-DNA for analytic purposes 
in a quick manner which is especially useful to identify recombinant DNA. This rapid 
isolation technique is based on the alkaline lysis of cells. The solution is neutralized with a 
mixture of KOAc and SDS. SDS complexes proteins and material from the bacterial wall, to 
which the bacterial chromosomal-DNA is bound. The KDS-complexes are insoluble and 
could be precipitated by centrifugation, whereas the plasmid DNA is recovered from the 
supernatant. Supercoiled plasmid DNA thus can be easily purified by centrifugation and used 
directly. A single bacterial colony was inoculated into 5 ml LB medium containing the 
appropriate antibiotic in a 15-ml Greiner tube and incubated overnight at 37 °C under 
vigorous agitation. Then 1.5 ml of bacterial culture was transferred into a microfuge tube and 
centrifuged (13.000 rpm, 30 sec, RT). The medium was removed by aspiration and the 
bacterial pellet was resuspended in 100 µl solution I under vigorous vortexing. Thereafter, 
200 µl of solution II was added, mixed (inverted not vortexed!) and incubated for 5 min on ice 
until the solution cleared up. The solution was neutralized with 150 µl solution III and mixed 
(inverted). After addition of 100 µl Chloroform, the solution was vortexed, followed by 
centrifugation (13.000 rpm, 10 min, RT). The supernatant was transferred to a fresh 1.5 ml 
reaction tube and the DNA was precipitated with 1 ml of ethanol for 15 min on ice, followed 
by centrifugation (13.000 rpm, 15 min, 4 °C). The pellet was washed with 150 µl ice cold  
70 % ethanol and centrifuged again (13.000 rpm, 5 min, 4 °C). The supernatant was removed 
by aspiration. The DNA pellet was dried at 37 °C and dissolved in 20 µl TE.  
 
2.2.2.3.2 Plasmid large scale preparation  
 
The DNA produced by this protocol was used for preparative purposes (e.g., cloning, DNA-
fragment isolation, sequencing). For large-scale preparation of plasmid DNA, 250 ml LB 
medium in a 1-liter flask containing the appropriate antibiotic was inoculated with 200 µl of 
overnight bacterial culture or 10 µl of glycerol stock, and incubated overnight at 37 °C under 
vigorous agitation. The bacterial suspension was transferred into a GSA-beaker and 
centrifuged (3000 rpm, 4°C, 15 min) using a JA13-rotor. The medium was aspirated and the 
bacterial pellet was re-suspended in 100 ml STE buffer and centrifuged again (3000 rpm, 4°C, 
15 min). The resulting bacterial pellet was re-suspended in 10 ml of solution I, and 1 ml of a 
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of lysozyme solution (10 mg/ml) was added. The solution was incubated for 10 min on ice. 
After addition of 20 ml solution II the sample was incubated for 10 min at RT. Thereafter,  
15 ml of solution III were added and the sample incubated for 10 min on ice, followed by 
centrifugation (6000 rpm, 15 min, 4°C). The supernatant was filtered into a fresh GSA-beaker 
through four layers of gauze bandage. 25 ml of isopropanol were added, the solution was 
mixed, and after an incubation of 10 min at RT centrifuged (6000 rpm, 15 min, 4°C). The 
resulting DNA/RNA-pellet was washed with 15 ml 70 % ethanol and centrifuged (6000 rpm, 
5 min, 4°C). The DNA/RNA-pellet was dissolved in 3 ml of TE pH 8.0, 3 ml of 5 M LiCl 
were added, mixed and centrifuged (10.000 rpm, 10 min, 4°C). The pellet containing the 
RNA was discarded and the DNA in the supernatant was precipitated with 6 ml isopropanol 
by centrifugation (10.000 rpm, 10 min, 4°C) after in incubation of 10 min at RT. The DNA-
pellet was washed again with 70 % ethanol, dissolved in 500 µl of TE pH 8.0 and incubated 
with 20 µl RNAse A at 37°C for 30 min. Then 520 µl 1.6 M NaCl/13% PEG solution was 
added, mixed, and centrifuged (13000 rpm, 10 min, 4°C). The pellet was dissolved in 400 µl 
of TE pH 8.0. The proteins were removed by extraction with phenol, then with 
phenol/chloroform (1:1) and finally with chloroform . The aqueous phase (400 µl) was 
transferred to a fresh 1.5 ml reaction tube and the DNA precipitated by addition of 100 µl 10 
M ammonium acetate and 1 ml of ethanol. The solution was incubated for 10 min at RT and 
centrifuged (10.000 rpm, 4°C, 10 min). The DNA-pellet was washed in 200 µl of 70 % 
ethanol. The DNA-pellet was dissolved in 500 µl of TE pH 8.0. The DNA was quantified by 
spectrophotometry and the quality of purified DNA was analyzed by gel electrophoresis . 
 
2.2.2.4 Purification and analysis of nucleic acids 
2.2.2.4.1 Phenol/Chloroform extraction 
 
To remove protein and lipid contaminations from DNA-solutions a Phenol extraction was 
performed. For this purpose the Phenol solution was saturated with TE pH 8.0. DNA-solution 
were first extracted with an equal volume of Phenol, followed by a Phenol/Chloroform 
mixture (1:1 v/v) and finally Chloroform. The sample was centrifuged (13.000 rpm, 2 min, 
RT) to separate organic and aequous phases. The DNA in the upper aequous phase was 
precipitated with ethanol . 
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2.2.2.4.2 Ethanol precipitation 
To concentrate DNA solutions or to exchange the working buffer (e.g., different enzymatic 
reactions) the DNA was precipitated by addition of 1/10 (v/v) 3 M sodium acetate and 2.5 
volumes of ethanol, followed by centrifugation (13.000 rpm, 15 min, 4 °C). The supernatant 
was aspirated, 70 % ethanol was added and the sample centrifuged (13000 rpm, 5 min, 4 °C). 
The DNA was dissolved in TE pH 8.0. 
 
2.2.2.4.3 Quantification of nucleic acids (Spectrophotometry) 
 
Nucleic acids like DNA and RNA show a maximal absorption at a wavelength of 260 nm. 
Therefore the detemination of the optical density (OD) of nucleic acids solution at the 
indicated wavelength is a measure for its concentration in solution. Reference values are: 
 
nucleic acid    OD260   concentration (µg/µl) 
Double stranded DNA  1   50 
RNA     1   40 
Oligonucleotides   1   33 
 
In contrast, proteins have a maximal absorption at a wavelength of 280 nm. To evaluate the 
purity of a nucleic acid solution the quotient (OD260/OD280) is observed. Reference values are: 
 
nucleic acid    quotient  
RNA solution    1.9 – 2 
DNA solution    1.6 – 1.8 
 
2.2.2.4.4 Analysis of DNA by agarose DNA-gel electrophoresis 
 
Under neutral or alkaline pH conditions, the phosphate groups of DNA chains (phosphate 
groups) become ionized into polyanions. As a consequence, DNA fragments placed within a 
porous matrix (agarose gel) and subjected to a difference in electric potential travel toward the 
anode. Under these conditions, small linear fragments or tightly packed supercoiled circular 
DNA molecules migrate faster through the pores of the gel relative to their larger or more 
loosely packed (open circle DNA, nicked plasmids) counterparts. In this respect, the porous 
matrix acts as a molecular sieve. By using this technique, known as gel electrophoresis, it 
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becomes possible to separate DNA molecules of different size or conformation. The main 
factor affecting the mobility of a DNA fragment is the viscosity of the matrix in which it is 
placed. 0.5 % (w/v) agarose gel is used for molecules of the size ~6 kbp, at the other end of 
the scale 2 % (w/v) agorose gel is used to separate much smaller DNA molecules in the range 
of 50 to 2000 bp. Plasmid DNA was cleaved with restriction enzymes and subjected to 
electrophoresis using 1 x TBE running buffer. To visualize the nucleic acids, Ethidium 
bromide was added directly to the agarose gel matrix at a concentration of 0.5 µg/ml. After 
running, the gel was photographed under 254 nm UV light on a transilluminator. 
 
2.2.2.4.5 Purification of DNA from Agarose gel slices 
2.2.2.4.5.1 DNA preparation by electroelution 
 
DNA-fragments separated by electrophoresis were cut out from the agarose gel with a sharp 
scalpel. The gel slice was transferred to a dialysis bag filled with 0.1 x TBE and sealed at the 
ends with dialysis clips. The bag was immersed in a shallow layer of 0.1 x TBE in an 
electrophoresis chamber and the DNA was electroeluted out of the gel slice for 1 h at 200 V. 
The process was monitored with a hand-held ultraviolet lamp. Before DNA recovery, the 
polarity was inversed and the same voltage applied for 2-3 min in order to liberate the DNA 
stuck to the inner side of the dialysis bag. The buffer content of the dialysis bag was 
transferred to a fresh 1.5 ml microfuge tube and the DNA precipitated by adding 0.1 v of 3 M 
sodium acetate and 2.5 v of ethanol, followed by incubation at –80 °C for 30 min. After 
centrifugation at 12.000 g for 15 min, the DNA was washed with 70 % ethanol, centrifugated 
once again, and dried in a Speed-Vac. The amount and quality of the DNA fragments were 
checked by gel electrophoresis. 
 
2.2.2.4.5.2 DNA preparation using the QIAEX II system (Roche) 
 
The separated DNA-fragment was cut out from the gel with a sharp scalpel. The gel slice was 
transferred in a 1.5 ml reaction tube and weighed. Three volumes of buffer QX1 was added to 
one volume of gel (e.g. 100 mg => 300 µl). The sample was incubated at 50 °C (~5 min) to 
dissolve the gel slice. Thereafter, 10 µl of the QIAEX II binding matrix was added and the 
sample was incubated at 50 °C for further 10 min with gentle agitation. The matrix (with the 
bound DNA) was pelleted (30 sec, 13.000 rpm), the elution buffer aspirated and the matrix 
resuspended in 500 µl washing buffer QX1. The sample was centrifuged as before, the 
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supernatant aspirated and the matrix resuspended in 500 µl buffer PE. After centrifugation 
this step was repeated and thereafter, the matrix was air-dried for 15 min. To elute the DNA, 
the matrix was resuspended in 20 µl 10 mM Tris/HCl pH 8.5 and incubated for 5 min at room 
temperature. The suspension was centrifuged (30 sec, 13.000 rpm) and the DNA containing 
supernatant transferred into a new 1.5 ml reaction tube. The quality of DNA was determined 
by gel electrophoresis . 
 
2.2.2.5  Manipulation of nucleic acids 
2.2.2.5.1 Restriction of plasmid-DNA 
 
With restriction enzymes it is possible to cleave the DNA double strand in a site specific 
manner. All restriction enzymes were purchased from Roche and used at the optimal 
temperature with the recommended 1 x restriction enzyme buffer (supplied as 10 x). If 
possible double digests were performed at one time. The maximal enzyme volume used per 
sample was 1/10 (v/v) and an activity of 3 U/µg of DNA. The restriction reaction was 
analyzed by gelelectrophoresis and fragments used for further cloning eluted . 
 
2.2.2.5.2 Preparation of blunt-end DNA fragments 
 
If there were no compatible restriction sites available for a cloning step using sticky ends, the 
generated protruding ends had to be blunted for cloning (blunt ends) by a fill in reaction with 
free nucleotides. Therefore, fragments Phenol/Chloroform extracted and ethanol precipitated. 
The fragments were resolved in 30 µl sterile H2O. 4 µl M-restriction buffer, 4 µl nucleotide 
mix III and 2 µl Klenow fragment of DNA-polymerase I (5 U/µl) were added and the sample 
incubated for 30 min at 37 °C. Free nucleotides were removed by ethanol precipitation or gel 
electrophoresis. 
 41
Molecular cloning of DNA fragments by ligation 
 
The stable storage of DNA-fragments for further analysis and/or cloning is achieved by 
inserting the fragments into an appropriate plasmid vector by ligation of the free fragment 
ends with the free plasmid-vector ends. This reaction is mediated by the enzymatic action of a 
DNA ligase. This enzyme catalyzes the formation of a phosphodiester bond between the 3´-
hydroxyl and 5´-phosphate groups of the nucleotides located on the separate DNA fragments 
(in trans) in order to yield a continuous molecule. Ligation was performed in a total volume of 
20 µl in sterile microfuge tube containing 2 µl of 10 x ligase buffer and 2 µl (1U/µl) of T4 
DNA ligase. The ratio of 3 times molecular excess of the insert over the vector was 
maintained (using~100 ng of the vector), and  incubated for a minimum of 12 hrs at 16 °C 
(blunt ends). For cloning steps using sticky ends incubation times of up to 5 hrs at room 
temperature were sufficient. 
 
2.2.2.6 Isolation of total RNA from cells (RNeasy® Mini Kit) 
 
Preparation of RNA was performed by using the RNeasy® Mini Kit (Qiagen). Confluent cell 
layers were washed three times with PBS and cells were resuspended in 500 µl RLT lysis 
buffer supplemented with 5 µl β-Mercaptoethanol. The lysate was transferred onto a 
QIAshredder® column and centrifuged (13.000 rpm, 2 min) and sheared three times through a 
20-gauge needle (0.5 diameter) for further mechanical lysis. One volume of 70 % ethanol was 
added and the sample mixed by pipetting. The sample was transferred to the RNeasy® mini 
column and centrifuged (13.000 rpm, 15 sec). The bound RNA was washed in two steps with 
700 µl RW1 buffer followed by 500 µl RPE buffer and centrifuged each time as above. The 
bound RNA was eluted with 50 µl RNase-free water and the RNeasy® mini column 
centrifuged (13.000 rpm, 1 min). The concentration of the RNA was determined 
photometrically. 
 
2.2.2.7 Preparation of first strand cDNA 
 
To detect specific mRNA by PCR, the puified RNA had to be reverse transcribed into 
complementary DNA. To accomplish this, a RNA-dependent DNA-polymerase 
(SuperScriptTM II RT, Invitrogen) from M-MLV (Moloney Murine Leukemia Virus) was 
used. 
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sample composition   condition   time 
1 µg RNA 
1 µl random primer (250 ng) 
2 µl dNTP-mix (5 mM) 
add 13 µl H2O 
     65 °C    5 min  
transfer on ice 
4 µl first strand buffer (FSB, 5 x) 
2 µl DTT (0.1 M)  
     42 °C    2 min 
1 µl SuperScriptTM II RT 
     25 °C    10 min 
     42 °C    1 h 
     70 °C    15 min 
The cDNA was stored at –20 °C and 1 µl of the cDNA was used per PCR reaction. 
 
2.2.2.8  RT-PCR analysis (Polymerase chain reaction, Mullis et al., 1986)] 
 
PCR permits the selective in vitro amplification of a particular DNA region by mimicking the 
phenomenon of in vivo DNA replication. The standard amplification protocol contains 3 steps 
which are repeated for the appropriate times. In the first step the two DNA strands are 
separated at 94 °C (Denaturation). In the second step primers (2.1.7) are permitted to bind to 
their targets (Annealing). The temperature of this step is calculated according to the lowest 
melting temperature of the used primers: 
 
Tm (melting temperature): (G/C) x 4 °C + (A/T) x 2 °C – mismatches x 4 °C 
 
In the third step the heat stable DNA polymerase (Taq-Polymerase, Roche) synthezises the 
complementary strands of the templates by elongation of the annealed primers at their 3’ ends 
for the indicated times (depending on the length of the fragment to be amplified) at 72 °C 
(Elongation). The three steps are repeated until a sufficient amount of the desired fragment is 
amplified. All PCR reactions were performed in a T3 Thermocycler (Biometra, Göttingen, 
Germany). The reaction components were mixed in a sterile 0.5 ml microfuge tube. PCR 
products for expression analysis as in the current thesis were amplified by a mix of Tag/Pwo 
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polymerases using the Expand high fidelity PCR system (Roche, Mannheim, Germany) since 
Pwo DNA Polymerase synthesizes DNA 10 times more accurately than Tag DNA Polymerase 
due to its inherent 3´-5´ exonuclease proofreading activity. For qualitative analysis 1/10 of the 
PCR reaction was checked by gel electrophoresis. 
 
PCR-sample (25 µl)      Cycling programm 
 
1 µl (50 ng of pcDNA 3.1 full length endoglin)   1) 94 °C 5 min 
3 µl forward primer (SM012, 300 ng)   2) 94 °C 15 sec 
3 µl reverse primer (SM091, 300 ng)   3) 54 °C 30 sec  x 35 
2.5 µl 10x PCR buffer (Roche)    4) 72 °C 2 min 
0.5 µl 10 mM dNTP mix      5) 72 °C 10 min 
0.75 µl High fidelity polymerase (Roche)   6) 4°C   - 
14.25 µl sterile H2O 
 
2.2.2.9 Purification of PCR-products 
 
For cloning of the DNA-fragment in pGEM®-T Easy the whole PCR sample was run on a gel 
and the corresponding DNA-fragment was purified  and used for ligation . 
 
2.2.2.10 DNA-sequencing 
 
All primers were obtained from MWG-Biotech AG (2.1.7) and sequence reactions were 
performed with the ABI Prism BigDye® termination reaction mix. 
 
sample (vol: 20 µl) 
8 µl of BigDye® termination reaction mix 
40 ng primer 
500 ng DNA  
add 20 µl H2O 
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cycle temperature     time    repeat  
95 °C        5 min  
95 °C        30 sec 
55 °C        20 sec    50  
60 °C        4 min 
4 °C        - 
 
The sequencing reaction products were purified on Centri-Sep spin columns, dried in a Speed 
Vacuum system, re-suspended in 20 µl template suppression reagent (TSR), denatured at 95 
°C for 2 min and then separated on the ABI PRISM 310 Genetic Analyzer (PE Applied 
Biosystems) automatic sequencer.  
 
2.2.3 Heterologous gene expression in eukaryotic cells 
2.2.3.1 Collagen coating of culture dishes 
 
Primary hepatocytes have to be plated on a collagen substrate for optimal culture conditions. 
Therefore, culture dishes were coated with collagen type I isolated from rat tail (Becton & 
Dickinson). The collagen stock solution (2 mg/ml) was diluted 1 :40 in 0.1 % acetic acid and 
5 ml was applied to each culture dish for 2 hrs. Subsequently the supernatant was aspirated, 
the dishes were washed two times with PBS and stored at 4 °C.  
 
2.2.3.2 Eukaryotic cell culture 
 
For the experiments shown in this thesis the following celllines have been used: COS-7 
(ATCC No. CRL-1651), L6E9 (Cristina Cardoso, Max Delbrück Center for Molecular 
Medicin) and CHO (ATCC® Number CCL-61) In addition primary rat hepatocytes were 
used. Hepatocytes were isolated from rat liver according to method introduced by Seglen, 
1976. All cells were cultured in a humidified incubator at a temperature of 37 °C in the 
presence of 5 % CO2.  
L6E9 cells were cultured in DMEM containing 20 % FCS whereas COS-7 cells were cultured 
in DMEM containing 10 % FCS. Hepatocytes were plated in Hepatozym on collagen coated 
dishes. 1 h after plating the medium was changed with new Hepatozym. CHO cells were 
cultured in RPMI medium containing 10 % FCS.  
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The cells were plated in sufficient amounts under the indicated conditions. 24 hrs after plating 
medium was renewed. A medium change was performed every second day using 2 ml (6 well 
plate) or 10 ml (culture dish, 10 cm). 
 
2.2.3.3 Subculture of cells 
 
Cultures (COS-7, L6E9, CHO) which reached a confluency of 90 – 100 % were subcultured. 
To do this properly it is necessary to obtain a single cell suspension first, by using proteolytic 
enzymes, such as trypsin. The medium was removed by aspiration, cells washed with 3 ml 
PBS/1 x trypsin. Thereafter cells were incubated in PBS/1 x trypsin for 4-7 min at 37 °C until 
the cells were detached from the dish. The cells were examined microscopically to make sure 
that rounding had started. Culture medium was added to inactivate the proteolytic enzyme. 
The cells were dispersed by gently pipetting a few times and an aliquot was removed for cell 
counting in a Neubauer chamber. Appropriate numbers of cells were then transferred onto 
new culture dishes. 
 
2.2.3.4 Cryopreservation and storage of cell lines 
 
This procedure allows the storage of cell lines by cryopreservation. In order to avoid crystal 
formation which can produce irreversible damage to the cell structure, a cryopreservative such 
as 10 % dimethyl sulfoxide (DMSO) must be added. The medium was removed by aspiration, 
cells were washed with 3 ml PBS/1 x trypsin and incubated with 2 ml PBS/1 x trypsin for 4-7 
min at 37 °C. The cells were examined microscopically to make sure that rounding of the 
cells had commenced. Once the cells were detached culture medium was added, the cells 
gently resuspended, cell suspensions pooled together, counted and centrifuged at 1000 rpm 
and 4°C for 5 min. The cell pellet was resuspended at a density of 1-2 x 106 cells/ml in 
medium. To this suspension an equal volume of freezing medium (2 x) [2.1.8.2.1] was added 
and the suspension dispensed 1 ml aliquots into sterile cryotubes, frozen and stored in liquid 
nitrogen or at –80°C. 
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2.2.3.5 Thawing of cryopreserved cells 
 
An aliquot of frozen cells was immediately thawed, plated in 10 ml culture medium on a 10 
cm culture dish and incubated at 37 °C, 5 % CO2 in humidified atmosphere. 24 hrs later the 
medium was exchanged to remove residual cytotoxic DMSO. 
 
2.2.3.6  Transient transfection of eukaryotic cells 
 
Transient transfection was performed using two different transfection media which are both 
commercially available. COS-7 cells, CHO cells and hepatocytes were transfected using the 
FuGENETM reagent. In case of L6E9 cells the lipofectamine reagent in combination with the 
plus reagent was used. 
Transient transfection with the FuGENETM6 reagent was performed one day after suculture at 
50-80 % confluency (cell lines) or one day after seeding (hepatocytes). In general, the cells 
were seeded in 6-well plates at a density of 2-3 x 105 cells per well in 2 ml medium. 1 h 
before the transfection the medium was exchanged. In case of hepatocytes the medium was 
exchanged from Hepatozym to the standard DMEM medium. CHO cells were transfected in 
standard RPMI medium. Cells were transfected with 2 µg of expression plasmids or 1 µg of 
the (CAGA)12-MLP-Luc reporter and 3 µl of FuGENETM6 per 1 µg DNA. The medium and 
FuGENETM6 were mixed in the first microfuge tube, while the DNA was pipetted into the 
second microfuge tube. After the appropriate incubation time the content of micrfuge tube 1 
was transferred droppwise into the microfuge tube 2. following a second incubation time the 
suspension was transferred droppwise onto the cells.  
Transfection schedule: 
 
component       time 
100 µl DMEM/RPMI medium 
3x Y µl FuGENETM6 
        10 min (room temperature) 
Y µg DNA 
+ DMEM/FuGENETM6 
        15 min (room temperature) 
 
 47
24 hrs after transfection the medium was exchanged (DMEM or RPMI) in the morning. In the 
afternoon the medium was exchanged again and the serum content was lowered to 0.2 % FCS. 
48 hrs later the cells were either harvested for western blot analysis, supernatants were 
collected and TCA precipitated for western blot analysis. In case of luciferase experiments the 
cells were induced after 24 hrs for a time period of 16 hrs. 
Transient transfection with the Lipofectamine reagent was performed one day after suculture 
at 50 - 80 % confluency. In general the cells were seeded in 6-well plates at a density of 2 x 
105 cells per well in 2 ml medium. 1 h before the transfection the medium was exchanged to  
1 ml DMEM without supplements. Cells were transfected with 2 µg of expression plasmids or 
1 µg of the (CAGA)12-MLP-Luc reporter and 3 µl Lipofectamine reagent and 4 µl Plus 
reagent per 1 µg DNA. The DMEM, DNA and Plus reagent were mixed in the first microfuge 
tube, while DMEM and Lipofectamine reagent were pipetted into the second microfuge tube. 
After the appropriate incubation time the content of micrfuge tube 1 was transferred into the 
microfuge tube 2. following a second incubation time the suspension was transferred 
dropwise onto the cells.  
Transfection schedule: 
 
component       time 
100 µl DMEM  
4x Y µl Plus reagent 
Y µg DNA 
        15 min (room temperature) 
100 µl DMEM 
3x Y µl Lipofectamine 
+ DMEM/Plus reagent 
        15 min (room temperature) 
 
6 hrs after transfection the medium was exchanged (DMEM including 10 % FCS). After 24 
hrs the medium was exchanged. Medium was exchanged again and the serum content was 
lowered to 0.2 % FCS. 24 hrs later the cells were induced for luciferase experiments for 16 
hrs. 
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Luciferase measurement 
 
For performing the luciferase measurements, samples stimulated with TGF-β1 for 6 – 16 hrs 
were wahed three times with PBS. The cells were resuspended and lysed in 350 µl 1 x Cell 
Culture Lysis Reagent (Promega). The celllysate was incubated 5 min on ice and afterwards 
centrifuged (10.000 rpm, 10 min, 4 °C). The cleared supernatant was stored at –20 °C or 
directly utilized to determine the luciferase activity. The measurement was executed using the 
Steady-Glo-Luciferase Assay Kit (Promega). For each sample 100 µl LAR substrate buffer 
and 20 µl of the cell lysate were mixed in a 96 well microtiterplate and samples were 
mesasured for a 2 sec time interval in a Microbeta 1450 Jet Liquid Scintillation & 
Luminescence Counter. In order to standardize the samples the protein concentration of the 
samples was determined by using the DC-method. Luciferase activities were normalized to 
the protein content of each sample. 
 
2.2.4  FPLC fractionation of serum proteins 
 
To characterize the serum CD105 a molecular-weight fractionation of serum proteins was 
carried out using the fast performance liquid chromatography (FPLC) method by gel 
filtration. A size exclusion superdex 200HR 10/30 column (Äkta Purifier, Amersham 
Pharmacia-Biotec, Uppsala, Sweden) was used and calibrated by a run of known proteins 
covering different molecular weights included in a standards [as Blue dextran 2000, 
thyroglobulin, gamma globulin, albumin, ovalbumin (chicken), myoglobin (equine), vitamin 
B12, L-tyrosine, ferritin and catalase]. The Kav was calculated from the peak fractions of each 
standard protein and from the peak fraction of each sample and by application of the 
following equation: 
Kav = (Ve – V0) / (Vt – V0)  
(V0 = void volume, Vt = total gel bed volume, Ve = elution volume of protein of interest, Kav = 
value of protein of interest) 
As an internal standard, the recombinant ECD of human CD105 was used (Cat. No. 1097-EN, 
R&D Systems). Serum samples (300 µl) of healthy controls and patients with liver cirrhosis 
were analyzed by FPLC. Elution of proteins was performed using PBS–Dulbecco buffer 
(Biochrom KG, Berlin, Germany) with a flow rate of 0.3 ml/min. The endoglin elution profile 
was determined by ELISA. 
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2.2.5 Statistical analysis 
 
Data are given as minimum, maximum, and median values. Separately for each of the study 
groups investigated 95% confidence intervals for the median values of the CD105 serum 
levels measured were computed for each patient group. The degree of association between 
CD105 and AFP was assessed by calculation using the Spearman rank correlation coefficient 
for each of the following three subgroups: liver cirrhosis, HCC and HCC with liver cirrhosis. 
The non-parametric Wilcoxon rank sum test was used for pair-wise comparison of CD105 
values between different patient groups. 
ROC analysis was carried out to establish the diagnostic sensitivity and specificity of CD105 
and AFP concentrations. The accuracy criterion was chosen for selection of an “optimal” cut-
off value for serum CD105 as well as AFP (dividing positive from negative test results) – that 
is, the chosen cut-off values maximize the accuracy of the corresponding diagnostic test. ROC 
curves were plotted for various situations; Moreover, the areas under the ROC curves (AUCs) 
were calculated, as well as for sensitivities and the specificities that were, reached with the 
optimal cut-off value. Parallel diagnostic testing was performed in all situations in order to 
judge whether the diagnostic values (sensitivity and specificity) of the two single markers 
(CD105 and AFP), that were reached using the optimal cut-off values calculated in the ROC 
analyses, could be improved if the combination of the two markers were used. In this parallel 
diagnostic testing situation, test positives were considered to be all patients that had a positive 
test result for at least one of the two markers, whereas test negatives were those patients who 
had negative results for both markers (assessed using the optimal cut-off values for both 
markers, CD105 and AFP, calculated in the previous ROC analyses). 
As the aim of this study was to generate new hypotheses rather than to confirm hypotheses 
obtained from the literature or one`s own research, an explorative study design was used. 
Therefore, all statistical analyses were conducted in an explorative manner – that is, an α-
adjustment was not carried out. Therefore, P values of P ≤ 0.05 could be considered to be 
statistically significant (with respect only to the study population investigated). 
All statistical analyses were performed using MedCalc Version 7.3.0.1 (MedCalc software; 
Mariakere, Belgium), S-Plus 6.1 (Insightful Corporation, Seattle, WA, USA) and SigmaPlot 
9.0 (Systat Software, Inc., Point Richmond, CA, USA). 
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3 Results 
 
The results are presented in two parts according to the topics raised in the aim of the study. In 
the first part of the results (3.1) Soluble endoglin as biomarker for the diagnosis of cirrhosis 
and developing HCC was evaluated. For this purpose, the serum endoglin concentrations were 
measured by ELISA in the patients groups with chronic liver disease and compared the results 
to a control population, respectively. In addition the value of serum endoglin was compared 
with this of established commen tumour marker α-fetoprotein (AFP) 
In the second part (3.2), the function of the soluble endoglin and whether this soluble 
fragment of the membrane receptor could have an effect on TGF-β1/Smad3 signaling were 
analysed. In order to solve this question, the rat soluble extracellular domain of endoglin was 
cloned and heterologously expressed in different cellular systems. The functional aspects 
were examined with regard to the role of endoglin on the profibrogenic TGF-β1/Smad3 
signaling pathway using a Smad3 specific luciferase reporter system.  
 
3.1 Soluble endoglin as biomarker for the diagnosis of cirrhosis and developing HCC 
 
3.1.1 Clinical and laboratory data of the analyzed patients and control groups 
 
The clinical and laboratory data for every patient in different subgroups and controls are 
collected in the reference Table [from R1a-R1f in Appendix]. The median of age for the 
healthy controls (n = 70; 54 m. and 16 f.) was 50.5 years. The respective median of age in the 
fibrosis subgroup (n = 19; 9 m and 10 f) was 47 years, in the cirrhotic subgroup (n = 57; 39 m. 
and 18 f.) the median of age was 60 years. HCC associated with cirrhotic liver subgroup (n = 
45; 31 m. and 14 f.) the median of age was 57 years, whereas in HCC patients group (n = 9; 6 
m. and 3 f.) the median of age was 63 years. All of the data were summarised in Table 1.  
The most common underlying etiologies for liver cirrhosis without HCC were alcohol abuse 
(n = 19; 33%), virus hepatitis (chronic viral hepatitis B and/or C infection, n = 17; 29%), or 
cryptogenic (n = 14; 24.5%). The associated etiologies in liver cirrhosis with HCC were viral 
hepatitis (n = 32; 71%), alcohol (n = 6; 13%) or both factors (n = 7; 16%), while in HCC 
without cirrhosis the associated etiology was mainly cryptogenic (n = 5; 55.5%), viral 
hepatitis (n = 3; 33.5%) and chronic alcohol abuse with viral hepatitis (n = 1; 11%). The 
corresponding data set is summarized in Table 2. 
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Table 1: Characteristics of the individuals in the subgroups included in this study. Age (range and median 
value) and gender of the individuals in the subgroups are indicated. 
 
Data and 
subgroups 
healthy 
controls 
non-liver-
diseased 
Liver 
fibrosis 
liver 
cirrhosis 
HCC Plus liver 
cirrhosis HCC 
(n. of cases) 70 94 19 57 45 9 
age (years) 50.5 60 47 60 57 63 
Range (Y) (36-67) (21-85) (21-72) (38-82) (38-78) (54-74) 
gender 
(m/f) 54/16 43/51 9/10 39/18 31/14 6/3 
 
Table 2: Etiologic factors in each patient subgroup. In the columns the subgroups of patients are spitted in the 
patient numbers (and percentages with respect to the total subgroup) belonging to the different etiologies. 
Patients subgroups 
and etiology 
 
 
total number
(m/f) 
Hepatitis
n. (%) 
Alcoholic 
n. (%) 
Hepatitis 
and 
alcoholic 
n. (%) Cryptogenic
Liver fibrosis 19 (9/10) 2 (10%) 0 0 17 (90%) 
Liver cirrhosis 57 (39/18) 17 (30%) 19 (33.5%) 7 (12%) 14 (24.5%) 
HCC with cirrhosis 45 (31/14) 32 (71%) 6 (13%) 7 (16%) 0 
HCC 9 (6/3) 3 (33.5%) 0 1 (11%) 5 (55.5%) 
 
3.1.2 Measurement of serum sCD105 concentrations  
 
For the measurement of the sCD105 concentration in the serum samples of the described 
collective, we used a commercially available ELISA kit (R&D systems). This ELISA kit is 
specific for the detection of human sCD105 including monoclonal antibodies for capturing 
and detection of sCD105. To establish this ELISA kit in our laboratory for the “routine” 
measurement of the afore mentioned samples, the variation coefficient of the assay was 
determined. To evaluate the intra-assay variation one control sample was measured in 
multiple repeats in duplicate manner with the same ELISA kit. The calculated variation 
coefficient for the intra-assay precision was 3.0 %. The inter-assay precision was determined 
by including the same control sample (which was stored in aliquots) in each measurement 
with a new ELISA kit in parallel to the used patient samples. Thereby, the calculated inter-
assay precision was 6.5 %. Here it is important to note, that the used control sample for the 
precision analysis was stored in aliquots at – 80°C, so that the samples used in the control 
measurements had to be thawed on ice just one time before usage. The analysis of the 
sCD105 concentrations showed that the median concentration of sCD105 in the serum 
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samples of healthy controls was 3.7 µg/l, and 95 % confidence interval (CI) was between 3.4 
and 4.0 (µg/l). In the serum of the non-liver-diseased and non-cancer-diseased control patients 
the median for sCD105 concentration was 3.9 µg/l, and the 95 % CI was 3.7-4.2 (µg/l) as in 
Table 3. There was no significant difference in sCD105 concentrations between the two 
control groups. Patients with liver cirrhosis plus HCC subgroup had the highest sCD105 
concentrations with a median of 7.4 µg/l and the 95 % CI was between 6.4-8.8 (µg/l). sCD105 
concentrations in the fibrotic liver subgroup had a median of 3.5 µg/l and the 95 % confidence 
interval was between 3.3-4.1 µg/l. While in serum samples of patients with liver cirrhosis the 
median for sCD105 concentration was 5.8 µg/l, and 95 % CI was between 5.0 and 6.3 µg/l. 
HCC patients without cirrhosis had a median 5 µg/l, and a 95 % CI was 3.8 -7.5 µg/l. All 
these data are summarized in Table 3. 
The comparison between the patients subgroups showed that there was a significant elevation 
for sCD105 concentration in the HCC plus cirrhosis subgroup with respect to the other groups 
[to the fibrosis subgroup the P-value was 0.0001, the cirrhosis subgroup (P = 0.0006) and 
HCC only subgroup (P = 0.0134). In the fibrotic liver subgroup (n= 19 cases , without history 
of viral hepatitis), sCD105 was not significantly elevated in the serum if compared to the 
controls groups (for healthy control P= 0.8218; non liver non cancer disease P = 0.2479) as in 
Table (4), figure (8). 
 
Table 3: Median value, range and 95 % CI of sCD105 in every subgroup. 
 
healthy 
controls 
non-liver-
diseased 
liver 
fibrosis 
liver 
cirrhosis 
HCC plus 
liver cirrhosis HCC 
(n) 70 94 19 57 45 9 
Median 
endoglin 
(µg/l) 3.7 3.9 3.5 5.8 7.4 5.0 
Range(µg/l) 2.5 - 7.8  2.4 - 15.1 2.8 - 7.4 2.8 - 12.6 2.4-12.0 3.3 - 8.5 
95%-CI 
(µg/l) 3.4 - 4.0 3.7 - 4.2 3.3 - 4.1 5.0 -  6.3 6.4 - 8.8 3.8 - 7.5 
 
  53
 16 
14 
12 
10 
sCD105 
µg/l 
8 
6 
4 
2 
0 
       N =         70                 94                 19                 57                 45                  9
                  healthy            non-liver        liver             liver           HCC and         HCC
                      controls          diseased         fibrosis       cirrhosis    cirrhosis
Figure 8: Statistical summary of sCD105 concentration in the subgroups by box-and-whiskers plots. 
Comparisons between subgroups are illustrated using Box-and-Whiskers-plots, where the line in the box 
indicates the median per group, the box represents 50% of the values, and horizontal lines show minimum and 
maximum values of the calculated non-outlier values; dots indicate outlier values. 
 
 
Table 4: Statistical summary of sCD105 measurements by box-and-whiskers plots. P-values of 
nonparametric Wilcoxon rank sum tests between different subgroups of the study are given in the Table (bold 
number = significant)  
 
 
non-liver 
diseased 
liver 
fibrosis 
liver 
cirrhosis 
HCC plus 
liver cirrhosis HCC 
healthy 
controls 
0.0564 0.8218 <0.0001 <0.0001 0.0013 
non-liver 
diseased 
 0.2479 <0.0001 <0.0001 0.0097 
liver fibrosis   0.0001 <0.0001 0.013 
liver cirrhosis    0.0006 0.4662 
HCC and liver 
cirrhosis 
    0.0134 
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Measurement of the serum α-fetoprotein concentration 
 
To evaluate the potential of sCD105 as a marker for patients at high risk to develop a 
hepatocellular carcinoma, sCD105 should be thoroughly analysed and compared with a 
clinically established marker. Therefore serum concentration of AFP was measured using the 
AxSYM  analyser used in our routine laboratory. The median of AFP concentrations for the 
different subgroups are listed in Table (5). The median was 4.0 µg/l and 95% CI was between 
3.4 and 4.9 in patients with liver cirrhosis. In HCC patients with concomitant liver cirrhosis 
the median of alpha fetoprotein was 5.2 µg/l, and 95% CI was 3.3 - 11.3 µg/l. 
As depicted in Table (5), the median AFP concentration of the patient subgroups and healthy 
control seemed to be normal (i.e. up to 10 µg/l). There was a wide range values for α-
fetoprotein in the different patients subgroups. 
 
Table 5 Median of the serum alpha feto-protein concentration, range and 95 % confidence interval in the 
subgroups. 
  
healthy 
controls 
non-liver-
diseased 
liver  
fibrosis 
liver 
cirrhosis 
HCC plus  
liver 
cirrhosis HCC 
(n) 70 94 19 57 45 9 
Median 
AFP 
(µg/l) 3.1 3 2.9 4 5.2 5.6 
Range 
(µg/l) 1.2 - 10.1 0.7 - 11.2  1.0 - 8.5 0.8 - 153.9 2.4 - 460000 2.0 - 763.0
95%-CI 
(µg/l) 2.6 - 3.6 2.6 - 3.6 1.8 - 4.8 3.4 - 4.9  3.3 - 11.3 2.3 - 388.0
 
 
3.1.4 Correlation of sCD105 and AFP  
 
By using the Spearman rank correlation analysis it was shown, that sCD105 serum levels 
were mild to moderate positively correlated with AFP in both patients with liver cirrhosis (r = 
0.358, P = 0.0073), and positively correlated in patients with liver cirrhosis and HCC (r = 
0.479, P = 0.0015) [Figure 9 a, b]. In Table (6) the results of the multiple logistic regression 
investigating the impact of two markers (sCD105, AFP) and two covariates (age, gender) on 
the risk for development of HCC in cirrhotic patients. From this regression analysis it is 
obvious that serum sCD105 has the most significant impact on the risk for development of 
HCC in cirrhotic patients when compared to AFP. 
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Figure 9 (a and b): Spearman rank correlation analysis of sCD105 and AFP.  
The degree of association between sCD105 and AFP in the two liver cirrhosis groups (wirhout or with HCC) 
was assessed. (a) calculation of the logarithmic transformed Spearman rank correlation coefficient (r) was 0.358 
between sCD105 and AFP in the liver cirrhosis subgroup. (b) r value was 0.479 in the liver cirrhosis plus HCC 
subgroup.  
 
 
Table 6: Multiple logistic regression investigating the impact of two markers (sCD105, AFP) and two 
covariates (age, gender) on the risk for development of HCC in cirrhotic patients. Results are given as 
estimated regression coefficients and standard errors, P-values of the Wald chi-square-test, odds ratios and 
corresponding 95% confidence intervals for each of the markers and covariates included in the logistic 
regression model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[0.398; 2.609] 1.019 0.9695 0.240 0.009 Gender 
0.973 
1.002 
1.289 
 - 
odds ratio 
[0.998; 1.007] 0.3522 0.002 0.002 AFP 
[0.936; 1.012] 0.1781 0.020 -0.027 Age 
[1.070; 1.553] 0.0077 0.095 0.254 CD105 
 - 0.7025 1.335 -0.510 intercept   
95% CI P value standard  
error 
regression 
coefficient 
variable 
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3.1.5 Diagnostic sensitivity and specificity of sCD105 and AFP 
 
To determine the sensitivity and the specificity of sCD105 and AFP we performed a ROC 
analysis (Fig. 10a, b). The optimum cut-off values reached and the corresponding area AUC 
for sCD105, according to different subgroups, are shown in figure 10a. The sensitivity was 
tested for sCD105 between the different subgroups. It varied from 57.8%-84.4%, while the 
specificity of sCD105 for HCC in the liver cirrhosis subgroup versus the healthy controls was 
highest (91.4%) with respect to the other studied groups.  The specificities of sCD105 in the 
other studied subgroups varied between 77.8% and 89.9%. The ROC analysis for AFP 
concentrations in these subgroups showed sensitivities, ranging from 42.2% to 57.8%, 
whereas the specificity was around 84% (Figure 10b). Sensitivity and specificity values of 
sCD105 could not be further improved by the use of the combination of sCD105 and AFP at 
these cut-off values as it is depicted in Table (7). 
 
 
 
Figure 10: ROC analysis of CD105 and AFP. Various ROC analysis for serum sCD105 and AFP. The areas 
under the ROC curves (AUCs) were calculated with the corresponding standard errors and 95% confidence 
intervals. An AUC= 1 (100%) is characteristic for an ideal test, whereas an AUC= 0.5 (50%) or less indicates a 
test of no value.  
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Table 7: ROC analysis of sCD105 and AFP to determine the sensitivity and specificity of both markers. 
This Table contains the AUC, sensitivity (%) and specificity (%) for both AFP and sCD105 at certain cut-off 
values between liver patient subgroups and controls.  
 
sCD105 
area 
under 
the 
curve 
(AUC) 
standard 
error 
95% 
confidence 
interval 
Sensitivity 
(%) 
95% 
confidence 
interval 
Specificity 
(%) 
95%   
confidence 
interval 
optimal 
cut-off 
(µg/l) 
(1) 0.698 0.053 0.599; 0.785 57.8 0.422; 0.723 78.9 0.661; 0.886 6.9 
(2) 0.890 0.034 0.818; 0.941 84.4 0.705; 0.935 91.4 0.823; 0.968 5.0 
(3) 0.859 0.038 0.790; 0.912 84.4 0.705; 0.935 89.4 0.813; 0.948 5.1 
AFP 
(1) 0.614 0.057 0.512; 0.708 42.2 0.277; 0.578 84.2 0.721; 0.925 7.7 
(2) 0.704 0.051 0.612; 0.786 57.8 0.422; 0.723 85.7 0.753; 0.929 4.8 
(3) 0.722 0.049 0.640; 0.794 57.8 0.422; 0.723 84.0 0.705; 0.908 4.8 
 
 
3.1.6. C-reactive protein in the liver fibrotic and liver cirrhotic subgroups: 
 
The median for the two subgroups fibrotic, and cirrhotic were 5 mg/l and 14 mg/l, 
respectively. These two subgroups, which are associated with inflammation, did not reveal 
any significant correlation between serum sCD105 level and C-reactive protein concentration 
(Spearman rank correlation coefficient r = 0.118 and r = 0.207 respectively). 
 
3.2 Functional analysis of soluble endoglin 
 
Having shown that the soluble endoglin concentration in the serum is elevated in the case of 
cirrhosis and even more in patients which suffer from cirrhosis accompanied by HCC, we 
next asked if this circulating endoglin could have any functional consequence for TGF-β 
signaling espacially in liver cells contributing functionally to the progression of cirrhosis to 
HCC. To solve this question we analyzed the function of the soluble endoglin on TGF-β 
signaling in an established cellular assay, based on the TGF-β/Smad3 dependent (CAGA)12-
MLP Luc reporter. For this analysis we decided to heterologously express the extracellular 
domain (ECD) of rat endoglin. The data published so far concerning the role of the membrane 
inserted as well as the soluble endoglin all rely on assays in which the human orthologue of 
endoglin has been used irrespective of the origin of the cellular system used for the analysis 
[Letamendia et al., 1998; Obreo et al., 2004 ; Venkatesha et al., 2006]. Although these data 
are accepted and produce comparable results we thought of using the rat soluble receptor 
because the cells we were going to use for the functional analysis, i.e. L6E9 myoblast cells and 
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primary hepatocytes, were of rat origin. As a basis for this analysis the full length rat endoglin 
has been cloned for the first time in our laboratory. With respect to the functional analysis of 
the soluble endoglin there has been only one study published currently. In this study the 
commercially available soluble recombinant  ECD of human endoglin (R&D) was used in cell 
culture experiments of human umbilical vain endothelial (HUVEC) cells. As a standard this 
protein was included in our initial functional experiments. 
 
3.2.1 Cloning of the ECD of rat endoglin 
 
For the cloning of the extracellular domain of rat endoglin, structural characteristics of the 
receptor protein had to be taken into account. These include the putative protease cleavage 
site, the antibody epitopes and the domain structure of the full length receptor as shown in 
Fig. 11. The soluble endoglin that naturally occurs in the serum is most likely a proteolytic 
product of the membrane receptor. As has been described for many other membrane receptors 
a portion of the extracellular domain (ligand binding domain) is shedded by a protease to 
generate a soluble part, i.e. soluble endoglin, and a remnant part (transmembranal domain and 
C-terminal domain) residing in the membrane. The putative protease cleavage site is located 
147 amino acids before the beginning of the transmembrane domain [Raab et al., 1999; 
Llorca et al., 2007] (Fig. 11). In order to detect the heterologously expressed soluble endoglin 
(s-Eng) in western blot experiments by  
 
 
 
Figure 11: Structural and functional characteristics of the sequences surrounding the transmembranal 
domain. Alignment of the juxtamembrane part of the ECD, transmembranal domain and C-terminus of human, 
mouse and rat endoglin. Indicated is the putative protease cleavage site (upper part, red letters, grey box), the 
epitope of the rat specific anti endoglin antibody PPabE1 (middle part, red letters italics, grey box), the 
transmembranal domain (middle part, lower part, grey box and line on the top), the epitope of the commercially 
available antibody sc-6199 (lower part, grey box) and the TGF-β RII phosphorylation site in the ICD (serine 626 
and 627). The boundary between the extracellular domain and the transmembranal domain is indicated below the 
middle panel (red arrow, ECD). 
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a specific antibody, we had to preserve the epitope of the PPabE1 antibody (Fig. 11) in our 
expressed protein. Since the epitope is located C-terminally from the putative protease 
cleavage site, at which the shedding of the endogenous endoglin is facilitated, the antibody 
PPabE1 will detect only the heterologously expressed s-Eng, but not the endogenous, shedded 
s-Eng (Fig. 11). To be a functionally active receptor, most of the TGF-β receptors have to 
dimerize. To achieve this dimerization in case of a soluble receptor lacking the intracellular 
domain, some soluble receptor domains have been fused to the Fc portion of the human IgG, 
which is a disulfide linked dimer. The interaction of the IgG domains forces in addition the 
receptor domains to associate leading to a functional receptor (Komesli et al., 1998). In case 
of  endoglin it has been previously shown that the extracellular protein moiety comprises 
cysteins which mediate disulfide bounding and thereby dimerization of the monomeric 
soluble protein entities. Therefore no fusion to an dimerization inducing protein domain is 
necessary. 
 
Figure 12: Design of the 3’ primer to generate soluble Endoglin. Depicted is the boundary of the extracellular 
domain (ending with Glycine-Lysine-Glycine) and the transmembranal domain (amino acids underlined, starting 
with leucine-valine-leucine). By means of RT-PCR a stop codon was introduced (white type on black) 
substituting the AAA codon (lysine) in the full length endoglin sequence. In addition, a Not I restriction site was 
introduced (red type) for further subcloning steps. 
 
 
To generate the cDNA encoding the ECD-Endoglin we decided to amplify the part coding for 
the extracellular domain using the cDNA encoding the full length endoglin by RT-PCR 
(Appendix Fig. 31). A RT-PCR amplification step instead of restriction enzyme usage was 
necessary because obviously no appropriate restriction sites were available for further cloning 
steps. The 5’-primer for the amplification was chosen according to the published sequence 
(Meurer et al., 2005) and is not depicted in Figure 12. The corresponding 3’-primer contained 
in addition to the endoglin sequence two more features. As shown in Figure 12 we introduced 
a stop coden at the end of the coding region for the extracellular domain. This stop codon is 
followed by a sequence representing a Not I restriction site, which is suited for the cloning 
into the expression vector pcDNA3.1 (see Fig.12). Using the expression clone of endoglin as 
a template, we amplified the coding region for the extracellular domain of ECD-Eng (Fig. 
13A). 
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Figure 13: PCR amplification of the extracellular domain of rat endoglin (A) To amplify the extracellular 
domain of endoglin (ECD-Eng) we designed two specific primers. Primer 1 binds to the initiation region (5’ to 
the start ATG codon). Primer 2 is designed to bind to a region at the boundary between the ECD and TM domain 
of full length endoglin. In addition primer 2 is used to introduce a stop codon and this is followed by a Not I 
restriction site, for successive cloning into the expression vector pcDNA. (B) Result of PCR for the amplification 
of the ECD of endoglin. [ECD, extracellular domain; TM, transmembranal domain; CT, C-terminal domain] 
 
 
The corresponding PCR-fragment was eluted from the gel slice (Fig. 13B) and cloned into the 
cloning vector pGEM®-T Easy (Invitrogen) without further modifications. This initial cloning 
step was performed because sequence analysis of the PCR product in the pGEM®-T Easy 
vector is easier to handle, because the vector offers primer binding sites which can be used in 
addition to the endoglin internal primers. The vector primers are essential to check the 
sequence at the ends of the fragment, becuase this information is not available using the 
internal primers only. After ligation of the corresponding PCR-fragment into pGEM®-T Easy 
(appendix Fig. 32), Competent bacteria were transformed with the ligated recombinant DNA 
and the bacteria were plated onto growth plates containing the appropriate selection marker 
(ampicillin). Single resistent colonies were used to inocculate small scale cultures consisting 
of 5 ml growth medium including the selection marker. To determine if the clones contained 
recombinant vector-DNA, the DNA was prepared and analysed by restriction analysis (Fig. 
14). For convenience, the pGEM®-T Easy vector offers two EcoR I restriction sites in the 
corresponding multiple cloning region which enclose the inserted fragment on both sides. 
Therefore, when using this enzyme the inserted fragment is released from the vector (Fig. 
14A). A representative restriction analysis of a recombinant clone obtained in these 
experiments is depicted in Fig. 14B. The upper fragment represents the vector (pGEM®-T 
Easy, 3015 bp) and the lower band the fragment encoding soluble endoglin  
(ECD-Eng, 1737 bp), respectively (Fig. 14B). 
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Figure 14: Generation and analysis of the vector pGEM-ECD-endoglin. (A) Scheme to display the 
construction of the pGEM-ECD of endoglin. To recover recombinant plasmids, small scale LB medium cultures 
were inocculated with single colonies. (B) DNA was prepared and cut with EcoRI, which cuts at both sides of 
the inserted fragment in the multiple cloning region. 
 
 
The DNA of the corresponding clone was verified by sequence analysis, whereby it was 
shown that the sequence contained no mistakes. Because the pGEM®-T Easy vector 
(Appendix Fig. 33) is only suited for cloning and amplification of recombinant DNA the 
insert encoding the soluble endoglin had to be transferred into an appropriate vector for 
expression of proteins in eukaryotic cells. For this purpose, we used the pcDNA3.1 vector, 
which has been already used for expression of the full length endoglin (Meurer et al., 2005). 
This vector (pcDNA3.1) contains the constitutive active CMV (cytomegalovirus) promoter 
leading to high expression of foreign proteins in a variety of cellular systems (Appendix 34). 
To prepare a pcDNA3.1 vector with compatible ends, the pcDNA-HA-TβRIII (encoding 
betaglycan; Wang et al., 1992) was cut with the restriction enzymes EcoR I and Not I (Fig. 
15B). The pGEM-ECD-endoglin vector was also cut with the enzymes EcoR I (multiple 
cloning site) and Not I (introduced with the 3’-primer; Fig. 15A). The compatible cut vector 
pcDNA and the endoglin ECD-Eng encoding fragments (Fig. 15C) were eluted from the gel 
slice and used for a ligation reaction. The resulting products of this reaction were used to 
transform competent bacteria, which were plated in the presence of an appropriate selection 
marker, i.e. ampicillin.  
  62
 
Figure 15: Preparation of the expression vector pcDNA and the coding region of ECD-endoglin. To 
generate a recombinant expression clone for the analysis of the effects of the ECD-endoglin on TGF-β signaling, 
the ECD-Eng fragment had to be transferred into an eukaryotic expression vector. We chose pCMV-HA-TβRIII 
including betaglycan, removed the betaglycan coding fragment by cutting the DNA with the enzymes EcoR I 
und Not I. The cutted empty vector was gel purified. To prepare the fragment encoding the ECD of endoglin, the 
recombinant clone pGEM-ECD-endoglin was cut with EcoR I and Not I and ECD coding fragment was gel 
purified. Fragments to be eluted are marked by an asterisk (*). 
 
 
 
Figure 16: Restriction analysis of recombinant pcDNA-ECD-Eng clones. The purified receptor and vector 
fragments were used for a ligation reaction using T4-Ligase. JM105 bacteria were transformed and plated on LB 
dishes in the presence of ampicillin. Several single colonies were used to inocculate small scale cultures (5 ml). 
DNA was prepared from the bacteria and was cut with EcoR I and Not I in a double digest. One of the 
recombinant clones was used to inocculate a large scale culture. A) Representation of the recombinant vector. B) 
Restriction of recombinant clones with the restriction enzymes EcoR I/Not I. A molecular weight standard is 
indicated in the left margin in all gel figures. 
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Single, resistent colonies were used to inocculate LB-medium cultures, from which DNA was 
prepared and used for restriction analysis with the corresponding enzymes used for cloning, 
i.e. EcoR I/Not I. A representative analysis of three recombinant clones is shown in Figure 16. 
To obtain pure DNA of high quality for the transient transfection experiments in order to 
 
express the ECD of endoglin, DNA of the three recombinant clones was used to inocculate 
large scale cultures (50-100 ml). The prepared DNA was checked as described before by 
restriction analysis as well as sequence analysis to characterize the boundary between the 
CMV-promoter and the ECD-endoglin coding region (Fig. 17). The test restriction clearly 
showed that the recombinant pcDNA-ECD-Eng clones migrate at a higher molecular weight 
compared to the non-recombinant empty vector pcDNA (Fig. 17B). This finding was verified 
in addition by sequence analysis confirming that the transfer was successful (Figure 17C). 
 
 
C) 
 
Figure 17: Characterization of the pcDNA-ECD-Eng expression construct. A) Schematic representation of 
the recombinant expression clone B) The DNA of the large scale preparations was restricted with Not I. The 
molecular weight of the linearized DNA of recombinant clones was compared to the molecular weight of the 
linearized (Not I) DNA of the empty vector. C) The boundary between CMV-promoter and the ECD-Eng coding 
region was characterized by sequence analysis showing that the fragment is correct inserted. transcr. start, 
putative transcriptional start. 
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3.2.2 Expression of the soluble endoglin in COS-7 and CHO cells 
 
To test if the cloned expression vector leads to the expression and secretion of the ECD-
endoglin in sufficient and detectable amounts, we employed a cellular system, i.e. COS-7 
cells, which show a fibroblast morphology (Fig. 18) and are commonly used to overexpress 
recombinant proteins. In COS-7 cells the full length endoglin could be easily expressed in 
high amounts (Meurer et al., 2005) making it a promising system to express the ECD of 
endoglin. The ECD-endoglin has no membrane anchor, therefore the domain should be 
secreted into the medium. The standard culture conditions in the presence of 10 % fetal calf 
serum makes it difficult to analyze secreted proteins because of the high amount of proteins 
present in the serum (5-7.5 mg/ml protein in 1 ml DMEM including 10 % FCS).  
 
 
 
Figure 18: Cultured COS-7 cells. COS-7 cells were cultured in DMEM including 10 % FCS. Cell morphology 
is depicted under low (left) and high (right) plating density. (taken from the American type culture collection, 
ATCC) Magnification: 200x 
 
 
Due to the fact that the medium has to be concentrated for analysis, serum proteins (e.g. 
albumin) which are already present at very high concentrations, are enriched in parallel. This 
causes an overload of proteins in the single lanes, an underrepresentation of proteins of 
interest, and a low quality analysis. Therefore we made a compromise between maximal 
protein expression (using 10 % FCS) and the best possible analysis (using 0.2 % FCS). COS-
7 cells were transfected with three different recombinant pcDNA-ECD-endoglin clones and 
cultured in the presence of 0.2 % FCS. The medium was collected and cells were harvested 
after the appropriate time. The proteins present in the medium were precipitated with TCA 
and resuspended in loading buffer. Equal amounts of proteins of the supernatant and the cell 
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lysates were resolved in Western blot analysis using 4-12 % Bis/Tris gels under non-reducing 
conditions, to preserve the dimeric structure of ECD-Eng (Fig. 19). In contrast to the expected 
result, ECD-endoglin was detected in the supernatant only in neglegible amounts (Fig. 19, 
clones 1-3). On the other hand, in the cell lysates there were proteins detected corresponding 
in molecular weight to the ECD-endoglin monomer (Fig. 19, Endoglin ECD monomer) and a 
weaker signal with the apparent molecular weight of the ECD-endoglin dimer (Fig. 19, 
Endoglin ECD dimer). This results implied that the construct itself is expressed, but most of 
the heterologously expressed protein is present in the monomeric form and is not secreted. 
 
 
Figure 19: Heterologous expression of ECD-endoglin in COS-7 cells. COS-7 cells were transiently 
transfected with the Fugene6™ transfection reagent using all three recombinant pcDNA-ECD-endoglin clones 
(clones 1-3) or pcDNA empty vector (Co.). The supernatants were collected, cell lysates prepared and equal 
amounts of proteins from cell lysates and precipitated supernatants were analyzed by Western blot using 4-12 % 
Bis/Tris gels and MOPS running buffer. The blot membrane was developed using the rat endoglin specific 
antibody PPabE1. Equal protein loading is documented in Ponceau S stain. The molecular weight standard is 
indicated in the right margin. 
 
From the above shown experiments, it might be difficult to evaluate the functional expression 
of ECD-endoglin. To circumvent any problem arising from the insufficiency of COS-7 cells 
to efficiently secrete proteins, we switched to an alternative expression system, i.e. CHO cells 
(Fig. 20). These cells display an epithelial morphology and are easily transfectable by 
standard transfection reagents similar to COS-7 cells. In this cell type a lot of studies have 
been performed where especially secreted proteins were expressed (Saharinen et al., 1996). 
As described for the cultivation of COS-7 cells we used a reduced serum content (0.2 %) as a 
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prerequisite for a proper western blot analysis. CHO cells were transiently transfected using a 
standard procedure and the Fugene6™ transfection reagent. 
 
Figure 20: Cultured CHO cells. Depicted are CHO cells cultured in RPMI medium containing 10 % FCS. 
Cells were either cultured at a high density (left and right panel) or low density (middle panel). (taken from the 
American type culture collection, ATCC). Magnification: 200x 
 
For transfection in CHO cells, it was used only the recombinant pcDNA-ECD-endoglin clone 
2, which gave the “best” expression results in COS-7 cells. After harvesting the cells, the 
supernatants were collected and precipitated using TCA. The protein content of the cell 
lysates was measured and the amount of supernatant used of the single samples was 
calculated according to the protein content of the corresponding cell lysate so that the results 
of the supernatants are comparable between the different samples.  
Using this approach, ECD-endoglin was expressed in a high degree and a large amount of the 
protein is secreted into the supernatant. In contrast to the result obtained with COS-7 cells, in 
CHO cells no ECD-endoglin was detected in the cell lysate itself (Fig. 21). In addition, the 
comparison of the samples transiently transfected with ECD-endoglin and full length endoglin 
showed that the ECD-endoglin has a higher migration rate (Fig. 21, lane 1) than the full 
length endoglin (Fig. 21, lane 2) which fits with the fact, that the ECD of endoglin is missing 
the transmembrane and the intracellular domains. A further validation of the truncation is the 
finding that the antibody sc-6199 does not detect the ECD-endoglin, due to the absence of the 
epitope located in the intracellular domain of endoglin (Fig. 22). The expression analysis in 
CHO cells demonstrated that transient transfection using the recombinant clone 2 of ECD-
endoglin leads to the expression and secretion of the dimeric protein into the supernatant. 
Therefore, in the next step we performed functional experiments  in a cell line which is highly 
sensitive towards TGF-β1, the cytokine that has a strong impact on processes involving 
fibrosis and cirrhosis by activating one of the key intracellular mediators of ECM component 
synthesis, i.e Smad3. 
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Figure 21: Expression of ECD-endoglin in CHO cells. A and B, CHO cells were transiently transfected with 
either ECD-endoglin (ECD, clone 2), full length endoglin (FL) or with the pcDNA empty vector (Co.) using the 
Fugene6™ transfection reagent. Cell lysates and proteins from precipitated supernatants (supern.) were resolved 
in 4-12 % Bis/Tris gels and analyzed by immuno blot using the rat endoglin specific antibody PPabE1 (A) or the 
endoglin cross reactive antibody sc-6199 (B). Equal loading of  proteins was demonstrated by Ponceau S stain 
(A) lower panel. Molecular weight standards were indicated in the right margins. Note, ECD-endoglin (s-Eng) is 
only recognized in supernatants of transfected cells using PPabE1 (A, lane 1) and has a higher migration rate 
than full length endoglin (A, compare lanes 1 and 2).  
 
 
 
Figure 22: Structure of the full length and the soluble rat endoglin. Depicted are the structural features of 
endoglin including the signal peptide (yellow), the extracellular (ECD) ligand binding domain (blue), putative N-
glycosylation sites (yellow circles) and disulfide bridges in the extracellular domain that were indicated by 
linked S-letters. The C-terminal domain is indicated in red and is joined to the ECD via the transmembranal 
domain (purple). The length of the amino acid chains is shown beside the receptors. The putative protease 
cleavage site is indicated on the right side. The epitopes of the two antibodies used in this study are localized by 
green lines. Note that the epitope of the antibody sc-6199 is only present in the full length receptor. 
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3.2.3 Functional characterization of soluble Endoglin 
 
3.2.3.1 Functional analysis of soluble endoglin sCD105 in L6E9 cell line 
 
The cell line L6E9 is derived from the L6 myoblast cell line and is a model system to analyze 
TGF-β signaling and especially the role of endoglin which is not expressed by L6E9 cells 
(Scherner et al., 2007). L6E9 cells are highly sensitive towards TGF-β and express the 
corresponding signaling receptor type I (ALK5) and TGF-βRII neccessary for efficient signal 
transduction (Scherner et al., 2007). In addition it was shown that these cells do not express 
the modularory type III receptors betaglycan and endoglin (CD105) (Scherner et al., 2007). 
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Figure 23: L6E9 cell morphology, marker gene expression and activation of signaling intermediates. A), 
Morphology of L6E9 cells plated at different densities. B), L6E9 cells cultured in growth medium (GM, left 
panel), differentiation medium (DM, middle panel) or in DM in the presence of TGF-β1 (TGF-β1, right panel). 
Cells were monitored directly after plating (upper panel) and after three days of culture (lower panel). Note, 
prominent fusion of cells (myotubes) occurs only in DM (red arrows). C), Expression of matrix genes (collagen 
I) or muscle specific marker genes (myogenin) is nearly exclusive under the different culture conditions (left 
panel). The key profibrogenic mediator Smad3 is potently phosphorylated in response to TGF-β1 (right panel). 
To monitor equal protein loading the corresponding membranes were reprobed with antibodies against HSP70 
and β-actin (left panel) or total Smad2/3 (right panel). A molecuar weight standard is depicted in the left margin 
of the right figure. Magnification : 200 X 
 
 
 
Cultivation of L6E9 cells in growth medium (GM, 20 % FCS), leads to a myoblast, single cell 
appearance (Fig. 23B, left panel). When the cells are shifted to differentiation medium (DM, 
0.5 % FCS), the differentiation process is initiated. The cells align and fuse to form 
multinucleated myotubes (Fig. 23B, middle panel) (Nadal-Ginard, 1978; Blau et al., 1983). 
As a prerequisite the cellular transcriptional programm is changed. Instead of matrix genes, 
which are downregulated, muscle specific genes are expressed which are characteristic for 
this myogenic differentiation (Fig. 23C, left panel). In the presence of TGF-β, the 
differentiation of L6E9 cells under this conditions is blocked. This is monitored by an 
inhibition of fusion, down-regulation of myogenic genes and up-regulation of matrix genes 
like collagen I (Massague et al., 1986; Heino & Massague, 1990; Zentella & Massague, 1992; 
Fig. 23B, right panel). One of the key regulators of ECM gene expression switched on by 
TGF-β is the transcription factor Smad3, which is phosphorylated by ALK5 upon TGF-β1 
stimulation (Fig. 23C, right panel). To examine the effect of ECD-Eng on TGF-β signaling 
we analyzed the activation of Smad3 in the presence or absence of ECD-Eng using a Smad3 
specific luciferase-reporter (CAGA)12-MLP Luc (Dennler et al., 1998) (Appendix Fig. 35). 
This reporter construct is composed of a repeated oligonucleotide (12 repeats). The respective 
oligonucleotide was originally characterized in the plasminogen activator inhibitor 1 (PAI 1) 
promoter. Phosphorylated Smad3 in complex with Smad4 binds to this oligonucleotide and 
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activates the transcription of the reporter luciferase-gene (Fig. 24). As has been tested before 
(Scherner et al., 2007) transient transfection of L6E9 cells with high efficiency is not easy to 
achieve. Even when using the best suited transfection reagent “Lipofectamine” in 
combination with the Plus reagent transfection rates never exceed 10 %. Because of this 
limitation we could not detect the heterologously expressed ECD-Eng in concentrated 
medium. Nevertheless, the results obtained in the functional assay clearly confirmed the 
functional expression of the construct (Fig. 26). To analyze the Smad3 activation in L6E9 cells 
and the respective influence of ECD-Eng on this event, we transiently transfected L6E9 cells 
with the CAGA-luciferase read out system. In addition, cells were either transfected with the 
empty expression vector (pcDNA), the full length endoglin expression vector (FL-Eng) as a 
control or the ECD-Eng expression vector (Fig. 25 and Fig. 26). 
 
 
Figure 24: Schematic representation of the (CAGA)12-MLP Luciferase reporter (Dennler et al., 1998). 
Transcription of this artificial reporter is governed by binding of phosphorylated Smad3 to the CAGA-repeat 
element. In the presence of a minimal late promoter (MLP), luciferase is expressed. The amount of expressed 
luciferase is measured by determination of the luciferase activity in the samples using a standard protocoll as 
supplied by the manufacturer. The luciferase activity indirectly reflects the extend of Smad3 activation. 
 
 
To exclude a very high background signal due to the FCS medium content, the serum 
concentration was adjusted to DMEM containing 0.2 % FCS in the stimulation experiments. 
Therefore, the cells had to be cultured under this conditions at least two days before the 
stimulation experiment, to accumulate as much as possible of the ECD-Eng domain in the 
supernatant. In the presence of this low FCS conditions the cells initiate the myogenic 
differentiation (Fig. 25). 
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Figure 25: Morphology of L6E9 cells transiently transfected with empty vector, the extracellular domain of 
endoglin or full length endoglin and incubated or not with TGF-β1. L6E9 cells were transiently transfected 
with the CAGA-luciferase reporter in combination with empty vector (pcDNA control, left panel), extracellular 
domain of endoglin (ECD-Eng, middle panel) or full length endoglin (FL-Eng, right panel). For luciferase 
measurement cells were stimulated with TGF-β1 (upper panel) or left untreated (lower panel). Myotubes formed 
during cultivation are indicated by red arrows. Magnification: 200x 
 
 
For the luciferase measurement L6E9 cells were co-transfected with the CAGA-luciferase 
reporter and empty vector (pcDNA control) as a control, the extracellular domain of endoglin 
(ECD-Eng) or the full length endoglin receptor (FL-Eng). To induce the reporter construct, 
cells were stimulated with TGF-β1 (1 ng/ml; 24 hrs). Prior to harvesting the cells were 
photographed (Fig. 25). As expected control cells formed only myotubes in the absence of 
TGF-β1 (Fig. 25, left panel, lower row) whereas in the presence of TGF-β1 no myotubes 
were visible (Fig. 25, left panel, upper row). In ECD-Eng transfected cells obviously no 
myotubes were formed irrespective if TGF-β1 was present or not (Fig. 25, middle panels). On 
the other hand transfection of the full length endoglin in both instances with or without TGF-
β1 leads to formation of myotubes (Fig. 25, right panels).  
In the next step TGF-β1 induced luciferase activity was determined (Fig. 26). Stimulation of 
L6E9 cells transiently with the control vector transfected with TGF-β1 leads to a nearly 40 
fold induction of the luciferase activity when compared to the untreated sample (Fig. 26A, B, 
pcDNA). In contrast, when stimulating L6E9 cells in the presence of the soluble Endoglin the 
luciferase activity was strongly enhanced (Fig. 26A, B, ECD-Eng, black column).  
Even in cells, which were not stimulated with TGF-β1, there was a slight up-regulation of 
luciferase activity (Fig. 26A, B, ECD-Eng, white column). 
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Figure 26: Influence of ECD-Eng on CAGA-luciferase reporter activity. A and B, L6E9 cells were transiently 
co-transfected with the (CAGA)12-MLP Luc reporter in combination with empty vector (pcDNA, control), ECD-
Eng (ECD-Eng) or incubated with the commercially available human recombinant extracellular domain of 
endoglin (B), rhEndoglin). Cells were incubated with or without TGF-β1 and cell lysates analyzed for luciferase 
activity. B, One experiment out of several is shown in which the recombinant human endoglin has been used 
under diverse conditions. In all experiments this domain had no effect on Smad3 activation. rel. Luc factor, 
relative factor of luciferase induction compared to the unstimulated control.  
 
 
Because the commercially available extracellular domain of human endoglin decreased the 
CAGA-luciferase activity in human umbilical vein endothelial cells (HUVEC, Venkatesha et 
al., 2006) we also included this protein in our studies. As shown for one condition in Fig. 
26B, (rhEndoglin) the usage of this domain under several conditions did not modify the 
luciferase read out and therefore the Smad3 phosphorylation in our experiments. 
 
 
 
 
 
 
Table 8: Dataset of Figure 26. All cells were transiently transfected with the CAGA reporter construct (Reporter). The cells were co-transfected with empty vector (pcDNA) or 
soluble endoglin (sEng). Each sample was incubated with (+TGF-β1) or without (-TGF-β1) ligand. The rows represent data corresponding to each experiment. A) The relative 
induction factors (rel. Factor) are calculated from the normalized luciferase counts per second (LCPS/Prot). In the diagram the mean rel. Factors of three representative 
experiments are shown (Sum) as well as the corresponding standard deviation (SD). B) The cells were treated as described in (A) except that the cells of wells 5 and 6 were 
incubated in parallel with the human recombinant endoglin extracellular domain. 
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A) Data L6E9CAGA-luciferase measurements 
 
 
B) Data L6E9CAGA-luciferase measurements including hr Endoglin 
  
 
3.2.3.2 Functional analysis of soluble endoglin in primary rat hepatocytes. 
 
The previously outlined experiments clearly showed that the expressed soluble domain of rat 
endoglin has the potential to modulate TGF-β1/Smad3 signaling by increasing the Smad3 
activity in L6E9 myoblast cells. Therefore, we next asked if this protein also affects the 
signaling in hepatocytes, the cell type which upon transformation gives rise to the 
hepatocellular carcinoma. For this study we analyzed isolated, cultured primary hepatocytes 
(Fig. 27), which do not express endoglin endogenously (S. Meurer, unpublished). The cells 
were plated onto collagen I coated plates and cultured in Hepatozyme medium for at least 24 
hrs. The cells display an epithelial morphology and grow in connected groups of cells. 
Hereafter, the medium was exchanged to DMEM including 10 % FCS. Transient transfections 
and other treatments were performed in DMEM based medium with varying serum content. In 
the first step we tried to confirm the expression of ECD-Eng. In contrast to L6E9 cells, in 
primary rat hepatocytes high rates of heterologous protein expression are achieved by 
standard transfection methods, e.g. using the Fugene6™ transfection reagent.  
 
 
Figure 27: Morphology of cultured primary rat hepatocytes. Rat hepatocytes were isolated according to the 
collagenase method (Seglen, 1976). Cells were plated on collagen I support in Hepatozyme for 24 hrs. 
Magnification: 200x. 
 
In order to confirm the functional expression in hepatocytes we collected in addition to the 
cell lysate (for luciferase measurement) the cell culture supernatant for the detection of the 
secreted ECD-Eng. To enhance the sensitivity, the proteins of the supernatants were 
precipitated with TCA and resuspended directly in sample buffer.  
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Figure 28: Expression analysis of ECD-Eng in supernatants of primary hepatocytes. A, Primary 
hepatocytes were transient transfected with empty vector (lane 1, Co.), ECD-Eng (lane 2, ECD) and full length 
endoglin (lane 3, FL) using the Fugene6™ transfection method. Supernatants of transfected cells were harvested 
and proteins were precipitated using TCA and resolved in 4-12% Bis/Tris gels under non reducing conditions. 
After blotting the membrane was probed with the antibody PPabE1 directed against the endoglin N-terminus. B, 
Following stripping the membrane was reprobed with the antibody sc-6199 directed against the endoglin C-
terminus. Equal protein loading in each lane was monitored by staining the membrane with Ponceau S (A), 
lower). A molecular weight standard is indicated in the right margin (A, B). 
 
For the detection of the extracellular domain and to differentiate between the soluble and the 
full length endoglin, we successively probed the membrane with the antibody PPabE1 against 
the N-terminal domain of endoglin (Fig. 28A) and the antibody sc-6199 against the C-
terminal domain (Fig. 28B). In the western blot analysis, the sc-6199 antibody detected no 
protein in the supernatants of empty vector or ECD-Eng transfected cells (Fig. 28B). In 
contrast, the antibody PPabE1 recognized a protein with an apparent molecular weight of 97 
kD. This protein most likely represented the dimeric soluble Endoglin, because the monomer 
which appeard also in the supernatant shows a relative molecular weight of 64 kD (not 
shown). Therefore, we could conclude that the soluble endoglin is expressed and secreted by 
transient transfected hepatocytes.  
In the next step, the activation of the artificial Smad3 reporter was determined. The 
measurement of the luciferase activities in the corresponding cell lysates clearly demonstrated 
that ECD-Endoglin has a functional effect on TGF-β1/Smad3 signaling (Fig. 29). 
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Figure 29: CAGA-luciferase determination of  transiently transfected hepatocytes. As mentioned in Fig. 
26A and B hepatocytes were transiently transfected with empty vector (pcDNA), full length Endoglin (FL-Eng) 
or the extracellular domain of Endoglin (ECD-Eng). Cells were incubated either with (+ TGF-β1) or without (- 
TGF-β1). If indicated (SB), cells received the type I receptor inhibitor SB431542 which inhibits ALK5, ALK4 
and ALK7. The red line indicates the relative luciferase activity of 1 (pcDNA without TGF-β1) to which all the 
other samples were normalized. rel. Luc factor, relative factor of luciferase induction compared to the 
unstimulated control. 
 
When the cells where left unstimulated the basal luciferase activity was reduced in both 
samples, the full length and the soluble endoglin transfected cells when compared to the 
pcDNA control, respectively (Fig. 29, Co.). Application of TGF-β1 led to a strong induction 
of luciferase activity in the pcDNA control about 14 fold (Fig. 29, white bar, + TGF-β1). In 
the full length and soluble endoglin transfected cells luciferase activity did not exceed the 
activity of the untreated control (Fig. 29, grey bar and black bar, - TGF-β1) in response to 
TGF-β1. To further confirm that the analyzed TGF-β1 signaling, which is modulated by 
ECD-Eng, is transduced via the ALK5 kinase receptor, we stimulated cells in the presence of 
the type I receptor inhibitor SB431542, which inhibits the receptor-kinases of ALK5, ALK4 
and ALK7. Treatment with this inhibitor reduced the signal in all samples to that of the basal 
luciferase activity seen in the uninduced samples (Fig. 29, cf. panels Co. and panels TGF-
β1/SB). Therefore the full length endoglin and ECD-Eng causes a complete block of the TGF-
β1 induced ALK5/Smad3 signaling cascade. 
 Table 9: Dataset of Figures 29. All cells were transiently transfected with the CAGA reporter construct (Reporter). The cells were co-transfected with empty vector (pcDNA) or 
soluble endoglin (sEng). Each sample was incubated with (+TGF-β1), without (-TGF-β1) ligand or with TGF-β1 in the presence of the SB compound (SB431542; TGF-β1/SB). 
The rows represent data corresponding to each experiment. A) The relative induction factors (pb norm Fac) were calculated from the normalized luciferase counts per second 
(LCPS/Prot) by setting the unstimulated pcDNA LCPS/Prot count as 1 (Normalization first to protein amount, and subsequently normalization of all values to the unstimulated 
pcDNA control). The mean value of the induction factors of the two experiments is shown in the last column.  
A)   
  78
B) The relative normalized factors of all four experiments are included in the mean induction factors shown in B. 
The standard deviation is calculated from the four values 
 
 
 
 
3.2.4 Characterization of serum endoglin 
 
It has been mentioned in the introduction, that endoglin is able to bind TGF-β1 (Cheifetz et 
al., 1992; Barbara et al., 1999). The binding is restricted to the presence of the type I and type 
II TGF-β receptors. If these receptors are not present endoglin does not bind TGF-β (Lastres 
et al.,1996; Barbara et al., 1999) Venkatesha et al., 2006 reported that the soluble human 
recombinant endoglin was shown to inhibit the binding of TGF-β1 to the signaling receptor 
complex by performing cross linking experiments in HUVEC cells.  
To determine if endoglin interacts with any other protein in the serum, separation of serum 
proteins according to their molecular weight was performed by using fast pressure liquid 
chromatography (FPLC). The presence of endoglin in the eluted fractions was verified by a 
specific ELISA for the detection of human endoglin. The relative molecular weight was 
determined according to a panel of proteins included in a calibration standards which were 
run on the column before the separation of endoglin (Reference Table 2, Fig. 36). The peak 
fractions of sCD105 for the patients and control samples (patients, P1-P4 upper panels; and 
controls C1-C2) had a Kav value of 0.134. Serum sCD105 showed the same elution profile as 
the dimeric, recombinant human sCD105 (mixed with and without serum), with a Kav value of 
0.134. sCD105 was eluted with a single peak for the patients (Fig. 30 P1-P4, upper two 
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panels), the healthy controls (Fig. 30, middle panel) and the recombinant human protein (Fig. 
30, lower panel) the elution volume in which the highest concentration of sCD105 for most of 
samples was found about 10 ml. This Kav represents a molecular weight around 400 kD and 
does therefore not only display the dimeric protein structure. Because the recombinant human 
Endoglin ECD showed (when mixed with serum) the same tendency to high molecular weight 
complexes, it seems to be a characteristic of the soluble endoglin in the serum to aggregate or 
interact with other serum components. 
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Figure 30: Elution profile of sCD105 using FPLC fractionation of serum proteins. FPLC enrichment of 
serum sCD105. Serum protein samples (300 µl) of 4 patients (P1-P4, upper two panels), 2 healthy controls 
(control 1, 2; middle) and recombinant human sCD105 (rh endoglin lower panel) were fractionated by FPLC. 
Note that serum sCD105 eluted at the same position as the recombinant human sCD105 and Kav was calculated 
for the peak fractions of each sample according to the equation: Kav = (Ve – V0) / (Vt – V0) (V 0 = void volume, Vt 
= total gel bed volume, Ve = elution volume of protein, Kav = value of protein of interest). 
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4 Discussion 
 
4.1  Clinical value of sCD105 
 
Hepatocellular carcinoma is one of the most prevalent solid cancers worldwide, and its 
incidence is still rising in different countries. It is defined as a malignant tumour derived from 
hepatocytes, being a primary malignant epithelial tumour of the liver [Harada et al., 1980; 
Flicker et al., 1997]. Identification of HCC in high-risk patients, who are at a potentially 
curable stage, is still an unsolved clinical problem and screening procedures for HCC in 
patients with liver cirrhosis includes like determination of serum AFP, the use of ultrasound 
and a variety of other radiological techniques. At present, assessment of AFP levels in 
conjunction with ultrasound is the “standard procedure” for screening for high-risk patients 
[Pateron et al., 1994]. As elevated AFP is found only in 40%-75% of patients with HCC and 
the reported diagnostic value of AFP for detecting HCC varies widely (sensitivity of 39-97%, 
specificity of 76-95%, and a positive predictive value of 9-32%) when used for screening of 
high-risk populations [DiBisceglie et al., 1988; Sherman et al., 1995; Gebo et al., 2002], there 
is up till now a strong need to find a complementary or supplementary biochemical marker for 
screening for HCC in high-risk patients in early stage. Taking advantage of the fact that HCC 
is a “hypervascular”cancer, we focused on a marker which is associated with angiogenesis, 
i.e. the soluble TGF-β receptor endoglin (sCD105). It is known that the expression of 
endoglin is linked to the activation state of the endothelium being higher expressed in 
activated endothelial cells [Graulich et al., 1998]. Thus, in cases where active angiogenesis 
takes place, endoglin expression should consistently increase. With respect to tumorigenesis, 
the diagnostic value of soluble endoglin has been proven in the prediction of the metastasis 
risk in tumors like breast cancer or colon cancer patients [Li et al., 2000a; Yu et al., 2003; 
Dales et al., 2004]. From the epidemiological studies, it is well established now that chronic 
inflammatory liver disease has the potential to promote the development of HCC, and the 
pathophysiologic process most commonly associated with the disease is cirrhosis, found in up 
to 80% [Okuda, 2000; Arrieta et al., 2006; ElSaadany and Giulivi, 2006]. In the developed 
world the most likely causes for the development of cirrhosis are alcohol ingestion and 
increasingly hepatitis C infection and unfortunately once the cirrhosis is established in these 
chronic inflammatory liver diseases, the rate of HCC development is 1-4% per year [Johnson 
and Williams, 1987]. In our patient subgroups the most common causes of liver cirrhosis and 
HCC were viral hepatitis and alcoholic abuse, followed by cryptogenic cirrhosis (25 %) 
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Based on the present study sCD105 did not show a significant elevation in our fibrotic 
liver patients subgroup, who had a persisting high aspartate-aminotransferase and alanine-
aminotransferase levels for more than 6 months but were negative for markers of viral 
hepatitis. More interestingly, a significant elevation in sCD105 occurred with the progression 
from early fibrosis to cirrhosis followed by an additional offset in values when HCC develops 
on the basis of cirrhosis.  
It was found that in the fibrotic subgroup sCD105 levels (median 3.5 µg/l; 95% CI was 
3.3 -4.1; P=0, 8) were similar to the values found in the healthy control subgroup (Table 3 and 
4). A significant elevation in the sCD105 concentration was seen in the cirrhotic subgroup 
(median = 5.8 µg; 95% CI was 5.0-6.3; and P = 0.0001) compared to fibrotic liver subgroup, 
and even more interestingly that another increment in sCD105 values was seen in HCC with 
cirrhosis compared to cirrhotic liver patients (median= 7.4 µg/l; 95% CI was 6.4-8.8; P = 
0,0006). The tendency for elevation of sCD105 in the last stage of fibrosis (data not shown 
due to the their small number) and significant elevation in established cirrhosis may be in part 
explained by the findings of Torsney et al. They found that endoglin receptor expression is 
upregulated in activated and proliferating endothelial cells. In addition, the expression reaches 
a peak coinciding with maximal T cell infiltrate. They suggested that angiogenesis is 
intimately associated with inflammation and endoglin may be a candidate target for anti-
inflammation drug delivery [Torsney et al., 2002]. Clemente et al., also found that patients 
with advanced liver fibrosis, due to chronic hepatitis C infection, showed a significant 
elevation of sCD105 in comparison with patients displaying early fibrosis. Beside the 
elevation of sCD105 they also found an increased endoglin expression in the liver tissue itself 
as well as an increased in expression of the ligand TGF-β1 in chronic viral hepatitis patients 
(Clemente et al., 2006). Activation of endothelial cells activation as in inflammatory 
processes increase the endoglin expression. On the molecular basis hypoxia and TGF-β1 have 
been described to have a direct regulatory role in endoglin gene expression in endothelial cells 
as well as in human and rat mesangial cells [Rodriguez-Barbero et al., 2001; Sanchez-Elsner 
et al., 2002]. Because the TGF-β is upregulated in the process of fibrotic liver disease this 
may represent one mechanism which leads under certain conditions to inhancement the 
expression of the transmembranal endoglin. As our laboratory group and others have 
published, endoglin in the liver is not only expressed by endothelial cells, but also in hepatic 
stellate cells (HSC) and portal and septal myofibroblasts [Meurer et al., 2005; Clemente et al., 
2006]. HSC and their transdifferentiation is one of the key events in the establishment of liver 
fibrosis, and this process of transdifferentiation is promoted by TGF-β  [Gressner et al., 2006]. 
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However, if transdifferentiating HSC are a potential source for an increased endoglin 
expression is currently under investigation.  
However, we could not find a correlation between the CRP and sCD105 (Spearman 
rank correlation coefficient r = 0.118 and r = 0.207) in both the fibrotic and cirrhotic 
subgroup, respectively. This means that the sCD105 may be related more to the process of 
angiogenesis than to imflammation.  
The state of more significant elevation of soluble endoglin in patients suffered from 
HCC with cirrhosis in comparison to patients with cirrhosis may be due to neoangiogensis 
accompanied to hypoxia associated to neoplastic tissue [Fonsatti et al., 2003; Sanchez-Elsner 
et al., 2002; Miller et al., 1999], and this also may be related to the elevated of TGF-β in 
HCC (Ito et al., 1991; Ito et al., 1995; Song et al., 2002). 
The wide range of values for AFP concentrations and the high standard deviations of 
the mean values in the subgroups of patients with chronic liver diseases (fibrotic, cirrhotic 
with or without HCC) weakens the screening power (sensitivity and specificity) of ΑFP in 
general in high risk patients. 
The combination of the two parameters [sCD105 and α-fetoprotein], did not show an 
improvement with respect to sensitivity or specificity at the specific chosen cut-off levels of 
AFP and sCD105 as depicted in Table 7. In spite of this we suggest that if the cut-off level for 
α-fetoprotein was increased in this study, the sensitivity of AFP will be more decrease while 
the specificity will be higher, i.e sCD105 level of determination beside AFP may increase the 
sensitivity of the test for screening HCC in high risk group [Fig.10 and Table 7].  
The logistic regression model identified sCD105 as an independent marker that may 
have importance in the risk assessment for development of HCC in cirrhotic patients. This 
study also revealed a mild positive correlation between sCD105 and AFP in patients 
diagnosed as having liver cirrhosis (r = 0,358, P = 0,007) and the correlation between both 
markers in patients group suffering from liver cirrhosis with HCC was r = 0,479, P = 0,001. 
This mild to moderate correlation between the sCD105 and α−fetoprotein may be due to the 
fact that in HCC, synthesis of AFP occurs exclusively in neoplastic hepatocytes [Flicker et al., 
1997]. Whereas CD105 is highly expressed in endothelial cells of both peri- and 
intratumoural blood vessels, and its promoter is strongly active in endothelial cells [Graulich 
et al.,1999]. It is weakly expressed or absent on neoplastic non-endothelial cells [Fonsatti et 
al., 2003]. 
sCD105 expression was also demonstrated in cervical, endometrium, breast and 
gastric cancer, and seems to be a marker associated with advanced tumour stages, indicating a 
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poor prognosis in patients with solid tumours [Brewer et al., 2000, Salvesen et al., 2003; 
Dales et al., 2004; Yu et al., 2003]. The positive correlation between endoglin expression and 
tumour growth and metastasis was mainly obtained by immunohistochemistry. However, 
Yang and coworkers [Yang et al., 2006] showed that there is a correlation of the 
intratumoural microvascular density (IMVD) of CD105 immunostaining with the 
postoperative recurrence and metastasis of HCC. They could not find an association between 
liver cirrhosis and microvascular density (MVD-CD105). Moreover, Yang et al. [Yang et al., 
2006] note that some of the observed patients with a relapse of the tumour had low IMVD. 
Contrary, Ho and coworkers [Ho et al., 2005] postulated that a tumoural microvessel density 
(IMVD) by CD105 immunostaining in HCC did not correlate with the prognosis of patients. 
On the other hand they conclude that the presence of well-diffuse patterns of CD105 
expression in the adjacent non-tumorous liver could predict early disease recurrence 
 
4.2 Functions of sCD105 
 
The mechanism by which the soluble endoglin is generated is currently not known. It could be 
excluded that it is a genetically encoded splice variant of the full length receptor, because no 
additional slpice variant has been described beside the known variants, i.e. L- and S-endoglin. 
Therefore it is most likely that the soluble endoglin is generated posttranscriptionally by 
proteolytical cleavage of the membrane receptor. A corresponding protease cleavage site has 
been postulated [Raab et al., 1999; Llorca et al., 2007]. Surface endoglin receptors might be 
cleaved in similar way to the shedding process described in detail for betaglycan [Velasco-
Loyden et al., 2004] to generate a soluble extracellular domain of the endoglin molecule. 
However both, the mechanism of CD105 elevation in the circulation and the functional 
relevance of soluble endoglin in the serum remains to be analysed. To elucidate, if soluble 
endoglin has any relevant biological function, the rat extracellular part (ECD) of endoglin was 
heterologously expressed in two cell systems to evaluate the functionality of the construct, i.e. 
secretion of the corresponding ECD of endoglin. The expression in COS-7 cells resulted 
obviously only in the appearance of monomeric ECD of endoglin located in the cell lysates 
(Fig. 19). Only marginal amounts of ECD of endoglin were found in the culture supernatant. 
On the other hand, when using CHO cells, significant amounts of ECD in dimeric form where 
found/secreted into the culture supernatant (Fig. 21). We have previously shown that the full 
length endoglin was highly expressed in COS-7 cells, and a similar high expression was 
observed for the full length endoglin in CHO cells. Therefore, we are able to exclude that a 
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higher expression in CHO cells leads to a more effective secretion of the soluble domain. We 
conclude that the secretion machinery in COS-7 cells is not suited for these purposes. This has 
been confirmed in another study in our laboratory in an attempt to heterologously express 
TGF-β. In COS-7 cells secretion was achieved when supplementing the cells with a specific 
protease, i.e. furin. In CHO cells secretion was facilitated without any modifications. Because 
secretion is essential for the study of TGF-β function, CHO cells have been the system of 
choice for these analysis [Saharinen et al., 1996].  
The availability of the ECD of endoglin in the cell culture supernatant was a necessary 
prerequisite for functional analysis. The next question was, if this domain has any impact on 
TGF-β signaling, which is a critical regulator of the fibrotic response and also is involved in 
the regulation of the endoglin expression itself. To conduct this analysis, two different TGF-
β-sensitive cellular systems were employed s, i.e. L6E9 cells and primary hepatocytes. In both 
cell types Smad3 is potently activated in response to TGF-β. An established reporter system 
(CAGA)12-MLP Luc (Fig. 24) which contains a Smad3 binding sequence from the TGF-β 
inducible PAI-1 promoter [Dennler et al., 1998] was used to display the activity of Smad3. 
Although, it is found that full length endoglin provoked a similar effect in both cell types, i.e. 
inhibition of the TGF-β1 signal, the soluble expressed ECD of endoglin led to a strong 
enhancement of TGF-β/Smad3 signaling in L6E9 cells (Fig. 26). 
In contrast, the expression of sCD105 in primary hepatocytes caused an inhibition of 
TGF-β/Smad3 signaling comparable to that seen with the full length receptor (Fig. 29). In a 
previous study by Venkatesha et al., 2006, in which commercially available ECD 
recombinant human endoglin was used and this protein represents an identical part of the 
ECD as used in our experiments. They found that sCD105 blocks several functions of 
endothelial cell normally mediated by TGF-β, of which one was the (CAGA)12-MLP Luc 
assay. In a detailed analysis they unravel that the presence of sCD105 reduced the binding of 
TGF-β to the type II receptor in a dose dependent manner. The underlying mechanism was 
not analyzed, but may be explained by either of two options in addition to the difference 
between the two cells types used in the experiment. The first option is the sequestration of 
TGF-β and thereby reducing the effective ligand concentration present for binding to the type 
two receptor. In general the binding to the free soluble endoglin in solution is unlikely. It has 
been shown by several groups that the membrane bound endglin, when expressed in the 
absence of type I and type II receptors does not bind TGF-β [Barbara et al., 1999]. However, 
since it was reported that soluble circulating endoglin was detected complexed to TGF-β in 
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the serum of patients by ELISA, the soluble endoglin shares obviously not the same ligand 
binding characteristics with the membrane receptor [Li et al., 1998; Li et al., 2000b]. It is not 
known whether this change in ligand binding ability is induced by loss of the C-terminus 
(which may impart an inhibitory influence on ligand binding normally releaved by interaction 
with the type II receptor). On the other hand this observation may be due to an interaction 
with another soluble factor present in the serum and/or in the cell culture medium, which may 
modulate ligand binding to soluble endoglin. The general tendency of the sCD105 for protein 
interactions in the serum was pointed out in our FPLC analysis, in which the sCD105 eluted 
at a much higher molecular weight (~400 kDa), as would be expected for the dimeric protein 
(~130kDa). Albeit these general mechanisms may explain the findings in endothelial cells and 
hepatocytes, they do not solve the different behaviour of sCD105 in L6E9 cells and primary 
hepatocytes. A sequestration of TGF-β as well as an interaction with a common component 
would result in a similar response in both cell types. A notable difference in our experiments 
was the different expression level achieved in both cellular systems. Whereas we could not 
detect the soluble endoglin in supernatants of L6E9 cells, the protein was clearly detectable in 
the supernatants of expressing primary hepatocytes. This difference in expression was due to 
the highly variable transfection efficiencies in both cell types, beeing far lower in L6E9 cells 
compared to primary hepatocytes. If the function of the soluble domain is related to its 
concentration, the different outcomes could be explained. In addition, this would have 
consequences for the in vivo situation, where the concentration of soluble endoglin is localy 
high at the site of generation and decreases when it gets diluted in the system. 
Another category of proteins able to modulate signaling are soluble factors which 
regulate ligand binding to their cognate surface receptors. This mechanism facilitates a 
different response in cells expression the same subset of receptors [Massague 2000]. One of 
these regulators, i.e. CTGF, is expressed in both cell types [Obreo et al., 2004; Wickert et al., 
2007]. If there are expressed modulatory proteins in either cell type with the potential to 
provoke a differential responsiveness as seen in our experiments is currently not known.  
The inhibitory effect observed for TGF-β signaling in primary hepatocytes may lead in 
the liver to a protection of hepatocytes from the effects of TGF-β1, mainly apoptosis or 
epithelial to mesenchymal transition [Samson et al., 2002; Hayashi et al 2004 ; Kaimori et al., 
2007]. We suggest that this elevation of soluble endoglin reflect the over expression of 
endoglin receptor with the persistant chronic liver inflammation to counteract the effect of 
elevated TGF-β ligand which acts as potent growth inhibitor for preferentially epithelial cell 
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types, and plays a key role in the control of parenchymal apoptosis, and stimulates the 
production of ECM components. 
 
The results of this study led us to conclude that it may be useful to implement sCD105 in 
future diagnostic algorithms to identify patients with liver cirrhosis at high-risk for HCC. 
Therefore, further studies using serum samples from larger cohorts of patients are needed to 
evaluate the diagnostic value of this novel serum marker. 
In addition to the sCD105 value as a complementry biomarker in high risk patients, 
circulating soluble endoglin could excert a modulatory effect on the TGF-β1 signaling 
pathways. This effects may be different with respect to the target cell type encountering this 
soluble receptor domain, similar to the effects which were observed for the heterologously rat 
ECD endoglin in primary rat hepatocytes and L6 E9 rat skeletal muscle cells, of which both do 
not express endoglin endogenously. It was obvious that sCD105 inhibited TGF-β1/Smad3 
signaling, measured by the CAGA-luciferase reporter, in primary hepatocytes. In contrast, 
heterologously soluble endoglin had a stimulatory effect on TGF-β1/Smad3 signaling in L6 E9 
cells. From these findings we conclude that the presence of soluble endoglin in the 
circulation, due to a yet unknown mechanism, is not only a passive event (i.e passive 
shedding), but could modulate signaling of  TGF-β1. 
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5 Summary 
 
Liver cirrhosis and chronic viral hepatitis-B and -C infections are well-known risk conditions 
for the development of HCC, and identification of HCC in high-risk patients, who are at a 
potentially curable stage, is still an unsolved clinical problem. Therefore, the diagnostic 
potential and value of solube endoglin in patients with liver cirrhosis at high-risk of HCC was 
investigated. In addition, we elucidated the functional impact of heterologously expressed 
soluble endoglin on TGF-β1/Smad3 signaling by using an artificial reporter system for the 
detection of phosphorylated Smad3, i.e. (CAGA)12-MLP Luc. For the evaluation of sCD105 
as a marker for the occurence of HCC in high-risk patients, we measured the concentration of 
sCD105 in both, 121 patients of chronic liver disease visited Aachen university hospital 
during one year and 70 healthy individuals, constituting the control group. In parallel, AFP 
serum concentrations were measured, to compare the results of the sCD105 measurements 
with an established marker. The 121 patients were classified into 19 patients with liver 
fibrosis, 57 cirrhotic patients, 45 cirrhotic patients with HCC and 9 patients with HCC only. 
While sCD105 showed no significant difference in concentration between the healthy group 
with a median 3.7 µg/L and patients with first grade of liver fibrosis median 3.5 µg/L. The 
most important finding was the discriminatory potential of endoglin with respect to the 
severity of fibrosis first and malignant transformation as the second, i.e. that first sCD105 
concentration showed a significant (P value = 0.0001) higher value in patients with cirrhosis 
having a median of 5.8 µg/L compared to the fibrotic group. On the other hand, there is a 
further significant increase in sCD105 concentration in the cirrhosis with HCC group (median 
7.4 µg/L; P value = 0.0006) compared to the cirrhotic group. Moreover, sCD105 shows higher 
diagnostic sensitivity when compared to AFP (≥ 90.9 vs. 81.8%) and there was only mild to 
moderate correlation between these two parameters in the latter groups. For the functional 
analysis, the rat soluble endoglin was first cloned, followed by the functional expression of 
the protein in TGF-β sensitive cells, i.e. L6E9 cells and primary hepatocytes. The presence of 
the soluble endoglin in both of these systems modulated the TGF-β1/Smad3 signaling as 
evaluated with the phospho-Smad3 specific reporter (CAGA)12-MLP Luc.  
From the reported data we conclude that circulating sCD105 may be a complementary marker 
to identify patients with liver cirrhosis who are at high-risk of HCC. However, further 
confirmatory studies are needed to evaluate the application potential of this novel serum 
marker in a large cohort of patients. In addition, we showed that soluble CD105 has a role in 
TGF-β signaling, as we could clearly show by the heterologous expression of the rat soluble 
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endoglin. Therefore, it is most likely that the circulating soluble endoglin induces a 
pathophysiological effect by modulation of TGF-β signaling in responsive cells. 
 
Zusammenfassung 
 
Leberzirrhose und viral bedingte chronische Hepatitis-B und –C Infektionen stellen bekannte 
Risikofaktoren für das Auftreten von HCC dar. Die Identifizierung von Hoch Risikopatienten, 
bei denen ein kurativer Eingriff noch möglich ist, stellt derzeit ein ungelöstes Problem dar. In 
der vorliegenden Arbeit wurde aus diesem Grund das diagnostische Potential von löslichem 
Endoglin in Hoch Risikopatienten untersucht. Zusätzlich haben wir untersucht, ob lösliches 
Endoglin einen funktionellen Einfluß auf den profibrogenen TGF-β/Smad3 Signalweg hat. 
Zur Untersuchung der Relevanz von löslichem Endoglin bei der Identifizierung von HCC 
Riskopatienten haben wir dessen Konzentration in 121 Patienten mit chronischer 
Lebererkrankung sowie 70 gesunden Probanden gemessen. Zu Vergleichszwecken haben wir 
ebenfalls den etablierten Marker AFP bestimmt. Die 121 Patienten wurden unterteilt in 
Fibrotiker (19 Patienten), Zirrhotiker (57 Patienten), Zirrhotiker mit HCC (45 Patienten) und 
9 Patienten mit HCC. Zwischen gesunden Probanden (3,7 µg/L) und Fibrotikern konnte kein 
signifikanter Unterschied im löslichen Endoglin festgestellt werden. Demgegenüber stieg die 
Konzentration von löslichem Endoglin von Zirrhotikern (5,8 µg/L; P Wert 0,0001) im 
Vergleich zu den Fibrotikern und die Konzentration von löslichem Endoglin von Zirrhotikern 
mit HCC (7,4 µg/L; P Wert 0,0006) im Vergleich zu Zirrhotikern signifikant an. Im Vergleich 
zu AFP zeigte lösliches Endoglin eine höhere Sensitivität (> 90,9% vs. 81,8%) und es lag nur 
eine milde bis moderate Korrelation dieser Marker zwischen den beiden letzten 
Vergleichsgruppen vor. Zur Untersuchung der Funktion des löslichen Endoglins wurde dieses 
zunächst kloniert und hiernach in TGF-β sensitiven Zellen einer funktionellen Analyse 
unterzogen. Mit Hilfe des Smad3 spezifischen Reporters konnten wir zeigen, dass lösliches 
Endoglin TGF-β/Smad3 Signalweg modulieren kann. 
Zusammenfassend kann gesagt werden, dass Endoglin einen komplementären Marker 
darstellen könnte, um HCC in Risikopatienten zu diagnostizieren, dessen klinische Wertigkeit 
allerdings zunächst an einer größeren Kohorte von Patienten validiert werden müsste. 
Ebenfalls scheint lösliches Endoglin ein funktionelles Potenzial zu besitzen, indem es 
zumindest in vitro das profibrogene TGF-β/Smad3 Signal moduliert. 
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7   Appendix 
Description of cDNAs and vectors used in this thesis 
7.1 Sequence of the rat TGF-β receptor endoglin cDNA and corresponding translation. 
 
Figure 31: Structure of rat endoglin cDNA. The nucleotide and deduced amino acid sequence of the rat 
endoglin cDNA is shown. Nucleotides and amino acids are numbered on the right. The translational initiation 
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and termination codons are shown in white type on black. The signal peptide and the transmembrane region are 
marked by solid or intermitted lines, respectively (Meurer et al., 2005).  
7.2 pGEM®-T Easy sol-Endoglin 
 
Figure 32: Structure of the cloned rat extracellular domian of endoglin in pGEM. The nucleotide sequence 
of full length endoglin (7.1, RENDOFL) and soluble endoglin (sol-Endoglin) is shown. The amino acid sequence 
of the boundary between the extracellular domain and the transmembrane domain is shown on top of the nucleic 
acid sequence in the one letter code. The primer sequences used to amplify sol-Endg are underlined by an arrow 
and primer descriptions are indicated. Nucleotides (full length endoglin) are numbered on the right. The 
translational initiation and termination codons are shown in white type on black. The nucleic acid sequence 
corresponding to a part of the transmembrane region is marked by a solid line on the top. Restriction sites, used 
for successive cloning steps, introduced by the primer (Not I) or supplied by the vector (EcoR I) are designated 
and marked in red type. (RENDOFL, rat endoglin full length) 
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7.3 Map of pGEM®-T Easy Vector 
 
 
 
Figure 33: Structure of the pGEM®-T Easy vector (Invitrogen). (A) Schematic representation of the 
functional elements present in the vector. In the right margin the single cutting restriction enzymes with the 
respective position in the multiple cloning site is depicted. (B) Sequence positions positions of the elements 
depicted in (A) are indicated. (C) A detailed representation of the multiple cloning sites is shown. The site where 
the PCR fragment of soluble Endoglin was introduced and indicated in the figure by the box. The EcoR I 
restriction site (red) was used for further cloning steps. 
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7.4 Map of pcDNA3.1 Vector 
 
 
Figure 34: Structure of the pcDNA3.1 vector (Invitrogen). (A) Schematic representation of the functional 
elements present in the pcDNA3.1 vector. On the top the single cutting restriction enzymes with the respective 
position in the multiple cloning site is depicted. Enzymes utilized for the cloning are in red type. (B) Sequence 
positions of the elements depicted in (A) are indicated. (C) A detailed representation of the multiple cloning site 
is shown. The site where the PCR fragment of soluble Endoglin was introduced is indicated by the box. EcoR I 
and Not I restriction sites (red) were used for cloning. 
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7.5 Functional Map of (CAGA)12-MLP-Luc 
 
 
Figure 35: Structure of the pGL3-Basic/(CAGA)12-MLP-Luc vector (Promega). (A) Schematic 
representation of the functional elements present in the pGL3-Basic vector. In the right margin single cutting 
restriction enzymes with the respective position in the multiple cloning site are depicted. (B) Sequence positions 
of the elements depicted in (A) are indicated. (C) A detailed representation of the multiple cloning site is shown. 
(D) The site were the PCR fragment of soluble Endoglin was introduced is indicated by the box. The EcoR I and 
Not I restriction sites (red) were used for cloning. 
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Reference table (1a): Age, sex (f =2, m =1), sCD105 concentration (ng/ml), and α-fetoprotein concentration 
(ng/ml ) in healthy control group (n = 70 ). 
 
control healthy group 
No Age(y) sex Endoglin AFP 
1 36 1 4.1 2.9 
2 36 1 2.5 3.3 
3 48 1 3.9 4 
4 55 1 3.8 2.2 
5 61 1 3.7 8.4 
6 37 1 3.7 2.1 
7 57 1 3.4 2 
8 37 1 3.3 6.3 
9 41 1 4.3 3.3 
10 37 1 3.1 2 
11 44 1 3.3 4.8 
12 38 2 3.1 2.6 
13 58 2 3,3 10.1 
14 49 2 4 3.2 
15 36 1 3.4 5.2 
16 46 1 2.9 2.7 
17 47 2 3.2 1.7 
18 37 2 3.4 1.7 
19 38 1 3.7 2.3 
20 53 1 3.1 2.6 
21 38 1 2.8 3.6 
22 36 1 3.5 3.6 
23 42 1 3.9 4 
24 45 1 3.2 2.6 
25 44 1 4 4.3 
26 43 1 3.1 14 
27 43 1 3.4 4.1 
28 58 1 32 3.2 
29 36 1 2.5 2 
30 45 2 3.8 4 
31 36 1 2.7 2 
32 46 2 2.5 3.9 
33 61 2 3.6 2.4 
34 54 1 2.7 7 
35 42 1 3.9 2.8 
36 50 1 4.1 2.6 
37 45 1 3.2 4.5 
38 58 2 3.7 98 
39 43 1 3.3 2.5 
40 51 2 2.9 3.9 
41 50 1 2.7 2.9 
42 46 2 3.4 2.4 
43 49 1 4 22 
44 41 2 3.5 3.4 
45 61 1 3 2.1 
46 37 1 3 1.16 
47 63 1 7.8 3.2 
48 62 1 5.9 1.3 
49 60 1 5 3 
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50 52 2 5.6 3.8 
51 64 1 3.9 3.1 
52 54 2 4.3 4.1 
53 56 2 3.9 2 
54 66 2 4.3 5.8 
55 63 1 3.6 4.4 
56 67 1 5.9 4 
57 59 1 4.2 5.8 
58 59 1 5.5 3.9 
59 58 1 4.5 6 
60 56 1 5.3 1.6 
61 59 1 4.1 6.3 
62 57 1 5 3.6 
63 51 1 4.6 2.3 
64 59 1 4.6 2.8 
65 51 1 4.5 2 
66 56 1 4.3 3 
67 52 1 4.6 1.9 
68 54 1 4.9 3 
69 51 1 4.9 4.7 
70 51 1 3.9 1.7 
 
Reference table (1b): Age, sex (f =2, m =1), serum soluble endoglin concentration (ng/ml), and α− fetoprotein 
concentration (ng/ml) in non cancer non liver diseases as an internal control group.(n = 94 ). 
 
Non liver patients is as an internal control 
 Age(y) sex Endoglin AFP 
1 21 2 3.4 1.44 
2 25 2 4.9 0.7 
3 62 2 6.4 6.3 
4 48 1 3.8 1.79 
5 21 1 4.9 1.2 
6 39 2 3.1 1 
7 78 1 3.7 5.9 
8 66 1 3 2.3 
9 62 1 4.6 2.4 
10 40 2 4.2 2 
11 39 1 2.9 4.2 
12 68 2 3.7 4.8 
13 59 2 2.4 2.3 
14 60 2 3.5 2.9 
15 79 2 3.8 11.2 
16 76 1 4 1.4 
17 56 1 3.1 4.7 
18 51 2 3.3 4.8 
19 78 1 4.4 3.1 
20 43 2 4.3 2.1 
21 53 2 6 3.6 
22 59 2 2.4 3 
23 46 2 3.8 8.6 
24 73 2 3.6 2.7 
25 71 1 3.5 3.9 
26 51 2 3.6 2.7 
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27 78 2 3.9 2.5 
28 62 2 3.2 4.6 
29 66 1 3.8 2.6 
30 41 2 4.8 2.1 
31 65 1 3.8 3.9 
32 62 2 4.2 1 
33 62 1 9.9 1.24 
34 38 1 4.3 6.4 
35 71 1 3.7 8 
36 65 1 4.3 4.1 
37 65 1 5.3 2.1 
38 78 2 3.8 1.9 
39 54 2 3.4 1.4 
40 77 1 3.9 5.2 
41 37 1 2.8 1.6 
42 70 1 3.4 2.2 
43 85 2 4.4 3.7 
44 76 2 4.8 2.1 
45 49 1 3.6 3.5 
46 64 1 15.1 2.9 
47 76 1 3.1 3 
48 73 1 3.4 4 
49 41 2 3.8 1.7 
50 65 2 3.1 8.5 
51 41 2 3.7 2.2 
52 60 2 4 3.8 
53 63 2 3.4 3.6 
54 41 1 4.2 1.2 
55 52 1 4.8 5.7 
56 58 1 4.3 1.6 
57 72 2 4.7 7 
58 51 2 6.7 4.2 
59 75 2 3.7 9.1 
60 68 2 3.8 3.3 
61 56 2 3.1 2.7 
62 67 2 4.7 7.3 
63 51 2 4.5 2.8 
64 38 1 3.9 5.9 
65 56 2 3.5 4.2 
66 54 1 4.9 1.3 
67 59 1 3.7 3.5 
68 51 1 2.8 3 
69 67 2 5.7 1.8 
70 62 2 4.9 1.3 
71 66 1 5.1 1.2 
72 42 1 5 3.5 
73 67 1 4.5 3.4 
74 75 2 3.4 4.7 
75 39 1 4 1.1 
76 40 1 4.7 2.1 
77 54 1 3.8 3.6 
78 51 1 4.1 3.7 
79 68 1 6.3 5.24 
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80 54 1 3.2 4.1 
81 83 2 3.5 4.3 
82 66 2 5.1 3.2 
83 68 1 4.1 5.8 
84 42 2 3.6 3 
85 51 2 7.5 1.6 
86 62 2 4.1 1.4 
87 33 1 2.5 2.2 
88 48 2 4.7 1.8 
89 72 1 4.1 1.8 
90 61 2 6.4 4.3 
91 60 2 3.9 3.8 
92 75 2 3.4 4.1 
93 49 2 4.7 3 
94 58 2 3.2 3 
 
 
 
 
 
Reference table (1c): Age, sex (f =2, m =1), sCD105 (ng/ml), and AFP concentration (ng/ml) in fibrotic liver 
patients subgroup (n = 19). 
 
Fibrotic liver subgroup 
 Age sex Endoglin AFP 
1 60 2 5.4 6.5 
2 50 2 3.4 8.5 
3 66 2 3.8 5.8 
4 24 1 3.5 1.8 
5 26 2 3.2 1 
6 21 1 4.7 4.6 
7 51 1 4 2.1 
8 40 2 2.8 2.7 
9 58 2 3.3 5.4 
10 42 1 4.1 4.3 
11 53 2 3.4 3.6 
12 36 2 3.2 2.7 
13 21 2 3.9 4.8 
14 40 1 3.4 1.2 
15 41 1 7.4 1.4 
16 47 2 3.3 4 
17 52 1 3.9 1.7 
18 72 1 3.4 2.9 
19 47 1 5.8 2.5 
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Reference table (1d): Age, sex (f =2, m =1), sCD105 concentration(ng/ml), and AFP concentration (ng/ml) in 
cirrhotic liver patients subgroup (n = 57). 
 
 Cirrhotic liver subgroup   
 Alter sex Endoglin AFP 
1 61 1 5.4 2.1 
2 50 1 6.8 6.7 
3 51 1 5 4.9 
4 39 2 5.8 4 
5 78 1 6.3 5.5 
6 57 1 8.2 4 
7 46 1 4.9 3.3 
8 65 2 3.5 3.4 
9 41 1 9.5 2 
10 54 2 5.6 7.2 
11 56 1 7.4 2.5 
12 61 1 4.3 5.2 
13 66 1 4 3.3 
14 55 2 6.5 5 
15 56 1 9.4 9 
16 43 1 3.4 1.5 
17 64 2 5.1 3.58 
18 47 1 3.2 4.12 
19 50 1 4.7 3.4 
20 40 2 9.2 4.9 
21 44 2 7.7 3.7 
22 75 2 6.1 4.3 
23 60 1 3.8 153.9 
24 62 1 12.6 4.2 
25 63 2 11.7 16.1 
26 79 1 6.5 3.9 
27 69 2 6.4 2.2 
28 68 1 6.2 9.4 
29 59 2 6.3 7.4 
30 65 1 4.8 4.5 
31 62 1 4.4 3.7 
32 67 1 5.8 4.3 
33 75 1 3.2 0.8 
34 54 2 6.9 2.6 
35 73 2 2.9 1.3 
36 66 1 5.4 13.5 
37 64 1 6.5 7.7 
38 45 1 7.4 6.5 
39 67 1 4.2 1.9 
40 73 1 5.9 3.9 
41 49 1 2.8 1.9 
42 51 2 6 1.6 
43 38 1 7.2 6.4 
44 58 1 6 17.9 
45 54 1 4 3 
46 65 2 5.8 6.4 
47 78 2 5.1 8.1 
48 40 1 3.4 1.2 
49 40 1 5.2 1 
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50 72 1 3.4 2.9 
51 60 2 4.2 6.3 
52 82 1 9.3 26.8 
53 63 1 5.1 43 
54 66 1 7.5 2.6 
55 66 1 4.4 3.4 
56 50 1 6.3 3.8 
57 57 2 5 2.7 
 
Reference table (1e): Age, sex (f =2, m =1), sCD105 (ng/ml), and AFP concentration (ng/ml) in cirrhotic liver 
with HCC patients subgroup (n = 45). 
 
HCC with cirrhosis subgroup 
 Age sex Endoglin AFP 
1 43 1 7 2.2 
2 38 2 5.6 5 
3 44 1 5.2 2.4 
4 57 2 3.2 2.5 
5 59 1 9.8 2.4 
6 49 1 7.8 35.4 
7 43 1 10.2 2.8 
8 47 1 3.1 3.6 
9 63 1 8.8 7.2 
10 54 2 3 2.5 
11 65 1 7 3.5 
12 59 1 6.4 3 
13 45 2 7 9.4 
14 70 1 2.4 1.4 
15 50 1 4.9 2.1 
16 70 2 3.7 1.4 
17 54 1 11 18.9 
18 56 1 5.2 5.2 
19 46 1 8 25.9 
20 77 2 11.7 8.6 
21 51 1 8.2 2.8 
22 45 1 9.5 6.2 
23 62 2 11.4 8 
24 57 1 8.8 14.7 
25 39 1 4 2.4 
26 46 1 11.5 2.6 
27 59 1 5.6 5 
28 49 1 6.4 5 
29 48 1 6.6 1.8 
30 50 2 11.5 3..9 
31 58 1 11.4 7.4 
32 61 2 12 353000 
33 58 1 9.4 24.8 
34 63 2 10.4 21946 
35 50 1 7.4 1277 
36 75 2 7.9 21.4 
37 51 1 6.5 388 
38 66 1 6.3 1.7 
39 60 1 11.5 461100 
40 51 2 7.5 8.3 
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41 67 1 6 129.6 
42 72 2 6.1 4.3 
43 78 1 8.5 2792 
44 61 1 5.4 362 
45 76 2 8.8 86.8 
 
Reference table (1f): Age, sex (f =2, m =1), sCD105 concentration (ng/ml), and AFP concentration (ng/ml ) in 
liver patients with HCC patients subgroup (n = 9). 
 
HCC  subgroup 
 Age sex Endoglin AFP 
1 54 1 6.7 2 
2 63 2 8.5 15.1 
3 74 1 3.3 2.7 
4 63 1 4.6 763 
5 70 1 5.1 16.1 
6 62 2 5 113.9 
7 65 1 6 56 
8 59 1 4.6 2.5 
9 57 2 4.2 3.9 
 
 
Reference Table (2): showed the calibration data for the superdex 200 HR 10/30 column by specific standard 
proteins with their molecular weight and the elution volume at which every standard run through the column. Kav 
is calculated for thr tested protein from special formula. 
Protein MW Ve (ml) KAV MWlog Ve/V0
Blue Dextran2000 V0 8.19       
Thyroglobulin 667000 8.78 0.0437 5.824 1.072
Ferritin 440000 10.07 0.1391 5.643 1.2295
Catalase 232000 11.8 0.2672 5.365 1.4407
Gamma Globulin 158000 11.89 0.2739 5.199 1.4517
BSA 67000 13.06 0.3605 4.826 1.5946
Ovalbumin 44000 14.55 0.4708 4.643 1.7765
Myoglobin 17000 16.84 0.6403 4.23 2.0561
Cyancobalamin 4500 20.52 0.9126 3.653 2.5054
L-Tyrosine Vt               181 21.7  1  2.258  2.649
 
Kav = (Ve – V0) / (Vt – V0)  
(V 0 = void volume, Vt = total gel bed volume, Ve = elution volume of protein of interest, Kav 
= value of protein of interest) 
For purification of serum endoglin  
V0= 8,19  
Ve= 10 
Vt= 21.7 
Kav for serum sCD105 =1.81 / 13.51 = 0.134 
Ve/V0 for serum endoglin was 1.221 
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Figure 36: Diagram showing the calibration data of the FPLC (Superdex 200 HR 10/30). To calculate the 
molecular weight of the soluble endoglin, the data of of Kav for each standard protein (x-axis) were plotted 
against the log of the molecular weight of each standard protein (Y-axis). The log of molecular weight for serum 
endoglin was 5.58. 
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